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Introduction to the thesis
Ovarian cancer: epidemiology, diagnosis, and treatment
Epithelial ovarian cancer is the deadliest gynecological malignancy. Yearly, approximately 1100 
women are diagnosed in the Netherlands, 900 of which eventually succumb to the disease (1). 
Ovarian cancers are histologically classified as serous, mucinous, clear cell, endometrioid, 
transitional (Brenner), or squamous cell tumors (2). The histopathology of these subtypes has 
been the subject of many recent discussions, in which extra-ovarian origins are increasingly being 
recognized. Serous carcinomas were traditionally thought to originate from the ovarian surface 
epithelium, due repeated tissue damage at ovulation, but ovarian cortical inclusion cysts and the 
peritoneum at large were also putative sites of origin (3). However, the identification of precursor 
lesions in the fallopian tubes, termed serous tubal intraepithelial carcinomas (STICs), has challenged 
this view and resulted in the ‘tubal hypothesis’ for serous ovarian cancers (3,4). Recently, similar 
precursor lesions were found in the endometrium, further expanding the list of possible sites of 
origin (5). 
The origin of non-serous tumor types was also a topic of investigation in recent years. There is now 
some consensus that endometrioid and clear cell tumors can arise from atypical endometriosis 
lesions (6). In the case of mucinous tumors, the distinction between primary and metastatic 
disease is difficult. Primary mucinous ovarian cancers are now considered rare. Rather, they are 
often metastases from gastrointestinal tumors such as appendiceal pseudomyxoma peritonei (7). 
Deciphering the precise origin of ovarian cancer is not just interesting from an academic point 
of view, but carries important clinical consequences, because factors such as sensitivity to 
chemotherapy tend to differ between subtypes (3). Careful pathological examination is therefore 
of paramount importance.
Clinically, early detection of ovarian cancer is notoriously difficult. Ovarian cancer was historically 
referred to as ‘the silent lady killer’, because of its perceived lack of symptoms. In recent years it 
became clear that ovarian cancer is certainly associated with symptoms, but that these are quite 
aspecific and therefore not recognized as being indicative of a serious illness. Symptoms most 
predictive of ovarian cancer include persistent abdominal distension, appetite loss, postmenopausal 
bleeding, and early satiety (8). These symptoms usually only manifest themselves late in the disease 
process; hence, 70% of women are diagnosed with advanced stage ovarian cancer (1).
Debulking surgery and platinum-based chemotherapy are the mainstays of ovarian cancer 
treatment. Unfortunately, recurrence is a common problem, even after complete remission. In 
those cases, treatment options are palliative and dictated by whether or not the tumor is still 
platinum sensitive. Targeted agents, such as angiogenesis inhibitor bevacizumab, are currently 
being investigated in clinical trials (9). However, significant improvements in survival remain to be 
seen. 
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1Basic concepts of tumor immunology
The interaction between cancer and the immune system was recognized as early as the 19th century, 
when William Coley reported that administering Streptococcal toxin to patients with inoperable 
sarcomas could result in complete tumor regression (10). Over the next century, the concept of 
tumor immunology was frequently disputed, until in the mid-1980s tumor immunogenicity and the 
presence of auto-reactive T cells were further elucidated (11). 
The current paradigm of ‘cancer immunoediting’ describes the involvement of the immune system 
in both tumor prevention and shaping of tumor immunogenicity (12). This concept revolves around 
‘the three E’s’ of Elimination, Equilibrium, and Escape. Elimination applies to the subclinical stage 
of disease, in which the innate and adaptive immune system combine forces to eradicate (a limited 
number of) malignant cells. However, certain cells may escape elimination and enter equilibrium, 
a steady state in which cancer cells remain viable, but are under constant immunologic pressure 
by the adaptive immune system and outgrowth to full-blown tumor is prevented. The inherent 
danger in this situation is the emergence of immune resistant cells, which enable the formation 
of clinically apparent disease, thus entering the phase of escape (12). In this final stage, various 
immunosuppressive mechanisms may be at work, some of which are discussed in this thesis. 
Manipulating these unfavorable microenvironmental circumstances is key to developing clinically 
effective immunotherapy.
Immunotherapy has already shown real promise in several types of cancer. For instance, anti-
cytotoxic T lymphocyte associated antigen 4 (CTLA4) antibodies are now registered for adjuvant 
use in melanoma patients (13). Moreover, vaccination with human papillomavirus (HPV) peptides 
induced regression of high grade vulvar intraepithelial neoplasia (14). Successes like these are still 
elusive in ovarian cancer, but do underline the principle that modulating the immune system can 
change the tumor microenvironment for the better.
Recognition of tumor cells by the immune system
The immune system contains an elaborate system of checks and balances, to prevent auto-immune 
phenomena. In cancer, on the other hand, the immune system should recognize the patients’ own, 
malignantly transformed, cells. The distinction between healthy cells and tumor cells is provided 
by tumor antigens. When presented to naïve immune cells in the context of appropriate co-
stimulation, an immune response can be mounted against these antigens and thus against the 
malignant cells expressing them. 
Tumor antigens are traditionally divided in two classes: tumor specific antigens (TSAs) and tumor 
associated antigens (TAAs). TSAs are caused by gene mutations, whereas TAAs are over- or 
aberrantly expressed non-mutated molecules (15). TAAs are exclusively expressed on cancer cells, 
making them a prime target for immunotherapeutic intervention. However, because considerable 
inter-patient variation exists regarding their expression pattern, individualized approaches would 
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be needed (15).
A downside to the TAA vs. TSA classification of tumor antigens is that a certain amount of overlap 
exists, when antigens initially classified as TAAs turned out to be expressed on healthy cells as 
well. Therefore, a classification based on structure and source of the antigens is currently more in 
use, resulting in seven groups of tumor antigens: differentiation antigens (e.g. tyrosinase, gp-100), 
mutational antigens (e.g. β-catenin, caspase), amplification antigens (e.g. HER-2/neu, p53), splice 
variant antigens (e.g. ING1, NY-CO-37/PDZ), glycolipid antigens (e.g. MUC1), viral antigens (e.g. 
HPV), and cancer testis antigens (e.g. MAGE, NY-ESO-1) (16).
Lymphocyte subsets involved in the anti-tumor immune response
The immune system contains an innate and an adaptive branch. Innate immunity provides a first 
line of defense to pathogens. Examples of innate immune cells include neutrophils, dendritic cells, 
natural killer (NK) cells, and macrophages. An important characteristic of innate immunity is that 
it is not capable of antigen recognition, but rather responds to certain molecular patterns shared 
by microorganisms, or to inflammatory mediators produced by other components of the immune 
system. Secondly, it does not possess immunologic memory. 
In terms of tumor immunology, innate immunity can contribute to the anti-tumor immune response, 
for instance via antigen presentation to naïve T lymphocytes or by attracting immune cells through 
cytokine secretion. However, innate immunity is also viewed as an instigator of carcinogenesis. 
This is especially seen in states of chronic inflammation, where constant tissue damage and repair 
ultimately results in malignant transformation (17,18). Examples of such inflammatory cancers 
include cervical cancer (HPV), gastric cancer (Helicobacter pylori), esophageal cancer (Barrett’s 
metaplasia), colorectal cancer (inflammatory bowel disease), hepatocellular cancer (hepatitis B 
and C), lung cancer (asbestos, cigarette smoke) and Kaposi’s sarcoma (human herpesvirus type 8) 
(18).
The focus of this thesis is the role of the adaptive immune system in cancer. The adaptive immune 
system consists of T and B lymphocytes. CD3+ T lymphocytes are key players of the anti-tumor 
immune response. They are divided into several subgroups, based on their surface markers and 
functional characteristics. CD8+ cytotoxic T lymphocytes (CTL) are the principle effector cells, killing 
target cells via secretion of perforins and granzymes or via Fas-ligand (FasL) induced apoptosis. 
CD4+ T helper (Th) lymphocytes are a heterogeneous class of cytokine secreting T lymphocytes, 
with both pro- and anti-tumor effects. CD4+ T helper type 1 (Th1) lymphocytes mainly secrete 
interferon (IFN)-γ, as opposed to T helper type 2 (Th2) lymphocytes, which secrete interleukin 
(IL)-4, -5, and -13.  CD4+ CD25+ FoxP3+ regulatory T cells (Treg) are important in maintaining self-
tolerance, i.e. preventing auto-immunity. They inhibit other T lymphocytes, but also macrophages 
and dendritic cells by secretion of immunosuppressive cytokines such as IL-10 or via direct cell-cell 
contact. The most recently recognized member of the CD4+ family is the Th17 T lymphocyte. It 
principally secretes IL-17, which is known to stimulate angiogenesis and neutrophil recruitment 
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1(19). Intruigingly, it was found that Th17 share a common precursor with a subset of Treg. 
Activation of naïve CD4+ T lymphocytes in a Transforming Growth Factor (TGF)-β rich environment 
favors differentiation into Treg. When TGF-β and IL-6 are both present, the same naïve CD4+ T 
lymphocytes tend to end up as Th17 cells (20). Thus, Th17 and Treg are essentially two sides of a 
coin. The role of Th17 lymphocytes in tumor immunology is not fully elucidated yet, although both 
pro- and anti-tumor effects have been reported (19).
After activation by antigen recognition, some effector T lymphocytes are converted to memory T 
lymphocytes. Memory T lymphocytes respond more efficiently than naïve T lymphocytes to antigen 
recognition, resulting in a fast and large immune response when the antigen is encountered again. 
Memory T lymphocytes are subdivided based on their anatomical location, which is determined by 
the expression pattern of certain homing molecules. Effector memory T lymphocytes (TEM) express 
CCR5, which is involved in homing to inflammatory sites. Hence, TEM are primarily found in the 
circulation or in nonlymphoid tissues. They are a first line of defense against pathogens, geared 
towards immediate effector function. Central memory T lymphocytes (T
CM
) lack CCR5, but express 
CD62L and CCR7, enabling their entry into lymph nodes via high endothelial venules (HEVs). T
CM
 
selectively circulate through secondary lymphoid tissues and are precluded from entering epithelia 
and underlying tissues. They serve as a second line of defense, in case pathogens escape from their 
epithelial entry site to lymph nodes. However, even though they respond more slowly, T
CM
 have a 
higher proliferative capacity than TEM (21). 
Recent history of ovarian tumor immunology
In ovarian cancer, understanding of tumor immunology has taken great leaps forward over the past 
decade. A landmark paper in 2003 described how the presence of CD3+ T lymphocytes in advanced 
stage ovarian cancer predicts improved progression free and overall survival (22). When looking at 
lymphocyte subsets in more detail, the negative contribution of Treg to the anti-tumor immune 
response was a major finding. Curiel et al. first identified that Treg preferentially accumulate in 
tumor tissue and ascites of ovarian cancer patients, due to CCL22 production by tumor cells and 
microenvironmental macrophages (23). In their cohort of 70 ovarian cancer patients, presence of 
Treg was associated with reduced survival. Later studies confirmed the detrimental role of Treg, but 
added the notion that instead of absolute numbers of tumor infiltrating lymphocytes (TIL), their 
ratios compared to other immune cells determine outcome. For instance, a high CTL/Treg ratio was 
found to be more predictive of improved survival than high CTL or low Treg numbers on their own 
(24).
In recent years, another important focus of tumor immunology research in ovarian cancer was 
identifying which factors in the tumor microenvironment determine lymphocyte infiltration 
and/or function. For instance, expression of the endothelin B receptor (ETbR) on ovarian tumor 
endothelium was reported to be associated with fewer TIL and consequently a worse prognosis 
(25). These effects were mediated by downregulation of intercellular adhesion molecule-1 (ICAM-
14
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1), an adhesion molecule which facilitates T lymphocyte adherence and transmigration through the 
endothelium. Indeed, upon in vivo blockade of ETbR in ovarian cancer bearing mice, ICAM-1 was 
upregulated and numbers of TIL increased. However, no clinical effects were observed.
Ovarian cancer cells themselves can also actively inhibit lymphocytes. The pathway that probably 
gained the most attention in this respect is programmed cell death ligand (PD-L)-1. In a 2007 study, 
it was reported that PD-L1 expression in ovarian cancer specimens correlated to poorer prognosis 
and lower intraepithelial CTL counts (26). PD-L1 binds receptor PD-1, which is expressed on 
activated lymphocytes. PD-1 subsequently induces T lymphocyte anergy or apoptosis by interfering 
with downstream T cell receptor signaling. 
Outline of the thesis
In this thesis, we aimed to further characterize the immunologic environment of ovarian cancer. 
We examined T lymphocyte infiltrates and identified relevant immune regulatory markers in a large 
cohort of ovarian cancer patients. Furthermore, we assessed a potential T lymphocyte activating 
protein in vitro. The ultimate aim of the research presented here is to identify prognostic markers 
and possible targets for immunotherapy. 
Quantifying numbers of tumor infiltrating lymphocytes (TIL) can be viewed as a proxy measure 
for the intensity of an anti-tumor immune response in vivo. This approach has been used in many 
studies in large series of all major cancer types, gaining insight not only in the composition of 
lymphocyte infiltrates, but also in their associations with clinicopathological characteristics and 
patient survival. In chapter 2 we performed a systematic review, compiling all larger studies in 
which the prognostic significance of numbers of intratumoral CD3+, CD4+, CD8+, and FoxP3+ T 
lymphocytes was reported in solid malignancies. We performed meta-analysis to generate pooled 
estimates of survival outcomes for these T lymphocyte subsets. Importantly, these studies tend 
to have methodological differences, for instance in sample size, follow-up time, and methods of 
quantifying TIL and cut-off points. These factors may very well influence statistical outcomes and 
biological conclusions based on these outcomes. Therefore, we also tried to establish whether 
differences in methodology between studies were associated with the predictive value of TIL for 
patient survival.  
In chapter 3 we report our own results regarding the prognostic impact of TIL in ovarian cancer in 
a large cohort of patients with a lengthy follow up time. We analyzed the presence of CD8+ CTL, 
FoxP3+ Treg, and CD45R0+ memory T lymphocytes in primary ovarian cancer tissue and in omental 
metastases from 306 ovarian cancer patients. Cell numbers were correlated to clinicopathological 
characteristics such as stage, histology, and residual tumor after primary debulking surgery, as well 
as patient survival. 
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1An intact antigen processing and presentation apparatus is a prerequisite for an adequate anti-
tumor T lymphocyte response. In particular, tumor antigens need to be cleaved into peptide 
fragments, loaded onto a Major Histocompatibility Complex (MHC) molecule, and transported to 
the cell surface. This cell surface bound complex of MHC molecule and peptide can be recognized 
by antigen-specific T lymphocytes, which subsequently execute their designated function. Antigen 
processing and presentation components are frequently downregulated in various types of cancer, 
providing an immune escape mechanism by impeding T lymphocyte recognition of tumor cells. 
In chapter 4 we analyzed whether this is an issue in ovarian cancer. To this end, we performed 
immunohistochemical stainings for components of the multicatalytic constitutive proteasome 
(MB1), the IFN-γ inducible immunoproteasome (LMP7), endoplasmatic reticulum associated 
transporter proteins (TAP1 and TAP2), chaperone proteins which facilitate loading into the 
MHC class I molecule (ERp57, ERAP1), and finally MHC class I molecules (HLA-A, HLA-B/C) and 
associated β2 microglobulin (β2m). Results from these stainings were subsequently correlated to 
clinicopathological factors, lymphocyte infiltration, and survival.
Tumor cells frequently arm themselves against the immune system by expressing immunosuppressive 
molecules. Human leukocyte antigen (HLA)-E could be one of these. HLA-E is a nonclassical Major 
Histocompatibility Complex (MHC) molecule, characterized by its nonpolymorphic nature. HLA-E 
binds the CD94 receptor in conjunction with either the inhibitory NKG2A or the stimulatory 
NKG2C molecule. These receptors are usually expressed on natural killer (NK) cells, but also on 
some activated CD8+ T lymphocytes. Thus, the interaction between HLA-E and CD94/NKG2A is 
a potential threat to the efficacy of the anti-tumor immune response. In chapter 5 we set out 
to determine the expression of HLA-E and its receptors on ovarian and cervical cancer samples. 
Moreover, we analyzed associations between HLA-E expression and (the prognostic significance of) 
CD8+ T lymphocytes and NK cells.  
Identifying which factors determine the composition and magnitude of immune infiltrates in 
cancer could pave the way for immunotherapeutic interventions. In this context, chemokines could 
be influential. Chemokines are small molecules capable of inducing cell migration along a chemical 
gradient. They play important roles in for instance inflammation and infections, but also in the tissue 
formation and embryonic development. In cancer, they are implicated in attracting lymphocytes 
to the tumor, but also in angiogenesis and metastasis. In chapter 6, we examine the chemokine 
CXCL16 and its receptor CXCR6 in ovarian cancer. CXCL16 is a unique chemokine, because it exists 
not only in a soluble form (sCXCL16), but also as a transmembrane protein. sCXCL16 is generated 
via cleavage of transmembrane CXCL16 by metalloproteinases. We stained ovarian cancer tissue 
specimens for both transmembrane CXCL16 and CXCR6, and analyzed matching serum samples for 
sCXCL16. We determined associations between CXCL16 and CXCR6 expression, clinicopathological 
factors, and numbers of tumor infiltrating lymphocytes. Finally, we performed in vitro studies to 
assess the pathways involved in CXCL16 cleavage. 
16
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Another potential immunomodulatory protein is Galectin-9 (Gal-9). Gal-9 is a member of the 
galectin family of glycan binding protein, which is involved in embryonic development, tumor 
biology, and immune regulation. We found Gal-9 to be upregulated in ascites from ovarian cancer 
patients. Previous studies indicate that Gal-9 inhibits Th1 mediated immunity. However, in chapter 
7, we report a novel immune stimulatory effect of Gal-9 on T lymphocytes. We performed various 
cell culturing experiments in which peripheral blood mononuclear cells (PBMCs) were incubated 
with low dosages of Gal-9 for seven days, which is considerably longer than previously reported. 
Next, we characterized changes in lymphocyte subsets in detail using flow cytometry. 
Finally, in chapter 8, the results from this thesis are summarized and discussed, followed by an 
overview of future perspectives. 
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Abstract
Background: Tumor infiltrating lymphocytes (TIL) are often found in tumors, presumably reflecting 
an immune response against the tumor. We performed a systematic review and meta-analysis, 
aiming to establish pooled estimates for survival outcomes based on the presence of TIL in cancer. 
Methods: A Pubmed and Embase literature search was designed. Studies were included in which 
the prognostic significance of intratumoral CD3+, CD4+, CD8+, and FoxP3+ lymphocytes, as well as 
ratios between these subsets, were determined in solid tumors. 
Results: In pooled analysis, CD3+ TIL had a positive effect on survival with a hazard ratio (HR) of 
0.58 (95% confidence interval (CI) 0.43-0.78) for death, as did CD8+ TIL with a HR of 0.71 (95% CI 
0.62-0.82). FoxP3+ regulatory TIL were not linked to overall survival, with a HR of 1.19 (95% CI 0.84-
1.67). The CD8/FoxP3 ratio produced a more impressive HR (risk of death: HR 0.48, 95% CI 0.34-
0.68) but was used in relatively few studies. Sample size and follow-up time appeared to influence 
study outcomes. 
Conclusion: Any future studies should be carefully designed, to prevent overestimating the effect of 
TIL on prognosis. In this context, ratios between TIL subsets may be more informative. 
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Introduction
Tumor infiltrating lymphocytes (TIL) are frequently found in tumors, suggesting that tumors 
trigger an immune response in the host. This so-called tumor immunogenicity is mediated by 
tumor antigens. These antigens distinguish the tumor from healthy cells, thereby providing an 
immunologic stimulus (1). 
The concept of ‘cancer immunoediting’ describes how the immune system and tumor cells interact 
during the course of cancer development. It consists of three distinct phases, termed ‘the three E’s’ 
(2). Elimination entails the complete obliteration of tumor cells by T lymphocytes. In equilibrium, 
a population of immune resistant tumor cells appears. Simultaneously, there is an unremitting 
immunologic pressure on nonresistant tumor cells. This phase can last for years (2). Finally, during 
escape, the tumor has developed strategies to evade immune detection or destruction. These 
may be loss of tumor antigens, secretion of inhibitory cytokines or downregulation of Major 
Histocompatibility Complex molecules (3). Additionally, antigens may be ineffectively presented 
to the immune system, i.e. without appropriate co-stimulation, resulting in immunologic tolerance 
(3).
Many studies report a survival benefit associated with the presence of TIL (4-7). This suggests that 
TIL are effective at delaying tumor progression, despite being antagonized by the mechanisms 
mentioned above. However, it is important to distinguish between different types of T lymphocytes, 
because they all have different functions in the tumor microenvironment. 
CD8+ cytotoxic T lymphocytes (CTL) are directly capable of killing tumor cells. CD4+ T helper 
lymphocytes (Th) are a heterogeneous cytokine secreting class of T lymphocytes. T helper type 
1 lymphocytes (Th1) play a crucial role in activating CTL. Th2 lymphocytes stimulate humoral 
immunity and activate eosinophils. In terms of antitumor immunity, Th2 activation is less effective 
than Th1 activation (8). Besides the Th1 and Th2 subsets, a CD4+ regulatory T lymphocyte (Treg) 
subset suppresses effector T lymphocytes (9). In cancer, Treg preferentially traffic to tumors, as a 
result of chemokines produced by tumor cells and microenvironmental macrophages (9). In recent 
years, the hypothesis that ratios between different subsets are most predictive of prognosis has 
gained much attention. Frequently used ratios are CD8+/FoxP3+ (effector:regulatory) ratio and 
CD8+/CD4+ (effector:helper) ratio. These measures may provide a more comprehensive view of 
the events at the site of disease, since the immune system is not a collection of solitary agents, but 
rather a complex system of checks and balances – each subset being dependent upon collaboration 
with and authorization from other subsets. 
A commonly used approach to gain more insight in the in vivo interaction between tumors and 
the immune system is to quantify the numbers of TIL, and to relate these to tumor characteristics 
and prognostic outcome. These studies have been performed across many types of cancer, and 
many types of TIL, with widely differing sample sizes. We were interested in obtaining a more 
precise estimate of the effect of TIL on survival. Therefore, we undertook a systematic review and 
meta-analysis, aiming to establish pooled estimates for survival outcomes based on the presence 
of tumor infiltrating lymphocytes in different types of cancer. We assumed that the direction of 
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prognostic influence of TIL would be the same in all solid tumor types, but that only the magnitude 
of this effect might differ between tumor locations and/or stage of disease. Therefore, we felt it 
was justified not to focus on one particular tumor type.
Methods
Search strategy
We designed a broad PubMed and Embase search, using the following terms: prognosis[tw], 
prognos*[tw], mortality[tw], surviv*[tw], survival[tw], disease free survival, disease specific 
survival, progression free survival, tumor infiltrating lymphocyte*, intratumoral lymphocyte*, 
intratumoural lymphocyte*, intra-tumoural lymphocyte*, intra-tumoral lymphocyte*, TIL[tw], 
cancer[tw], malignancy[tw], malignan*[tw], neoplasm*[tw], tumor*[tw], tumour*[tw], 
carcinoma*[tw]. We used the following MeSH terms: ‘prognosis’, ‘mortality’, ‘survival’, ‘survival 
analysis’, ‘disease-free survival’, ‘lymphocytes, tumor-infiltrating’, ‘CD4+-Positive T-Lymphocytes’, 
‘CD8+-Positive T-Lymphocytes’, ‘neoplasms’. Additionally, possible missing papers were searched in 
reference lists of selected papers and related articles as suggested by PubMed. 
Inclusion criteria
We only included studies in which the prognostic significance of CD3+, CD4+, CD8+, and FoxP3+ 
lymphocytes was examined, including ratios between these subsets. These lymphocyte markers 
were chosen based on the assumption that these were the most frequently used markers. All 
papers in which only haematoxylin and eosin stained slides were used, or which did not incorporate 
a time-to-event survival analysis, were excluded. Similarly, immunologic clinical trials were rejected, 
because active immunotherapy aims to modify the presence or the composition of T lymphocyte 
subsets. We, however, were only interested in the prognostic relevance of TIL in the naturally 
occurring immunologic situation. Furthermore, we also excluded in vitro and animal studies.
Only studies in which intratumoral lymphocytes were quantified were included. The analysis of 
lymphocytes in tumor stroma was an exclusion criterion. This also applied to stromal lymphocytes 
combined with intratumoral lymphocytes (e.g. ‘tumor and surrounding stroma’). To be sure that 
the same definition of ‘intratumoral’ was used in all included papers, we excluded all studies in 
which the lymphocyte location was not clearly specified.  
We included studies in solid tumors of any kind. Haematological malignancies were excluded, 
because these are malignancies of the immune cells themselves. 
To increase the power of our analysis, it was decided to only include larger studies with N ≥ 100 
patients, to avoid publication bias that might exist among small studies. 
Finally, all included papers had to be published between January 2003 and February 2011 and 
written in English. In early 2003, the landmark paper by Zhang et al. was published (4). This paper 
subsequently inspired many authors to determine the prognostic significance of TIL in many types 
of cancer, and thereby formed a rational starting point for our literature search.
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Figure 1 shows a flowchart of the study selection process. The search yielded 2935 papers in 
Pubmed and 1026 papers in Embase, 584 of which were not found in Pubmed. Thus, 3519 unique 
papers were found. With the inclusion criteria mentioned above, the full text version of 106 papers 
was reviewed. Of these papers, another 54 were excluded because they did not fit the inclusion 
criteria. Specifically, four of these 54 were excluded due to the use of the same cohorts. Zlobec 
(10-12), Lugli (13), and Baker (14) et al. all used (selections of) the same cohort. One paper by 
Zlobec (12) was selected based on the reporting of hazard ratios and the use of the largest cohort. 
Papers by Milne (15) and Clarke (16) also stem from the same tissue microarray. Since Milne did 
not report hazard ratios, this paper was excluded, except in case of the FoxP3+ staining, which 
was not reported by Clarke. Finally, the cohorts used by Galon (6) and Pages (17) were the same. 
Pages’ paper was excluded, since only Galon’s paper enabled the estimation of HRs (see: Statistical 
analysis). Thus, 52 papers were included in the systematic review part of the study.
Data extraction
Data were extracted using a predefined form, recording: author, journal, year of publication, tumor 
type, lymphocyte subsets, location of lymphocytes, median follow-up time, scoring methods, cut-
offs for positive expression, number of TIL low and TIL high patients, outcome of univariate and/






























Figure 1 Flowchart of study selection process
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Unless indicated, we only report outcomes from the whole cohort included in these studies. 
Subgroup analyses are not specifically mentioned. Some studies were entirely performed in a 
subgroup of patients, for instance only in advanced stage patients. These studies are specified in 
the supplementary tables.  
The results from univariate Cox regression, i.e. hazard ratios (HRs) and 95% confidence intervals 
(CIs), were used for meta-analysis. For all lymphocyte ratios other than CD8/FoxP3, there were 
not enough studies available to perform meta-analysis. Therefore, all studies which only reported 
only these lymphocyte ratios, and not the results from the lymphocyte subsets on their own, were 
excluded from meta-analysis (18-20). 
Thus, we attempted to perform meta-analysis on 49 studies, which requires HRs and 95% CIs 
from univariate Cox regression analysis. Nine of these 49 papers reported HRs and 95% CIs for all 
stainings (7;12;21-27). Three papers only reported some stainings (16;28;29) and in two papers 
only stratified or subgroup analyses were mentioned (30;31). 35 papers did not report any HRs 
and CIs for progression or survival (4-6;15;32-62). The authors of 40 papers with (partially) missing 
data were contacted, but we were unable to trace three authors (37;39;62). Fifteen authors very 
kindly sent us the requested data (5;15;16;28;40-43;47;50;52-54;60;61). For the remaining studies, 
estimations of hazard ratios and 95% confidence intervals were attempted using the spreadsheet 
provided by Tierney et al. (63). This was successful in eight cases (4;6;29;35;38;46;51;59). In cases 
with partially missing data, the available data were used (30;31). Finally, fifteen studies for which 
no hazard ratios and confidence intervals could be obtained, were excluded from meta-analysis and 
only included in the systematic review part of this paper (32-34;36;37;39;44;45;48;49;55-58;62). 
Thus, ultimately 34/49 studies were included in the meta-analysis part of this study.
Assessment of study quality
Study quality was assessed using the predefined form by De Graeff (64), which was adapted from 
Hayes (65) and McShane (66). Briefly, the following criteria were scored: 1) are in- and exclusion 
criteria defined, 2) is the study prospective or retrospective, 3) are the clinical and pathological 
characteristics of the patients sufficiently described, 4) is the method used sufficiently described, 
5) is the outcome measure defined, 6) is the follow-up time recorded, and 7) does the study 
report the number of patients lost to follow-up or otherwise unavailable for statistical analysis 
(Supplementary table 1). Since this quality score is not validated, we did not exclude studies based 
on a low score.
Statistical analysis
All calculations were performed with HRs defined as the risk of death or progression for high TIL 
versus low TIL tumors. In studies which reported HRs for low TIL versus high TIL, the reciprocal of 
the HRs and CIs was taken to calculate the results the other way around.
Meta-analysis is generally performed with the natural logarithm of the HR and its standard error, to 
make the range of HRs symmetrical. After log transformation, a HR of 0 becomes minus infinity, a 
HR of 1 becomes 0, and a HR of infinity remains infinity (67). We calculated the log hazard ratio and 
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associated standard errors using the spreadsheet provided by Tierney et al. (63). 
Next, meta-analysis was performed with the DerSimonian Laird model for random effects, using the 
inverse of variance as a weighing factor. All analyses were stratified by T lymphocyte subset. The I2 
statistic was used to evaluate heterogeneity. A value >50% on the scale of 0-100% was considered 
to indicate substantial heterogeneity between studies. Funnel plots were constructed to assess 
publication and/or selection bias. 
The studies in this systematic review and meta-analysis vary widely with regard to methodology. 
We wondered whether these differences would affect study outcomes. Additionally, we wanted to 
identify sources of heterogeneity which appeared in pooled analyses. Therefore, stratified analyses 
were performed for CD3+ and CD8+, because these subsets were investigated in the largest 
number of studies. All stratified analyses were carried out with overall survival only to increase 
uniformity. Differences between strata were assessed using the test for subgroup differences in 
Review Manager.
All analyses were performed using SPSS version 16.0 (SPSS, Chicago, IL, USA) and Review Manager 
version 5.0 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark). 
Results
Study characteristics
The 52 studies had a median quality score of 5 out of 8 (range: 3-8) and consisted of a median of 
160 patients (range: 100-1290), with a median follow-up of 47 months (range: 20-228), and were 
published in journals with a median impact factor of 5.07 (range: 1.15-47.05). All studies used 
immunohistochemistry as method for detecting TIL. 
Table 1 summarizes some important study characteristics. Most studies were performed in ovarian 
cancer, but studies in colorectal cancer (CRC) contained most patients. CD8+ was by far the most 
popular lymphocyte marker, since it was quantified in 73.3% of patients. Most studies used whole 
tissue slides to evaluate TIL, but studies in which tissue microarrays (TMA) were used, included 
more patients. This is consistent with the fact that TMAs are especially suited for high throughput 
analysis. Finally, counting TIL in representative areas of tumor was more popular than specifically 
selecting hotspots with highest infiltration rates.
Pooled analysis
We performed meta-analysis under the assumption of homogeneity, stratified by T lymphocyte 
subset. For CD3+, a general T lymphocyte marker, the results are shown in figure 2. The pooled HR 
and CI for overall and progression free survival are very similar, both pointing to a survival advantage 
associated with presence of TIL (HR 0.58, 95% CI of 0.43-0.78 for death, HR 0.53, 95% CI 0.39-0.73 
for progression). Only two studies used disease specific survival, with opposing results. However, 
there is a considerable degree of heterogeneity in the analyses, as well as slight asymmetry in the 
funnel plots (figure 5A). Eight studies could not be included in meta-analysis, because no HRs and 
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Figure 2 Forest plots of studies on CD3+ TIL. Hazard ratios (HRs) and 95% confidence intervals (CIs) from in-
dividual studies are depicted as squares and horizontal lines, respectively. The pooled estimate is shown as a 
diamond shape, where center represents the pooled HR and the horizontal borders represent the 95% CI. HRs 
are defined as high CD3 versus low CD3 counts, therefore a hazard ratio <1 represents a lower risk of death or 
progression associated with high CD3 counts. 
CIs were reported (Supplementary table 1, (32-34;36;55;57;58;62)). Three studies found significant 
positive influence of CD3+ TIL on overall survival (58), disease specific survival (55) and disease 
free survival (32), but four found no effect on overall survival (33;34;36;62). Of these four, two 
did find that progression free or disease free survival improved with CD3+ infiltration (33;36). The 
remaining study describes beneficial effects of CD3+ TIL on disease free survival, but not on overall 
survival (57). 
For CD8+, 23 studies were included in meta-analysis. The presence of CD8+ results in prognostic 
advantages for all survival endpoints tested (figure 3). Again, there was a considerable amount 
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Figure 3 Forest plots of studies on CD8+ TIL. Hazard ratios (HRs) and 95% confidence intervals (CIs) for death 
or progression associated with high versus low CD8 counts
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of heterogeneity present, but the funnel plot was more symmetric (figure 5B). Of the eight 
studies that could not be included in meta-analysis, seven reported improved overall survival 
(32;36;37;44;45;57;62). One study found a negative effect of CD8+ TIL on survival, but this did not 
reach statistical significance in multivariate analysis (39).
Meta-analysis of the six studies reporting overall survival in CD4+ revealed a pooled HR of 0.82, with 
a 95% CI of 0.69-0.98, which is statistically significant (p=0.03, data not shown). Heterogeneity was 
0%. Progression free survival (21;23;24) and disease specific survival (38;54) were not influenced 
by CD4+ TIL in pooled analysis (data not shown). Four papers were excluded from pooled analysis 
because Cox regression analysis was not performed. One of these report improved overall survival 
(37), but three other papers do not find a statistical significant effect of CD4+ TIL (28;36;39) 
(Supplementary table 3). 
FoxP3+ is a relatively selective Treg marker (68) and was used in all 22 studies we included. 
Surprisingly, meta-analysis on 18 of these showed no statistically significant impact on overall, 
disease specific, or progression free survival (figure 4). Heterogeneity was present, and the funnel 
plot was slightly asymmetric (figure 5C). Four studies were excluded from meta-analysis, two of 
these found no prognostic significance of Treg (34;48), while the remaining studies showed that 
Treg infiltration was associated with improved survival (49) and reduced relapse free survival (56).
Six studies have examined both CD4+ and FoxP3+ (7;21;23;26-28). Jordanova (28) and Gao (21) et 
Table 1 Characteristics of the included studies
Number of studies Number of patients
Types of cancer
   Ovarian 14 (26.9%) 2574 (20.7%)
   Colorectal 10 (19.2%) 3984 (32.0%)
   Lung 7 (13.5%) 2328 (18.7%)
   Hepatocellular 5 (9.6%) 909 (7.3%)
   Renal cell 3 (5.8%) 416 (3.3%)
   Other 13 (25.0%) 2234 (18.0%)
Types of lymphocytes*
   CD3+ 22 (20.0%) 4678 (37.6%)
   CD4+ 15 (13.6%) 2707 (21.8%)
   CD8+ 32 (29.1%) 9126 (73.3%)
   FoxP3+ 23 (20.9%) 4786 (38.5%)
   Ratios 18 (16.3%) 3017 (24.2%)
Type of tissue analyzed
   Tissue microarray 20 (38.5%) 6487 (52.1%)
   Whole tissue slides 32 (61.5%) 5958 (47.9%)
Areas of scoring
   Hotspots 15 (28.8%) 2651 (21.3%)
   Representative areas 37 (71.2%) 9794 (78.7%)
* Total percentage is >100% since most studies included >1 lymphocyte subset, percentage of total numbers 
of studies and total number of patients included
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Figure 4 Forest plots of studies on FoxP3+ TIL. Hazard ratios (HRs) and 95% confidence intervals (CIs) for death 
or progression associated with high versus low FoxP3 counts
al. found a no effect of CD4+, but a negative effect of FoxP3+ in univariate analysis in cervical and 
hepatocellular cancer, respectively. However, only Jordanova performed multivariate analysis, in 
which this effect did not hold. The remaining studies  et al. observe a prognostic effect of neither 
CD4+ nor FoxP3+ in esophageal, gastric, ovarian and renal cell cancer (7;23;26;27). 
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Stratified analysis
In case of CD3+, the pooled results from the seven smallest studies were strongly significant, while 
this was not the case with four larger studies (table 2). Similarly, studies with a shorter follow-up 
and high quality score showed a statistically significant pooled result, while this was not the case for 
those with a long follow-up or a low quality score. However, follow-up duration was not reported 
in all studies. Interestingly, the choice of tissue type also appeared to be influential. Using whole 
tissue slides as opposed to a TMA resulted in a lower pooled HR. Stratifying for tumor type was not 
entirely feasible, due to insufficient studies in similar cancer types. However, when comparing the 
two most popular malignancies, there were no significant differences between results in ovarian 
and colorectal cancer. Overall, heterogeneity was not decreased by performing stratified analysis, 
and is therefore from thus far unknown origins. 
For CD8+, the beneficial prognostic significance of CD8+ infiltration was more pronounced in studies 
with fewer patients and shorter median follow-up time. Again, ovarian and colorectal cancer were 
the most frequently used types of cancer, both with similar outcomes. Heterogeneity seemed to 
be especially affected by study size and follow-up duration, but the latter is probably influenced by 
the exclusion from this analysis of four studies which did not report follow up. 
Ratios between T-lymphocyte subsets
Relatively few studies incorporated T-lymphocyte ratios. Moreover, the use of different survival 
outcomes (overall, disease specific, disease free, and relapse free survival) decreased the potential 
for pooled analysis even further. Therefore, pooled analysis was only possible for the CD8/FoxP3 
ratio. 
Pooled analysis for the six studies reporting overall survival based on CD8/FoxP3 ratios was strongly 
significant with relatively low heterogeneity (HR 0.48, 95% CI 0.34-0.68, p<0.0001, I2=49% ) (7;26-
28;60;61). Furthermore, two studies report positive effects of a high CD8/FoxP3 ratio on disease 
specific (5;42) and progression free survival (42;61). 
In three studies, the CD3+/CD8+ ratio was used, but each used a different interpretation of this 
ratio. Han et al. (18) found an independent positive effect of either CD3+ or CD8+ compared to no 
CD3+ or CD8+ in ovarian cancer. In gastric cancer, Lee et al. (22) observed that high numbers of both 
CD3+ and CD8+ are favorable compared to low numbers of both cell types. Finally, Kobayashi (20) 
found that high numbers of CD8+ compared to CD3+ was not a prognostic factor in hepatocellular 
cancer. Naturally, for this ratio it is important to keep in mind that most CD8+ cytotoxic lymphocytes 
are also CD3+. 
The CD8+/CD4+ ratio was used in three studies (7;26;28), and found to be a positive prognostic 
predictor in one of these (7). Importantly, the CD4+ component also contains Treg. Thus, this ratio 
is more difficult to interpret than the CD8+/FoxP3+ ratio, since the CD4+ population can be very 
mixed. 
The FoxP3+/CD3+ and FoxP3+/CD4+ ratio were used in respectively one (29) and two (19;20) 
studies. All three studies found a negative prognostic effect associated with FoxP3+ preponderance.
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Discussion
Quantifying TIL by histopathology is a frequently used approach to gain insight in the immunologic 
activity against tumors. In this systematic review and meta-analysis, we analyzed larger studies of 
recent years to determine which similarities and differences exist between their results. 
CD3+ and CD8+ TIL turned out to have a positive effect on prognosis in meta-analysis, with HRs of 
respectively 0.58 (95% CI 0.43-0.78) and 0.71 (95% CI 0.62-0.82) for death from all causes. CD4+ TIL 
were associated with a slightly improved overall survival (HR 0.82, 95% CI 0.69-0.98) but its FoxP3+ 
regulatory subset not associated with overall survival (HR 1.19, 95% CI 0.84-1.67). All in all, these 
HRs represent statistically significant, but not dramatic differences in survival. The CD8/FoxP3 ratio 
produced a more impressive HR (risk of death: HR 0.48, 95% CI 0.34-0.68) but was used in relatively 
few studies. These results underline the need to examine FoxP3 and CD8 together. 
We performed this meta-analysis assuming that the prognostic effect of TIL would not differ greatly 
between types of cancer. We considered it unlikely that TIL infiltration strongly improves prognosis 
in one type of cancer, but has the complete opposite effect in another. However, clinicopathologic 
factors might affect the impact of TIL on prognosis, i.e. HRs moving closer to (but not crossing) 1 
in high stage or grade. We attempted to test this hypothesis post hoc in stratified analysis. These 
analyses were limited by the fact that sufficient numbers of studies were only available for ovarian 
and colorectal cancer. For these tumor types, we found no significant differences between pooled 
outcomes. Moreover, heterogeneity was not clearly affected. This indicates that the prognostic 
effect of CD3+ and CD8+ TIL are similar in ovarian and colorectal cancer and that heterogeneity in 
pooled analysis was caused by factors other than tumor type. 
Furthermore, stratified analysis provided some hints that methodological aspects such as sample 
size and follow-up time may have influenced outcomes of studies on CD3+ and CD8+ TIL. For 
CD3+ and CD8+ TIL, smaller studies produced more dramatic HRs than larger studies. Additionally, 
studies with a longer follow-up time were less likely to produce statistically significant results. 
Unfortunately, since not all studies report median follow-up times, these results are tentative. 
Differences in significant results based on sample size or follow up time may be caused by 
publication bias. This can be detected by funnel plots, but these are relatively crude and have a 
tendency for false-positivity. In our case, the funnel plots should be interpreted with caution since 
the number of studies in our meta-analysis is relatively small and consist of different populations 
(69). This means that the asymmetry may not just be caused by publication or selection bias, but 
also by inherent differences in study populations (69). Thus, although some asymmetry seemed to 
be present, we cannot conclude with certainty whether publication bias was an issue. 
In addition to the factors we tested in subgroup analysis, the determination of cutoff points also 
differed widely. Some studies use percentiles, tertiles or the median, while others use absence 
versus presence, the minimal p-value approach, or do not report a cutoff point at all. All studies 
used immunohistochemistry, which is notorious for its variability due to factors related to staining 
protocols or tissue fixation techniques. It is an attractive technique to use as primary screening, but 
the next step should be to validate the results in other models.
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These results raise the question whether biology or methodology is the source of the observed 
prognostic effects of TIL on survival. Biological support can be gained from studies into T 
lymphocyte kinetics, which offer a more detailed perspective. It has been shown that immune cells 
can proliferate in vitro in response to tumor specific antigens, and that the influx of immune cells 
into a tumor results in the induction of an inflammatory microenvironment (reviewed in (2;70)). 
Murine studies also demonstrated the potency of the immune system, when adoptive transfer of 
tumor specific CD8+ T lymphocytes resulted in complete eradication or regression of established 
tumors (71-74). Also, the increase in cancer risk seen after solid organ transplantation, when 
immunosuppressive drugs are used, suggests a prominent role for immune surveillance (2). 
Nonetheless, several biological mechanisms may at the same time prevent antitumor responses 
of TIL. For instance, lymphocytes present in the tumor might not always be active, due to immune 
escape or tolerance. Alternatively, the immune response may be skewed towards relatively 
ineffective Th2 or Treg responses. TIL may also be properly activated, but simply out of their league 
because of the speed of tumor growth. However, these hypotheses cannot be fully investigated in 
immunohistochemical studies. Some attempts at a more functional perspective have been made 
by staining for activation markers on lymphocytes such as Granzyme-B (21;75), CD25 (76), OX40 
(CD134) (76) and CD69 (77), or inhibiting co-stimulatory molecules such as PD-1 (78) and its ligand 
B7-H1 (79;80). These observations may provide a more precise view, but relatively few studies 
have used these markers. Moreover, more in vitro and animal based studies are still required to 
understand the exact dynamics.
Most likely, methodological aspects have had an effect on the magnitude of the effect seen in 
some studies, or on their likelihood to be published, but they are not solely responsible for study 
outcome. This is especially likely in the presence of evidence from in vitro and mouse studies, in 
which T lymphocytes are not evaluated on a statistical, but on a mechanical level. Nonetheless, 
the importance of differences in methodology and/or reporting was highlighted by Altman (81) 
and McShane et al. (66). They proposed guidelines for the reporting of prognostic marker studies, 
to encourage transparent reporting and to assist the reader in judging study quality (66). We used 
these guidelines in an adapted form  to assess study quality (64). Using these criteria, we observed 
that 19/52 studies (36.5%) failed to adequately report follow-up time and 22/52 (42.3%) not report 
clear in- and exclusion criteria. Importantly, only one of the included studies reached the maximum 
score of 8 points (31), mainly because all but two studies (29;31) were retrospective. Hoppin et al. 
(82) described nicely how retrospective tissue based studies can lead to bias, since the availability 
of tumor specimens in pathology archives may depend on a wide variety of factors such as patient 
age, tumor size, tumor grade and hospital in which the patient was diagnosed. An alternative to 
prospective studies is the structured collection of specimens from all patients and all hospitals 
in a region, and a very thorough description of patient demographics to analyze potential bias 
afterwards.
Our systematic review has some limitations of its own, inherent to its design. We included a very 
heterogeneous group of studies, consisting of many different types of cancer, different patient 
selection criteria and different types of methodology. As mentioned above, we felt it was justified 
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to pool them anyway, because we expected the biological actions of TIL to be independent of 
tumor type. Nonetheless, the effect size that TIL might have in terms of prolonging survival, is 
undoubtedly related to clinicopathological factors such as differentiation grade. These interactions 
can be corrected for in multivariate analyses. However, multivariate analysis is not suitable for 
pooled analysis, because the covariates used in multivariate analysis vary between studies, and 
because their outcomes cannot be estimated based on other data in the paper. 
Another limitation is that many studies had to be excluded from meta-analysis because they did 
not report HRs and CIs, but only Kaplan Meier curves and log rank tests. Only 9/49 (18.4%) reported 
HRs and CIs for some or all stainings. We managed to reduce the missing data by contacting authors, 
and by estimating outcome with the help of a spreadsheet (63). The latter may have introduced 
some imprecision, but we felt this was a risk worth taking in view of the alternative, i.e. excluding 
the studies. This highlights the importance of a uniform reporting of study outcomes and follow 
up time. 
A final limitation is our use of strict inclusion criteria, which resulted in exclusion of smaller studies. 
This was intended to eliminate studies with little precision, but thereby also reduced the number 
of studies included in this meta-analysis because small studies are published relatively frequently. 
Hence, stratified analysis was not possible for all TIL subsets. Moreover, stratified analyses were 
performed in relatively limited numbers of studies. The results from these analyses should therefore 
not be interpreted strictly based on their numerical outcome, but rather as general suggestions for 
designing future studies.
In conclusion, we found evidence that TIL moderately influence prognosis, but this influence is 
more pronounced in studies incorporating lymphocyte ratios. However, the exact magnitude of TIL 
on prognosis remains somewhat mysterious due to methodological factors. Improving study quality 
is an essential step toward uncovering the real clinical relevance of TIL. Moreover, just quantifying 
TIL may not take the dynamics of the tumor microenvironment into account. Any future studies 
should have a very strict design, with large sample sizes to increase statistical power, a uniform way 
of analyzing survival outcomes, and a long and specified follow-up period. 
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Abstract
Purpose: Ovarian cancer patients with intra-tumoural CD3+ T-lymphocytes in primary tumour 
tissue have a better prognosis. This study aims to analyze the presence and relative influence of 
three important T-lymphocyte subsets, tumour-infiltrating CD8+ cytotoxic T lymphocytes (CTL), 
CD45R0+ memory T-lymphocytes and FoxP3+ regulatory T-lymphocytes (Treg), in primary tumour 
tissue and omental metastases of patients with ovarian cancer.
Experimental Design: The number of CD8+, CD45R0+ and FoxP3+ T-lymphocytes was determined 
by immunohistochemistry on a tissue micro array containing ovarian tumour tissue and/or omental 
metastases obtained at primary debulking surgery from 306 FIGO stage I-IV ovarian cancer patients. 
Immunohistochemistry data were correlated to clinicopathological parameters and survival data.
Results: High number of CD8+ CTL and a high CD8+/FoxP3+ ratio in ovarian-derived tumour tissue 
were associated with increased disease specific survival and proved to be independent prognostic 
factors in multivariate analyses. In advanced stage patients, the presence of CD8+ CTL, CD45R0+ 
memory T-lymphocytes, FoxP3+ Treg or a high CD8+/FoxP3+ ratio in ovarian-derived tumour tissue 
was associated with an increased disease-specific survival in univariate analysis, as was the presence 
of CD45R0+ memory T-lymphocytes and FoxP3+ Treg in omental metastases. Furthermore, in 
advanced stage patients CD8+ cytotoxic and FoxP3+ regulatory T-lymphocytes infiltrating ovarian-
derived tumour tissue were independent predictors of increased prognosis.  
Conclusions: T-lymphocytes infiltrating primary and metastatic ovarian cancer sites are associated 
with improved prognosis. These associations are especially distinct in advanced stage patients, 
underlining the potential for immunotherapy as a broadly applicable therapeutic strategy.
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Introduction
Ovarian cancer is the most frequent cause of death from gynaecological malignancies, with an 
overall mortality of 60%. Due to its lack of specific symptoms, 70% of patients present with advanced 
disease. Initial treatment consists of cytoreductive surgery and platinum based chemotherapy. 
Even when initial treatment is successful, many patients relapse. There is no curative secondary 
treatment in case of residual disease after chemotherapy or relapse (1;2). Therefore, new 
therapeutic strategies are under investigation (3). Immunotherapy is one of these strategies and 
has yielded especially promising results in fundamental and animal research. However, clinical 
applications have only shown limited efficacy. Further knowledge is necessary to develop strategies 
to increase clinical efficacy of immunotherapy. 
Tumour-infiltrating lymphocytes (TIL) were found to correlate with improved prognosis in several 
types of cancer, among which ovarian cancer (4-9). The presence of TIL is considered a reflection 
of the immune response to the tumour. However, not all T-lymphocyte subsets contribute 
equally to this observed positive effect on prognosis. Invasion by cytotoxic T lymphocytes (CTL) 
has been found to be advantageous in ovarian cancer (7) and several other types of cancer (10-
13). The role of CD4+ T lymphocytes is ambiguous. Non-regulatory CD4+ helper T lymphocytes, 
especially of the Th1 subset, are considered to be beneficial in cancer in general (14). Regulatory 
CD4+ T-lymphocytes (Treg) have a physiological function in preventing autoimmunity. They 
may induce peripheral tolerance, and, in doing so, suppress immune responses. In cancer, Treg 
traffic to tumours as a result of chemokines produced by tumour cells and micro-environmental 
macrophages (15). There, they suppress effector T-lymphocytes by secreting transforming growth 
factor β (TGF-β) and interleukin 10 (IL-10) or by direct cell-cell contact (15). Treg have been found 
to unfavourably influence prognosis in ovarian cancer (15;16). From a functional point of view, the 
ratio between effector T-lymphocytes and regulatory T-lymphocytes may be even more interesting, 
as was demonstrated by Sato et al. (7) who showed that high ratios of CTL/helper T-lymphocytes 
and CTL/Treg were of prognostic significance, whereas no significant association between the 
number of tumour infiltrating T-lymphocytes in general or subsets (Treg / helper T-lymphocytes) 
and overall survival were found in ovarian cancer. A less well studied T-lymphocyte subset are 
memory T-lymphocytes, which may arise after the initial immune response against an antigen. In 
cancer, memory T-lymphocytes mediate long-term immunity against tumours (17). The presence 
of intra-tumoural memory T-lymphocytes is associated with increased survival in hepatocellular 
(18) and colorectal cancer (5;17). To our knowledge, no studies have been published investigating 
the presence of memory T-lymphocytes in ovarian cancer. In summary, patients with tumour-
infiltrating T-lymphocytes mount an immune response against their tumour, the success of which 
seems to depend on the relative concentrations of different T-cell subtypes.
No reports have been published describing possible differences in T-lymphocyte infiltration patterns 
between primary tumour sites and metastases. The omentum is a frequent site for metastases in 
ovarian cancer, due to the displacement of tumour cells by the peritoneal fluid stream. We decided 
to study the presence of infiltrating T-lymphocytes in omental metastases, which was greatly 
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facilitated by the fact that omentectomy is a routine part of cytoreductive surgery. We compared 
the results with infiltrating T-lymphocytes in tissue, taken from the primary ovarian tumour. 
Aims of the present study were to determine the presence of CD8+ CTL, CD45R0+ memory 
T-lymphocytes and FoxP3+ Treg in primary tumour specimens and simultaneous omental 
metastases of patients with ovarian cancer and to determine their prognostic impact.
Methods
Patients
As of 1985 the Department of Gynaecological Oncology at the University Medical Center Groningen 
(UMCG) keeps a computerized database of patients with malignant epithelial ovarian cancer 
treated at this hospital at any time point during the course of their disease, prospectively collecting 
information on clinicopathological characteristics and follow-up. 
For this study, ovarian cancer patients were selected if primary surgery was performed by a 
gynaecological oncologist from the UMCG between May 1985 and June 2006 and if paraffin-
embedded ovarian and omental tumour tissue was available. 
Patients were staged according to FIGO classification (19). Tumours were graded and classified 
according to WHO criteria by a gynaecological pathologist (20). Adjuvant chemotherapy consisted 
of different platinum-based treatment regimens. Response to chemotherapy was evaluated 
according to WHO criteria (21). After treatment, patients were followed-up for at least 10 years 
with gradually increasing intervals. Follow-up data were completed for all patients until January 
2007. 
Institutional Review Board Approval
For the present study, all relevant data were retrieved from our computerized database into a 
separate anonymous database. In this separate, password-protected database, patient identity 
was protected by study-specific, unique patient codes, which were only known to two dedicated 
data managers, who also have daily responsibility for the larger database. In case of uncertainties 
with respect to clinicopathological and follow-up data, the larger databases could only be checked 
through the data managers, thereby ascertaining the protection of patients’ identity. According to 
Dutch law no approval from our IRB was needed.
Tissue microarrays
Tissue microarrays (TMAs) were constructed as described in previous studies (22;23). In 
brief, paraffin-embedded tissue blocks containing tumour in ovarian and omental tissue, and 
corresponding haematoxylin & eosin (H&E) stained slides were retrieved from the pathology 
archives. Representative areas of tumour were marked on the H&E stained slides. Next, using 
these H&E slides for reference, four 0.6 mm core biopsies were taken from each tumour specimen 
and arrayed on a recipient paraffin block using a tissue microarrayer (Beecher instruments, Silver 
47
3
Prognostic significance of tumor-infiltrating T-lymphocytes in primary 
and metastatic lesions of advanced stage ovarian cancer
Spring, Maryland, USA). Adhesion of cores to the recipient block was accomplished by placing the 
blocks in a 37oC oven for 15 min. For staining, 4μm sections were cut from each TMA block. H&E 
staining was performed to verify the presence of tumour in the arrayed samples.
Immunohistochemistry
TMA sections were stained with mouse monoclonal antibodies recognizing CTL (anti-CD8; Dako 
cytomation, Glostrup, Denmark), memory T-lymphocytes (anti-CD45R0 clone OPD4; Labvision, 
Fremont CA, USA) and Treg (anti-FoxP3 m22509, Abcam, Cambridge, UK). In brief, TMA sections 
were dewaxed in xylene and rehydrated using graded concentrations of ethanol to distilled water. 
After antigen retrieval, endogenous peroxidase activity was blocked by submersion of sections 
in a 0.3% H2O2 solution for 30 min. Sections were incubated with the primary antibody for 60 
min at room temperature (dilutions: anti-CD8 1:20; anti-CD45R0 1:50; anti-FoxP3 1:100). Sections 
incubated with anti-CD45R0 and anti-FoxP3 were subsequently incubated with DAKO Envision+ for 
30 min. For sections incubated with anti-CD8, RAMpo (dilution 1:100) and GARpo (dilution 1:100) 
were used as secondary and tertiary antibodies respectively. The antigen-antibody reactions were 
visualized with 3,3’-diaminobenzidine or NovaRED™ (Vector Laboratories, Burlingame) for anti-
FoxP3 staining. Sections were counterstained with haematoxylin.
Figure 1 Immunohistochemical staining of tumor-infiltrating T-lymphocytes in ovarian cancer tissue. A. Flow 
diagram showing the type of tissue analyzed and the percentage of patients lost from analysis. Patients were 
excluded from analysis when less than two tissue cores with at least 20% tumor were present for evaluation. B. 
Intra-tumoral CD8+ T-lymphocytes, C. CD45R0+ T-lymphocytes, D. FoxP3+ T-lymphocytes at 400x magnification.
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Table 1  Clinicopathological characteristics and survival data





Mean (SD) 57.2 (13.5) 56.8 (13.8) 59.6 (12.2)
DSS (months)







Stage I 67 (21.9%) 67 (24.8%)
Stage II 24 (7.8%) 25 (9.3%)
Stage III 171 (55.9%) 145 (53.7%) 116 (78.9%)
Stage IV 42 (13.7%) 32 (11.9%) 30 (20.4%)
Missing 2 (0.7%) 1 (0.4%) 1 (0.7%)
Tumour type
Serous 171 (55.9%) 147 (54.4%) 105 (71.4%)
Mucinous 36 (11.8%) 35 (13.0%) 6 (4.1%)
Endometroid 41 (13.4%) 38 (14.1%) 13 (8.8%)
Clear Cell 21 (6.9%) 18 (6.7%) 7 (4.8%)
Adenocarcinoma 13 (4.2%) 10 (3.7%) 5 (3.4%)
Mixed Tumours 15 (4.9%) 14 (5.2%) 5 (3.4%)
Other 9 (2.9%) 8 (3.0%) 6 (4.1%)
Tumour Grade 
Grade I 52 (17.0%) 51 (18.9%) 6 (4.1%)
Grade II 80 (26.1%) 76 (28.1%) 28 (19.0%)
Grade III 135 (44.1%) 113 (41.9%) 91 (61.9%)
Undifferentiated 14 (4.6%) 11 (4.1%) 9 (6.1%)
Missing 25 (8.2%) 19 (7.0%) 13 (8.8%)
Residual disease
< 2 cm 162 (52.9%) 157 (58.1%) 47 (32.0%)
>= 2 cm 123 (40.2%) 92 (34.1%) 94 (63.9%)
Missing 21 (6.9%) 21 (7.8%) 6 (4.1%)
Chemotherapy
No chemotherapy 42 (13.7%) 40 (14.8%) 12 (8.2%)
Platinum-based 117 (38.2%) 104 (38.5%) 48 (32.7%)
Platinum & taxane based 113 (36.9%) 96 (35.6%) 69 (46.9%)
Other regimen 27 (8.8%) 24 (8.9%) 16 (10.9%)
Unknown 7 (2.3%) 6 (2.2%) 2 (1.4%)
DSS = disease-specific survival; FIGO = International Federation of Gynaecology and Obstetrics.
Scoring
All stainings were scored independently by two observers. Observers had no prior knowledge of 
clinicopathological information. For the anti-CD8 and anti-CD45R0 staining, the number of cells 
with membrane staining within tumour epithelium was counted for each core. For the anti-FoxP3 
staining, the number of cells with nuclear staining within tumour-islets in every core was counted. 
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To obtain a high concordance rate with whole tissue slides, we decided that minimally two cores 
with a minimum of 20% tumour tissue had to be present on the TMA for a sample to be entered 
into analysis (23). Subsequently, we calculated the number of intra-tumoural cells per 0,283 mm2 
of tumour (i.e. one whole core consisting of 100% tumour tissue), to correct for differences in the 
amount of tumour tissue and to standardize the analysis. This calculation entailed dividing the 
total number of intra-tumoural cells in cores containing ≥20% of tumour by the total percentage of 
tumour tissue present in these cores.
Statistics
The distribution of all TIL subtypes was positively skewed. For further analysis, we therefore 
decided to categorize patients using the bottom tertile (p33) as a cut-off value (7). However, when 
the bottom tertile equalled zero, a subdivision based on the presence or absence of these cells 
was made for further analysis. Associations between clinicopathological characteristics and intra-
tumoural T-lymphocytes were tested using the χ2 test. Differences in numbers of tumour-infiltrating 
T-lymphocytes between primary ovarian tumour tissue and omental metastases were tested using 
Wilcoxon Signed Ranks test. Disease-specific survival (DSS) was defined as date of surgery until 
death due to ovarian cancer or date of last follow-up. DSS was estimated using Kaplan Meier and 
Log Rank test was used to assess for survival differences between groups. Cox proportional hazards 
models were used for multivariate analyses and were stratified for type of chemotherapy. Only 
variables that were significantly associated with DSS in the univariate analyses were entered into 
multivariate analyses. Survival analyses were performed in the total population as well as in a 
subgroup which included all advanced stage patients. For all tests, p-values <0.05 were considered 
significant. All p-values were tested two-sided. All statistical analyses were performed using SPSS 
14.0 software package for windows (SPSS Inc., Chicago, IL, USA).
Results
Study population
From a total of 306 ovarian cancer patients, sufficient paraffin-embedded ovarian and/or omental 
tissue containing epithelial ovarian carcinoma was available for construction of the TMA (figure 
1a). Tumour-containing ovarian tissue was available from 270 patients. From 111 (41.1%) of these 
patients tumour-containing omental tissue was also available. Only tumour-containing omental 
tissue was available from an additional 36 patients. Clinicopathological characteristics of patients 
are summarized in Table 1. Forty-two patients did not receive chemotherapy, 28 of whom were 
diagnosed with FIGO stage I disease. The remaining 14 patients were either not fit or unwilling 
to receive chemotherapy. Of the patients treated with chemotherapy 89.5% received a platinum-
based regimen. The median survival for all patients was 37.4 months with an estimated 5-year 
disease specific survival of 41%. 
50
Prognostic significance of tumor-infiltrating T-lymphocytes in primary 





































































































































































































































































































































































































































































































































































































































































































































































































Prognostic significance of tumor-infiltrating T-lymphocytes in primary 
and metastatic lesions of advanced stage ovarian cancer
Tumour-infiltrating T-lymphocytes
Intra-tumoural CD8+, CD45R0+ and FoxP3+ T-cells were present in 91.2%, 47.0% and 53.2% of 
primary ovarian tissue, respectively (representative examples in figure 1b-d), while intra-tumoural 
CD8+, CD45R0+ and FoxP3+ T-cells were present in 96.2%, 49.3% and 73.1% of omental metastases, 
respectively. 
In both ovarian and omental derived tumour tissue, the number of tumour-infiltrating T-lymphocytes 
was positively associated with each other for all subtypes (Tables 2 and 3). Although the median 
number of tumour-infiltrating T-lymphocytes was higher for omental than ovarian tissue, no 
differences in intra-tumoural T-lymphocytes were observed between ovarian and omental tumour 
tissue within patients for whom both samples were available (data not shown).
Association of tumour-infiltrating lymphocytes with clinicopathological parameters
Table 2 and 3 show the relationship of clinicopathological parameters to the presence of intra-
tumoural TIL in ovary and omentum derived tumour tissue respectively. In ovarian tissue, the 
presence of FoxP3+ cells was positively associated with advanced stage disease (p=0.031). 
Furthermore, patients with poorly differentiated tumours were more likely to have intra-tumoural 
FoxP3+ cells compared to patients with well-differentiated tumours (p=0.011). Also, patients 
younger than 59 years at time of diagnosis were more likely to have a low CD8+/CD45R0+ ratio 
than older patients (data not shown: 48.5% vs. 34.3%, p=0.036).
In omental metastases, high CD8+ T-cell numbers were associated with <2 cm residual disease after 
primary debulking surgery (p=0.035). A similar association was found for FoxP3+ cells, which were 
more often present in patients with residual disease of <2cm (p=0.028). 
Survival analysis
In agreement with expectations, well-known prognostic factors such as age ≥ 59 years, advanced 
stage disease, poorly differentiated tumours, serous tumours and ≥2 cm residual disease after 
primary debulking surgery were associated with a shorter disease specific survival (data not shown). 
Furthermore, univariate analysis of disease specific survival showed an initial survival advantage 
for patients with high numbers of intra-tumoural CD8+ cytotoxic T-lymphocytes in ovarian-derived 
tumour tissue, which subsides after 10 years of follow-up (p=0.042, figure 2a). Disease-specific 
survival was not influenced by the presence of CD45R0+ memory T-lymphocytes, FoxP3+ regulatory 
T-lymphocytes in ovarian tissue. However, median DSS of patients with a high CD8+/FoxP3+ ratio in 
ovarian-derived tumour tissue was twice as high as for patients with a low CD8+/FoxP3+ ratio (50.0 
vs. 23.0 months, p=0.014, figure 2b). For the CD8+/CD45R0+ ratio a trend was observed towards a 
longer median DSS in patients with a high ratio (51.7 vs. 30.9 months, p=0.056). 
We subsequently repeated univariate survival analyses using a subgroup consisting of patients with 
advanced stage disease. Interestingly, in this subgroup a prolonged median DSS was observed for 
all T-lymphocyte subsets studied in ovarian-derived tumour tissue, except for the CD8+/CD45R0+ 
ratio (30.5 vs. 15.6 months, p=0.076), i.e. CD45R0+ lymphocytes (n=155, 37.3 vs. 16.4 months, 
p=0.009, figure 2c), CD8+ lymphocytes (n=150, 30.3 vs. 12.2 months, p=0.012, figure 2d), FoxP3+ 
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lymphocytes (n=149, 30.3 vs. 14.0 months, p=0.008, figure 2e) and a high CD8+/FoxP3+ ratio 
(n=146, 30.3 vs. 14.6 months; p=0.016, figure 2f). Similarly, univariate analysis of disease-specific 
survival differences based on the presence of TIL in omental metastases, which are by definition 
present only in patients with advanced stage disease, showed an increased survival in patients 
with intra-tumoural FoxP3+ Treg (25.6 vs. 14.7 months, p<0.008, figure 2g) and CD45R0+ memory 
T-lymphocytes (24.3 vs. 15.6 months, p=0.031, figure 2h).
Multivariate analysis was performed stratified for type of chemotherapy. For all patients as well as 
the advanced stage subgroup, the above-mentioned well-known prognostic factors and tumour-
infiltrating T-lymphocytes were entered into the Cox proportional hazards model (table 4). In the 
analysis using all patients, CD8+ lymphocytes and CD8+/FoxP3+  ratio were independent prognostic 
factors for DSS (HR 0.36, 95% C.I. 0.22-0.59, p<0.001; resp. HR 0.53, 95%C.I. 0.32-0.85, p=0.009), 
next to commonly acknowledged risk factors as stage of disease, differentiation grade and amount 
of residual tumour after primary debulking surgery. When analyzing only patients with advanced 
stage disease, a high number of CD8+ cytotoxic T-lymphocytes in ovarian-derived tumour tissue 
was demonstrated to be an independent prognostic factor for longer DSS (HR 0.35, 95% C.I. 
0.21-0.60, p<0.001), as was the presence of FoxP3+ Treg (H.R. 0.55, 95%C.I. 0.34-0.88, p=0.013). 
Additionally, multivariate analysis was performed using the absolute number of tumour-infiltrating 
T-lymphocytes instead of the dichotomized variables (data not shown). Unlike CD8+ lymphocytes, 
FoxP3+ lymphocytes infiltrating tumour epithelium remained an independent factor for longer DSS 
(HR 0.937, 95%C.I. 0.88-1.00, p = 0.035). 
Discussion
The observation of an improved survival of patients with intra-tumoural T-lymphocytes suggests an 
important role for the immune system in the natural course of ovarian cancer (9). In the present 
study, we analyzed the relative contribution of different tumour-infiltrating T-lymphocyte subtypes 
to this observed improvement of survival. To our knowledge, this is the first study to examine the 
prognostic influence of different tumour-infiltrating T-lymphocytes in primary as well as metastatic 
lesions. We show improved disease-specific survival in advanced stage ovarian cancer patients with 
CD45R0+ memory T-lymphocytes and/or FoxP3+ regulatory T-lymphocytes infiltrating ovarian-
derived tumour tissue and/or omental metastases. In addition, we also confirm important previous 
observations by others of improved survival in patients with either a high number of tumour-
infiltrating CD8+ cytotoxic T-lymphocytes or a high CD8+/FoxP3+  ratio (7).
Intra-tumoural CD45R0+ T-lymphocytes, present in approximately 50% of patients, were associated 
with increased DSS when present in ovarian-derived tumour tissue and omental metastases. 
Although its expression is not restricted to memory T-lymphocytes, CD45R0 is commonly used as 
a marker for memory T-lymphocytes (5;17;24). Upon antigenic stimulation, naïve T-lymphocytes 
differentiate into effector T-lymphocytes, but also memory T-lymphocytes can be formed. The 
latter assure a strong and speedy immune response on subsequent exposures to the same antigen. 
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The presence of tissue-infiltrating memory T-lymphocytes thus implies prior exposure to an antigen 
encountered in the tissue environment, which in case of tumour-infiltrating memory T-lymphocytes 
may very well reflect an anti-tumour response of the immune system. The presence of a survival 
benefit for patients with high levels of infiltrating memory T-lymphocytes was previously described 
in colorectal cancer (5;17). The cell numbers seen in these studies were remarkably higher than 
those used in our study (cut-off values 80-250 cells/mm2), which may be explained in several ways. 
Firstly, no distinction was made between tumour- and peri-tumoural stroma infiltrating cells in 
these studies, whereas we only report tumour-infiltrating memory T-lymphocytes. Secondly, when 
Figure 2 Disease-specific survival (in months) of ovarian cancer patients based on tumor-infiltrating lympho-
cytes. Cumulative survival time was estimated by the Kaplan–Meier method. Log Rank test was used to evalu-
ate survival differences between groups. High numbers of CD8+ T-lymphocytes (a) and a high CD8+/Foxp3+ 
ratio (b) in ovarian derived tumor tissue were associated with improved survival in FIGO stage I–IV disease. In 
advanced stage patients, a survival benefit wasobserved for patients with CD45R0+ T-lymphocytes (c) CD8+ 
T-lymphocytes (d), FoxP3+ T-lymphocytes (e) a high CD8+/FoxP3+ ratio (f) in ovarian-derived tumor tissue. Fur-
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repeating our analysis on the total cell count/core we still did not observe levels similar to that in 
colorectal cancer, although results for the survival analysis were comparable to the analysis with 
tumour-infiltrating memory T-lymphocytes only (data not shown). A more likely explanation is that 
the higher number of infiltrating lymphocytes in colon tissue could be considered inherent to its 
daily exposure to foreign products and pathogens, an observation which does not hold for ovarian 
tissue.
Our data show that patients with intra-tumoural CTL infiltrations and/or a high CTL/Treg ratio 
in tumour-containing ovarian tissue consistently have the longest disease-specific survival, 
confirming the results previously described in a smaller population of ovarian cancer patients (7). 
However, unlike previous studies in ovarian cancer addressing the prognostic influence of Treg 
(7;15), we found tumour- infiltrating Treg to be an independent positive factor for disease-specific 
survival in patients with advanced stage disease. One possible explanation is the fact that although 
FoxP3 is currently the best marker available for immunohistochemical staining of Treg on paraffin 
embedded tissue, it is not exclusively expressed in regulatory cells. Recently, it was shown that 
activated CD4+CD25- effector T cells transiently express FoxP3, without having regulatory activity 
(25;26). Possibly, the positive prognostic effect of the presence of FoxP3+ cells in our samples can 
be attributed to the staining of not only suppressive, but also activated T-lymphocytes expressing 
FoxP3.  Similar observations of positive effects of Treg have however previously been reported 
in studies on immune cell malignancies and head and neck squamous cell carcinoma (HNSCC), 
some of which further phenotyped the FoxP3+ cells. A high number of Treg is associated to longer 
survival in follicular lymphoma and classic Hodgkin’s lymphoma (27;28). In HNSCC where higher 
numbers of circulating Treg were present in patients without evidence of disease after primary 
treatment compared to patients with active disease, loco-regional Treg were associated with better 
loco-regional control (29;30). Furthermore, the possible protective role for Treg against cancer 
was also illustrated in murine models of colorectal cancer, which show that adoptive transfer of 
CD4+CD25+ regulatory cells results in regression of adenomas (31;32).  Although we find that the 
presence of Treg is associated with an increase in disease-specific survival, we also find that 1) 
the absolute number of Treg present does not seem to alter this positive prognostic effect, 2) 
the presence of Treg is strongly associated with high numbers of CTL, and 3) a high CTL/Treg ratio 
is associated with a longer disease-specific survival. It thus seems plausible that it is not merely 
the presence of Treg, but rather the infiltration of tumour by T-lymphocytes in general which is 
responsible for the observed survival advantage, as was previously reported by Zhang et al. (9). In 
this point of view, infiltration of tumour epithelium, or any other inflammatory site, by lymphocytes 
is naturally accompanied by regulatory T-cells and the effectiveness of immune responses depends 
on the proportion of the different lymphocyte subtypes present instead of on the presence of a 
particular subtype. 
Unlike previous studies of TIL in ovarian cancer, we have also studied the prognostic influence of 
TIL in omental metastases of ovarian cancer patients. Although TIL in omental metastases were 
not independent predictors of disease-specific survival, we did show an increased survival in 
univariate analysis for advanced stage patients with memory T-lymphocytes and Treg infiltrating 
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omental metastases. Interestingly, median numbers of TIL were higher in omental metastases than 
in ovarian-derived tumour tissue and the percentage of patients with Treg in omental metastases 
was substantially higher than for ovarian-derived tumour tissue. The omentum may be considered 
a secondary lymphoid tissue as it contains large aggregates of macrophages and lymphocytes, the 
so-called milky spots. These milky spots contain mostly macrophages (68%), but T-lymphocytes are 
also present (10%) (33). The high percentage of patients with Treg observed in omental metastases 
and the higher median cell counts as compared to ovarian-derived tumour tissue may be a 
reflection of the lymphoid function of the omentum. 
In summary, we show that memory T-lymphocytes infiltrating ovarian-derived tumour tissue and 
omental metastases are associated with increased disease specific survival in patients with advanced 
stage disease. Unexpectedly, the presence of regulatory T-lymphocytes in ovarian-derived tumour 
tissue is also an independent factor for increased disease specific survival. However, the fact that 
a high CTL/Treg ratio independently predicts increased survival as well, suggests that it is not so 
much the presence of Treg as the presence of TIL in general that is responsible for the observed 
survival effect. Our results support the notion that different T-lymphocyte subsets play a unique 
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Abstract
Objective: To investigate the expression and to determine the prognostic impact of components of 
the antigen processing and presentation pathway (APPP) in ovarian cancer.
Methods: Expression of MB1, LMP7, TAP1, TAP2, ERp57, ERAP1, β2-microglobulin and the 
α-chains, HLA-B/ C and HLA-A, of the MHC class I molecules was evaluated on tissue microarrays 
containing primary tumor samples from 232 FIGO stages I–IV  ovarian  cancer  patients. Expression 
levels were correlated to clinicopathological data and disease specific (DSS) survival.
Results: Patients with expression of all components of the  MHC class  I complex, i.e. HLA-A+–
β2-m+  and HLA-B/C+–β2-m+ patients, more often had expression of LMP7, a component of the 
immunoproteasome than patients with other phenotypes (p < 0.001). These patients were also 
more prone to loss of MB1, part of the constitutive multicatalytic proteasome (p < 0.05). Nuclear 
MB1 expression was an independent predictor of worse DSS (HR 1.94, 95% CI 1.16–3.26, p = 0.012). 
The HLA-B/C+–β2-m+ phenotype was an independent predictor of a better prognosis (HR 0.63, 
95% CI 0.40–0.99, p = 0.047). Median DSS was longer for patients with normal nuclear expression 
of LMP7 (57.4 vs. 31.0 months, p = 0.029).
Conclusions: The prognostic influence of the proteasomal subunit MB1 and the MHC class I 
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Introduction
Ovarian cancer is the second most common gynecological cancer and the leading cause of death 
from gynecological malignancies in the Western world (1). The exploration of immunotherapy as a 
new treatment modality for this disease relies on evidence of improved clinical outcome when intra-
tumoral T-lymphocytes are present in ovarian cancer patients, which is most likely a reflection of an 
anti-tumor immune response (2). Immunotherapy can potentially overcome the poor survival rate 
seen with standard treatment, i.e. surgical debulking and adjuvant platinum based chemotherapy 
(3;4), by inducing or augmenting anti-tumor immune responses. Different strategies have been 
employed, including adoptive transfer of anti-tumor T cells or natural killer (NK) cells, as well as 
active immunization with tumor antigens, such as p53. Contrary to some promising murine studies 
(5-7), immunotherapeutic trials in human subjects have only reached minimal clinical benefit (8;9). 
This may partly be due to the development and exploitation of immune escape mechanism by the 
tumor. Down-regulation or absence of components of the antigen processing and presentation 
pathway (APPP) is believed to be such mechanism as presentation of antigens either processed 
within the MHC class I or the MHC class II pathway is a prerequisite for recognition by CD8+ 
cytotoxic and CD4+ helper T-lymphocytes, respectively (10;11). 
The mainstay of the anti-tumor immune response is via MHC class I. In the MHC class I pathway, 
cytoplasmic and nuclear proteins are degraded by the interferon-γ inducible subunits LMP7, LMP2 
and LMP10 (components of the immunoproteasome), which can replace subunits MB1(X), delta(Y) 
and zeta(Z) of the multicatalytic constitutive proteasome (10-14). Immunoproteasomes are 
generally thought to be more efficient at the production of antigenic peptides than the constitutive 
proteasome (13) and they tend to produce more and on average slightly longer peptides (15). 
Immunoproteasomes are preferentially located near the endoplasmic reticulum (ER), whereas 
the constitutive proteasome can be found throughout the cytoplasm (16). Proteasomes may 
also be present in the nucleus, especially in case of cell stress (17). Next peptides of a suitable 
length are transported from the cytoplasm into the endoplasmic reticulum by the transporter 
associated with antigen processing (TAP), consisting of subunits TAP1 and TAP2 (10;11;13;14;18). 
Once in the ER, aminopeptidases such as endoplasmic reticulum aminopeptidase 1 (ERAP1) 
can further trim peptides to a correct size for adequate MHC class I binding. Chaperones (e.g. 
ERp57) facilitate loading of peptides into the MHC class I molecule (10;11;19-21). Finally, a fully 
assembled heterotrimeric MHC class I/peptide complex (α-chain, β2-microglobulin and a bound 
antigenic peptide) is transported to the cell surface, where it may be recognized by CD8+ cytotoxic 
T lymphocytes (11;13;14;20). A schematic overview of this pathway is given in figure 1.
Although defects and down-regulation in all of the aforementioned components have been 
identified in several types of cancer, most APPP defects have some, little or no significant relation 
with clinical parameters and disease outcome (11;22-32). In ovarian cancer, a study of five APPP 
components recently showed that the number of down-regulated components is an independent 
prognostic factor (33). We investigated the expression and clinical relevance of these and essential 
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additional components of the APPP in paraffin embedded tissues obtained from a large series of 
well-documented ovarian cancer patients. 
Materials and methods
Patients
Patients were identified from a database containing clinicopathological and follow-up data of all 
epithelial ovarian cancer treated with primary debulking surgery according to standard treatment 
protocols by gynecological oncologists of the University Medical Center Groningen (Groningen, 
The Netherlands) between May 1985 and April 2003. Patients were selected if sufficient paraffin 
embedded tissue was available. All patients were staged according to the FIGO classification, and 
resected tumors were graded and classified by a gynecological pathologist based on the World 
Health Organization criteria. Adjuvant chemotherapy was given if indicated. Follow-up of all 
patients was performed regularly up to ten years with gradually increasing intervals.
Figure 1 Schematic overview of the MHC class I dependent antigen processing and presentation pathway
65
4
Down-regulation of proteasomal subunit MB1 is an independent 
predictor of improved survival in ovarian cancer
Institutional review board approval
All clinicopathologic and follow-up data of patients referred to the Department of Gynecologic 
Oncology of the UMCG are prospectively collected and stored in a computerized database. For the 
present study, all relevant data were retrieved from our computerized database and transferred 
into a separate password-protected anonymous database. Patient identity was protected by 
study-specific unique patient codes. Patients’ true identity was only known to two dedicated 
data managers, who have daily responsibility for the larger database. In case of uncertainties 
with respect to clinicopathologic and follow-up data, the larger databases could only be checked 
through the data managers. Based on this information, according to Dutch law no further approval 
from our Institutional Review Board was needed.
Tissue samples and construction of tissue microarrays
Paraffin-embedded tissue blocks and corresponding hematoxylin & eosin stained slides constructed 
from tumor tissue obtained at primary debulking surgery were retrieved from the pathology 
archives. Tissue microarrays (TMA) were constructed as described previously (34-36). Briefly, 
primary tumor samples were arrayed using a tissue microarrayer (Beecher Instruments, Silver 
Spring, Maryland) by taking four representative cores with a diameter of 0.6 mm from marked 
tumor sites from the individual paraffin embedded tumor block onto a recipient paraffin block at 
pre-defined array locations. For staining, 4μm sections were cut from each TMA block and applied 
to APES-coated slides. H&E staining was performed to verify the presence of tumor in the arrayed 
samples.
Immunohistochemical staining
TMA sections were dewaxed and rehydrated, whereupon antigen retrieval was performed in a citrate 
buffer (pH 6.0). Endogenous peroxidase activity was blocked by a 3% H2O2 solution, after which 
sections were incubated overnight at 4 ºC with the primary antibodies in the following dilutions: 
anti-MB1 (clone SJJ-3) 1:10, anti-LMP7 1: 100 (clone 1B3, Novus Biologicals, Heerhugowaard, The 
Netherlands), anti-TAP1 1:20 (clone H-300, Santa Cruz Biothechnology Inc., Heidelberg, Germany), 
anti-TAP2 1:20 (clone H-210, Santa Cruz Biothechnology Inc., Heidelberg, Germany), anti-ERp57 
(clone TO-2) 1: 20, polyclonal anti-ERAP1 1:100 , polyclonal anti-β2-microglobulin 1:400 ( DAKO, 
Glostrup, Denmark) and anti-MHC class I heavy chain antibodies HCA2 1: 500 (HLA-A) and HC-
10 1:100 (HLA-B/C). The anti-ERp57 and anti-MB1 antibodies were a gift from Dr S. Ferrone, 
University of Pittsburgh, Pittsburgh, PA. The HCA2 and HC-10 antibodies were a gift from Dr. J.J. 
Neefjes, Netherlands Cancer Institute, Amsterdam, The Netherlands. The anti-ERAP1 antibody was 
a gift from Dr. M. Tsujimoto, Riken, Wako, Saitama, Japan. Sections were subsequently incubated 
with DAKO Envision+ (Dako, Heverlee, Belgium). Antigen-antibody reactions were visualized with 
3,3-diaminobenzidine, the chromogenic substrate for peroxidase, and hematoxylin was used to 
counterstain the tissue. 
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Table 1 - Clinicopathological characteristics and survival data
Total (n=232) Early stage (n=64) Late stage (n=166)
Age (years)
Mean (SD) 57.7 (14.2) 53.1 (14.5) 59.7 (13.6)
5 year DSS 39% 79% 25%
FIGO Stage
Stage I 45 (19.4%) 45 (70.3%)
Stage II 19 (8.2%) 19 (29.7%)
Stage III 133 (57.3%) 133 (80.1%)
Stage IV 33 (14.2%) 33 (19.9%)
Missing 2 (0.9%)
Tumor type
Serous 128 (55.2%) 13 (20.3%) 115 (69.3%)
Mucinous 27 (11.6%) 18 (28.1%) 8 (4.8%)
Endometroid 33 (14.2%) 19 (29.7%) 14 (8.4%)
Clear Cell 17 (7.3%) 6 (9.4%) 10 (6.0%)
Adenocarcinoma 9 (3.9%) 2 (3.1%) 7 (4.2%)
Mixed Tumours 10 (4.3%) 5 (7.8%) 5 (3.0%)
Other 8 (3.4%) 1 (1.6%) 7 (4.2%)
Tumor Grade 
Grade I 39 (16.8%) 29 (45.3%) 9 (5.4%)
Grade II 52 (22.4%) 22 (34.4%) 29 (17.5%)
Grade III 104 (44.8%) 7 (10.9%) 97 (58.4%)
Undifferentiated 14 (6.0%) 2 (3.1%) 12 (7.2%)
Missing 23 (9.9%) 4 (6.3%) 19 (11.4%)
Residual disease
< 2 cm 119 (51.3%) 62 (96.9%) 55 (33.1%)
>= 2 cm 109 (47.0%) 2 (3.1%) 107 (64.5%)
Missing 4 (1.7%) 0 (0.0%) 4 (2.4%)
Type of chemotherapy
No chemotherapy 32 (13.8%) 21 (32.8%) 11 (6.6%)
Platinum containing 102 (44.0%) 22 (34.4%) 79 (47.6%)
Platinum & taxane containing 72 (31.0%) 13 (20.3%) 59 (35.5%)
Other 24 (10.3%) 7 (10.9%) 17 (10.2%)
Missing 2 (0.9%) 1 (1.6%)
DSS = disease specific survival; FIGO = International Federation of Gynaecology and Obstetrics.
Evaluation of immunostaining
Scoring was done independently by two investigators, without prior knowledge of the 
clinicopathological parameters. The semi-quantitative quality control system proposed by Ruiter 
et al. (37) was used, in which both intensity of staining and percentage of positive tumor cells are 
determined. The intensity of staining was scored as 0, 1, 2, or 3, indicating absent, weak, positive, 
or strong positive expression, respectively. The percentage of positive cells was scored as 0 for 0%; 
1 for 1–5%; 2 for 5–25%; 3 for 25–50%; 4 for 50–75% and 5 for 75–100%. The sum of both scores 
was used to identify three categories of expression: normal expression (total score 7–8), partial 
loss (3–6) and total loss (0–2), as previously described by Mehta et al. (28). Immunohistochemical 
staining demonstrated strong positive expression of all examined markers in stromal tissue and 
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Figure 1 Representative example of positive and negative / weakly positive staining pattern of several APPP 
components. a, b) MB1; c, d) LPM7; e, f) HLA-B/C; and g, h) β2-m expression by ovarian tumor cells (400x).
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Table 2 Expression levels of APM components
Normal Loss Missing
MB1 nucleus 156 (67.2%) 65 (28.0%) 11 (4.7%)
MB1 cytoplasm 127 (54.7%) 94 (40.5%) 11 (4.7%)
LMP7 nucleus 88 (37.9%) 134 (57.8%) 10 (4.3%)
LMP7 cytoplasm 56 (24.1%) 166 (71.6%) 10 (4.3%)
TAP1 189 (81.5%) 24 (10.3%) 19 (8.2%)
TAP2 185 (79.7%) 28 (12.1%) 19 (8.2%)
ERp57 147 (63.4%) 77 (33.2%) 8 (3.4%)
ERAP1 183 (78.9%) 39 (16.8%) 10 (4.3%)
Both components All other phenotypes Missing
HLA-A and β2-m 114 (49.1%) 102 (44.0%) 16 (6.9%)
HLA-B/C and β2-m 162 (69.8%) 56 (24.1%) 14 (6.0%)
Table 3 Associations of MHC class I components with other APPP components
















normal 73 (48.7%) 77 (51.3%) 0.048 102 (67.5%) 49 (32.5%) <0.001
loss 40 (63.5%) 23 (36.5%) 58 (90.6%) 6 (9.4%)
MB1 cytoplasm
normal 56 (45.9%) 66 (54.1%) 0.015 81 (66.4%) 41 (33.6%) 0.002
loss 57 (62.6%) 34 (37.4%) 79 (84.9%) 14 (15.1%)
LMP7 nucleus
normal 65 (76.5%)  20 (23.5%) <0.001 78 (91.8%)  7 (8.2%) <0.001
loss 48 (36.9%) 82 (63.1%) 83 (62.9%) 49 (37.1%)
LMP7 cytoplasm
normal 39 (72.2%) 15 (27.8%) 0.001 48 (88.9%) 6 (11.1%) 0.004
loss 74 (46.0%) 87 (54.0%) 113 (69.3%) 50 (30.7%)
TAP1
normal 109 (59.9%) 73 (40.1%) <0.001 143 (77.7%) 41 (22.3%) 0.001
loss 2 (8.3%) 22 (91.7%) 11 (45.8%) 13 (54.2%)
TAP2
normal 97 (56.1%) 76 (43.9%) 0.065 133 (76.0%) 42(24.0%) 0.299
loss 10 (37.0%) 17 (63.0%) 18 (66.7%) 9 (33.3%)
ERp57
normal 88 (62.0%) 54 (38.0%) <0.001 110 (76.4%) 34 (23.6%) 0.328
loss 26 (35.1%) 48 (64.9%) 52 (70.3%) 22 (29.7%)
ERAP1
normal 107 (60.1%) 71 (39.9%) <0.001 139 (77.7%) 40 (22.3%) 0.016
loss 7 (18.4%) 31 (81.6%) 23 (59.0%) 16 (41.0%)
Associations between APPP components and fully assembled MHC class I complexes were evaluated using 
the Chi square-test. Bold signifies p<0.05.
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tumor-infiltrating inflammatory cells, thereby providing an internal positive control. 
As the proteasome containing the MB1 or LMP7 subunit may be present in both the nucleus and 
cytoplasm (17) and a difference in intensity was apparent between these organelles, both were 
scored separately. Staining of ERp57, ERAP1, TAP1, and TAP2 was evaluated in the cytoplasm, while 
for β2-microglobulin, MHC class I α (heavy) chain (HC-10 and HC-A2) cell membrane staining was 
graded. 
Statistical Analysis
Patients were entered into analyses only when at least two cores with viable tumor cells were 
available. To perform statistical analyses, expression levels were dichotomized. Thus, for MB1, 
LMP7, ERp57, and ERAP1, patients with total and partial loss were taken together. TAP1 and 
TAP2 expression were naturally dichotomous, since no total loss was observed. Therefore, 
partial loss was set off against normal expression. Finally, components of MHC class I complex 
were dichotomized by comparing patients with a heavy chain+ - β2-m+ phenotype to patients 
with all other phenotypes. Associations between expression levels of the APPP components 
and clinicopathological parameters were tested using the 2 test. Differences in disease-specific 
survival (DSS) based on expression levels were plotted using Kaplan-Meier survival curves and 
evaluated by log-rank tests. DSS was defined as the time from primary debulking surgery until 
death due to ovarian cancer or the date of last follow-up. Subsequently, multivariate analysis was 
performed with Cox proportion hazards model and was stratified for type of chemotherapy. Only 
those variables that were significantly associated with DSS in univariate analyses, were entered into 
the Cox proportion hazards model.
All analyses were performed using SPSS version 14.0 software package for windows (SPSS Inc., 
Chicago, USA).  P values <0.05 were considered significant (tested 2-sided). 
Results
Patient characteristics 
Paraffin embedded tumor tissue was available for 259 ovarian cancer patients. Twenty-seven 
patients were excluded because no samples were available from primary debulking surgery. 
Patient characteristics are summarized in table 1. The majority of patients presented with serous 
histology, late stage, and/or high grade disease. Thirty-two patients did not receive chemotherapy, 
21 of whom were diagnosed with early stage disease. The remaining 11 patients were either unfit 
or unwilling to receive chemotherapy. Of the patients treated with chemotherapy 87.9% received 
a platinum-based regimen. Estimated five-year DSS rate was 39%. Median DSS was 33.8 months 
(95% C.I.: 22.2-45.4). 
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Figure 2 Disease-specific survival (in months) of FIGO stage I-IV ovarian cancer. Cumulative survival time was es-
timated by the Kaplan-Meier method. Log Rank test was used to evaluate survival differences between groups. 
A) Nuclear and B) cytoplasmic expression of MB1 is associated with worse disease specific survival. C) Nuclear 
expression of LMP7 is associated with better disease-specific survival. D) Better disease-specific survival was 
observed in patients with the HLA-B/C – β2-m phenotype.
Expression levels of APPP components
Expression levels of all APPP components are shown in table 2. Representative staining patterns 
of several components are depicted in figure 2. Percentages of missing data vary from 3.4-8.2%. 
Partial and/or total loss of expression was witnessed for all evaluated components. 
The presence of a heavy chain and β2-m are prerequisites for the formation of a stable MHC 
class I complex; co-expression of HLA-A and β2-m and HLA-B/C and β2-m was observed in 
49.1%, respectively 69.8% of patients. Relationships between HLA-A - β2-m or HLA-B/C - β2-m 
and other APPP components are shown in table 3. For both combinations, there was a striking 
paradox between MB1 and LMP7 expression, i.e.  the majority of HLA-A+ - β2-m+ and HLA-B/
C+ - β2-m+ patients had normal expression of nuclear and cytoplasmic LMP7, a component of the 
immunoproteasome, whereas these patients were more often prone to loss of nuclear and/or 
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Table 4 Multivariate Cox regression analysis of disease specific survival survival in ovarian cancer patients*
HR 95% CI p-value HR 95% CI p-value
Age ≥ 58 years 1.19 0.76-1.87 0.440 1.16 0.74-1.82 0.510
Grade III/undiff 2.09 1.26-3.47 0.005 1.94 1.16-3.22 0.011
Non-serous tumor 0.48 0.28-0.82 0.008 0.50 0.29-0.87 0.014
FIGO stage III/IV 2.99 1.15-7.74 0.024 3.11 1.19-8.15 0.021
Residual tumor 2.45 1.53-3.93 <0.001 2.46 1.54-3.93 <0.001
MB1 nucleus 1.94 1.16-3.26 0.012
MB1 cytoplasm 1.40 0.89-2.22 0.150
HR 95% CI p-value HR 95% CI p-value
Age ≥ 58 years 1.04 0.67-1.63 0.859 1.05 0.40-0.99 0.047
Grade III/undiff 1.72 1.04-2.82 0.033 1.92 1.16-3.20 0.012
Non-serous tumor 0.51 0.30-0.86 0.012 0.52 0.30-0.89 0.016
FIGO stage III/IV 2.96 1.18-7.39 0.020 2.93 1.17-7.34 0.022
Residual tumor 2.60 1.61-4.20 0.000 2.48 1.55-3.98 <0.001
LMP7 nucleus 0.73 0.47-1.13 0.163
HLA-B/C+ - β
2
-m+ 0.63 0.40-0.99 0.047
* Analyses performed stratified for type of chemotherapy; FIGO = International Federation of Gynecology 
and Obstetrics; HR = hazard ratio; CI = confidence interval; bold signifies p<0.05.
cytoplasmic MB1, part of the constitutive multicatalytic proteasome. Surprisingly, no relationship 
existed between MB1 and LMP7 expression (data not shown). 
We found that HLA-A+ - β2-m+ patients were also more likely to show normal expression of 
TAP1, ERp57, and ERAP1 than patients with loss of MHC class I components. HLA-B/C+ - β2-m+ 
patients often expressed TAP1 and ERAP1 while these components tended to be down-regulated 
in patients who lacked one or both components of the MHC class I complex (table 3). 
Association with clinicopathological factors
Loss of nuclear LMP7 was more frequently observed in patients ≥58 years old (67.8 vs. 51.5%, 
p=0.014; data not shown), as was the case for loss of cytoplasmic LMP7 (82.6 vs. 65.3%, p=0.003). 
The HLA-A+ - β2-m+ phenotype was more frequently observed in patients with FIGO stage III/IV 
disease (70.5 vs. 55.9%, p=0.043; data not shown). 
Association with disease-specific survival
Median DSS was 51.5 months shorter for patients with normal nuclear expression of MB1 as 
opposed to patients with loss of nuclear MB1 (figure 3a; median DSS 27.0 vs. 78.5  months, 
p=0.005). Likewise, DSS was shorter for patients with normal cytoplasmic expression of MB1 
(figure 3b; median DSS 30.5 vs. 60.2 months, p=0.024). On the contrary, nuclear expression of 
LMP7 was associated with improved DSS (figure 3c; median DSS 57.4 vs. 31.0 months, p=0.029).
DSS was more than twice as long in patients with the HLA-B/C+ - β2-m+ phenotype as opposed to 
patients with any another phenotype (figure 3d; median 45.2 vs. 21.1 months, p=0.015).
We repeated the univariate survival analyses in a subgroup containing 166 patients with advanced 
stage disease only (data not shown). Improved DSS was demonstrated based on down-regulation 
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of nuclear MB1 expression (median 45.2 vs. 17.8 months, p=0.008) and the HLA-B/C+ - β2-m + 
phenotype (median 25.7 vs. 13.4, p=0.028).
Multivariate analysis 
Only the above-mentioned variables that were significantly associated with DSS in the univariate 
analyses were entered into the Cox proportion hazards model, which was additionally adjusted for 
well-known prognostic factors (table 4). 
After stratification for type of chemotherapy, normal nuclear MB1 expression was found to 
be an independent prognostic factor for shortened DSS (HR 1.94, 95% CI 1.16-3.26, p=0.012). 
Furthermore, the HLA-B/C+ - β2-m+ phenotype was demonstrated to be an independent predictor 
of longer DSS (HR 0.63, 95% CI 0.40-0.99, p=0.047). Likewise, MB1 expression and the HLA-B/
C+ - β2-m+ phenotype were found to be independent predictors of DSS in the advanced stage 
subgroup (HR 1.78, 95% CI 1.06-2.98, p=0.028, resp. HR 0.55, 95% CI 0.35-0.87, p=0.010). 
Discussion
The antigen processing and presentation pathway bridges many cellular organelles, ultimately 
resulting in the MHC restricted presentation of a small peptide sequence on the cell surface. 
Recognition of this peptide-MHC complex by the immune system can lead to a potentially life-
prolonging anti-tumour immune response (2). Individual components of the APPP may have 
a prognostic value and/or a therapeutic potential. At the level of the proteasome, our study 
indicates that the presence of MB1 is an independent predictor of shorter DSS in ovarian cancer. 
In contrast, expression of LMP7 is associated with longer DSS. At the cell membrane level, the 
HLA-B/C+ - β2-m+ phenotype is a predictor of longer DSS. Furthermore, patients with heavy chain 
and β2-m expression are more likely to express LMP7, while patients lacking one of the MHC class 
I components more often express MB1. 
Whereas previous studies reported mainly on the immunoproteasome (22;27;28;38;39), we 
observed an important role for the constitutive proteasome. To our knowledge, the negative 
influence of MB1 expression on prognosis of (ovarian) cancer patients has not previously been 
described, and opposes the results of a study in renal cell carcinoma, where MB1 expression did 
not influence survival (39). It has been suggested that there is a reciprocal relationship between 
MB1 and LMP7, which may explain the observed negative prognostic influence of MB1 expression 
(39;40). We were, however, unable to find such an association between expression levels of LMP7 
and MB1. 
An alternative explanation for the survival benefit associated with MB1 loss might be a 
mechanism similar to that observed with proteasome inhibitors, e.g. Bortezomib (41). These 
agents inhibit the ubiquitin-proteasome pathway in tumour cells, resulting in accumulation of 
proteins involved in cell cycle regulation, proliferation, differentiation, and apoptosis. Ultimately, 
proteasome inhibitors increase apoptosis and decrease chemoresistance (42). Patients in whom 
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the constitutive proteasome is intrinsically down-regulated might enjoy a similar benefit. 
Nuclear expression of the immunoproteasome component LMP7 was associated with longer 
DSS. Similarly, differences in DSS based on LMP7 expression have been reported for several types 
of cancer  (28;38;39). These survival benefits can be interpreted as the result of immunologic 
mechanisms by which the generation of more immunogenic peptides results in more efficient 
activation of the immune system. Since LMP7 expression conveys a positive effect on DSS, 
proteasome inhibition might not be beneficial for patients expressing LMP7, which suggests that 
more selective proteasome inhibitors may be needed for optimal clinical benefit.  Alternatively, 
one could envision treating patients with agents that enhance LMP7 and/or MHC class I 
expression. Histone deacetylase inhibitors, e.g. trichostatin A and valproic acid, have been shown 
to have these properties, but more specific compounds would be desirable (43). 
The final step of the antigen processing and presentation pathway is cell surface expression of 
a fully assembled heterotrimeric MHC class I complex consisting of a heavy chain molecule, β2-
microglobulin, and a bound antigenic peptide. In this study, expression of the HLA-A and HLA-B/C 
heavy chain molecules was analyzed in combination with β2-microglobulin. We observed that the 
HLA-B/C+ - β2-m+ phenotype is an independent positive prognostic factor for DSS, confirming the 
recently published findings of Rolland and colleagues in ovarian cancer (44). 
Strikingly, we found that MB1 expression correlates with loss of the heavy chain+/ β2-m+ 
phenotype, while patients with LMP7 are likely to express the fully assembled MHC class 
I complex. This implies that in cases where the immunoproteasome dominates over the 
constitutive proteasome, effective antigen presentation is more likely. Moreover, the presence 
of upstream APPP components could be necessary for formation of a stable MHC class I complex 
(45). Thus, the generation of suboptimal peptide sequences by the constitutive proteasome is 
exacerbated by impaired presentation of the peptide on the cell surface, resulting in escape from 
immune detection, thereby promoting ‘immunoediting’, i.e. the selective outgrowth of tumour 
components with low immunogenicity. To further substantiate this, the association of expression 
of the (immuno)proteasome to tumor-infiltrating lymphocytes was determined using the results 
from a recently published study of tumour-infiltrating lymphocytes in the same population 
(46). Higher numbers of tumour-infiltrating CD8+ T-lymphocytes are more frequently observed 
in patients with loss of MB1 expression as well as in patients with positive LMP7 expression 
(data not shown).  Whether down-regulation of the constitutive and up-regulation of the 
immunoproteasome result in an increase in lymphocyte infiltration, or whether the presence of 
interferon-γ producing lymphocytes facilitates the switch from constitutive to immunoproteasome 
needs to be elucidated. 
While we found prognostic significance associated with components at either the beginning or 
the very end of the APPP, we did not detect any survival differences based on expression levels 
of proteins active at the level of the endoplasmatic reticulum. Summation of APPP components, 
however, similar to the approach of Han et al. (33) indeed correlated with worse survival in 
patients with down-regulation of one or more components as opposed to TAP1+ TAP2+ HLA-B/
C+ β2-microglobulin+ patients (data not shown). Furthermore, combination of these results with 
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a tumour-infiltrating lymphocytes revealed that patients with expression of all four components 
more frequently have an abundance of tumour-infiltrating CD8+ T-lymphocytes. Moreover, 
we also find that both the absolute number of APPP components and CD8+ T-lymphocytes 
are independent prognostic predictors of longer disease specific survival, next to some well-
acknowledged prognostic factors (33;46).  
In conclusion, our results underscore a pivotal role for the (immuno)proteasome and MHC class 
I complex in determining prognosis in ovarian cancer patients. In view of the complexity of 
the APPP, these results provide a rationale for targeting these specific components in targeted 
therapy in cancer.
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Abstract
HLA-E is a non-classical HLA class I molecule, which differs from classical HLA molecules by its 
non-polymorphic, conserved nature. Expression and function of HLA-E in normal tissues and solid 
tumors is not fully understood. We investigated HLA-E protein expression on tissue sections of 420 
ovarian and cervical cancers and found equal or higher levels than normal counterpart epithelia in 
respectively 89.4% and 83.7% of the tumors. Expression was strongly associated with components 
of the antigen presentation pathway, e.g. TAP, ERAP, b2m, HLA class I and II, and for ovarian cancer 
with tumor infiltrating CTL. This argues against the idea that HLA-E would compensate for the loss 
of classical HLA in tumors. In situ detection of HLA-E interacting receptors revealed a very low 
infiltrate of NK cells, but up to 50% of CTL expressed the inhibiting CD94/NKG2A receptor. In cervical 
cancer, HLA-E expression did not alter the prognostic effect of CTL, most likely due to very high 
infiltrating CTL numbers in this virus-induced tumor. Overall survival of ovarian cancer patients, 
however, was strongly influenced by HLA-E, because the beneficial effect of high CTL infiltration 
was completely neutralized in the subpopulation with strong HLA-E expression. Interestingly, these 
results indicate that CTL infiltration in ovarian cancer is only associated with better survival when 
HLA-E expression is low, and that intratumoral CTL are inhibited by CD94/NKG2A receptors on CTL 
in the tumor microenvironment.
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Introduction
HLA-E is a non-classical Major Histocompatibility Complex (MHC) class I molecule that is almost 
non-polymorphic, in contrast to its classical class I counterparts HLA-A, -B, and -C (1;2). There are 
two HLA-E subtypes, which differ by only one amino acid (3-5). This coding variation is located 
outside the peptide binding groove, and both HLA-E variants are indeed indistinguishable in their 
structure and peptide binding features (3-5). HLA-E normally presents a very limited variety of 
peptides, derived from signal peptide sequences of classical MHC class I. However, infections and 
transformation can mediate the presentation of alternative peptides (1;2). Surface expression 
of HLA-E is largely dependent on β2 microglobulin (β2m) as well as transporter associated with 
antigen processing (TAP) and tapasin (6;7). 
HLA-E/peptide complexes are ligands of the CD94 receptor in conjunction with the inhibitory NKG2A 
or the stimulatory NKG2C molecule, which are expressed on the majority of natural killer (NK) 
cells and some activated CD8+ T lymphocytes (CTL) (8;9). The presentation of ‘self’ signal peptides 
by HLA-E enables these lymphocytes to gauge the overall MHC class I expression on the surface 
of target cells. Engagement of CD94/NKG2A receptors on lymphocytes reduces the reactivity of 
NK cells or CTL, which protects against excessive immune-mediated tissue damage, for instance 
during infections (10;11). On the other hand, CD94/NKG2A expression can be induced in response 
to cytokines such as IL-15 (12) and transforming growth factor β (TGF-β) (13). These cytokines 
are frequently present in the tumor microenvironment, suggesting that CD94/NKG2A inhibitory 
receptors play a role in immune escape by tumor cells. 
With the availability of specific antibodies to detect HLA-E in native conformation (clone 3D12; 
ref. (6)) or as denatured protein (clone MEM-E/02; ref. (14)), we recently investigated the normal 
expression of HLA-E on human tissues in collaboration with the Human Proteome Resource 
program (HPR at www.proteinatlas.org). Expression on blood cells, endothelium, melanocytes and 
intestinal epithelial cells was confirmed (6;15-17). Furthermore, we observed a pattern of tissue 
staining that was very similar to that of classical MHC class I. 
Here, we determined the expression of HLA-E in 150 cervical and 270 ovarian cancer samples 
and analyzed its association with clinical and immunological parameters. Our results indicate that 
HLA-E is frequently overexpressed in these tumor types and positively associated with expression 
patterns of antigen processing components, classical HLA molecules and immune cell infiltrate. 
In situ analysis of the interacting receptors of HLA-E, i.e. the inhibitory CD94/NKG2A and the 
activating CD94/NKG2C, revealed a frequent expression of the inhibitory receptor on intratumoral 
CD8+ T cells. NK cells, the predominant cell type expressing CD94/NKG2A and CD94/NKG2C, were 
hardly found in both tumor types. Importantly, the beneficial prognostic effect of infiltrating CTL in 
ovarian cancer was neutralized by high expression of HLA-E, indicating that HLA-E hampers activity 
of anti-tumor CTL in the tumor microenvironment. 




Since 1985, the Department of Gynecological Oncology at the University Medical Center Groningen 
(UMCG) keeps a computerized database of patients with malignant epithelial ovarian cancer 
treated at this hospital at any time point during the course of their disease, prospectively collecting 
information on clinicopathologic characteristics and follow-up. For the current study, ovarian 
cancer patients were selected if primary surgery was performed by a gynecological oncologist from 
the UMCG between May 1985 and June 2006, and if paraffin-embedded ovarian tumor tissue was 
available (N = 270). Follow-up was updated in July 2009. Patients were staged according to FIGO 
classification (61). Tumors were graded and classified according to WHO criteria by a gynecological 
pathologist. Adjuvant chemotherapy consisted of different platinum-based treatment regimens. 
Response to chemotherapy was evaluated according to WHO criteria. Specimens from seven 
patients (three premenopausal, four postmenopausal) who underwent prophylactic bilateral 
salpingo-oophorectomy were separately included as controls for the HLA-E staining of normal 
ovarian epithelium.
We included all patients with cervical cancer who underwent radical hysterectomy with complete 
pelvic lymphadenectomy in the Leiden University Medical Center (LUMC) from 1985 to 1999, for 
whom formalin-fixed, paraffin-embedded tissue available, and had not received radiotherapy or 
chemotherapy before surgery (N = 150). All patients had FIGO stages I and II disease, since higher 
stages are treated by primary chemoradiation. Tumors were HPV typed by PCR and sequencing. 
For all patients, a minimum of five years of follow up was available. Histologic specimens of normal 
cervices from women who underwent hysterectomies for benign uterine diseases with no cervical 
abnormalities (n = 9) were used as a control group in all section stainings. 
Immunohistochemistry
Previously described ovarian (20) and cervical cancer (21) tissue microarrays (TMA) were used, 
which were constructed as described previously (62;63). TMA sections were stained with mouse 
monoclonal antibodies recognizing HLA-E (clone MEM-E/02, Abcam ab2216). In brief, TMA 
sections were dewaxed in xylene and rehydrated using graded concentrations of ethanol to distilled 
water. After antigen retrieval using citrate buffer, endogenous peroxidase activity was blocked by 




 solution for 30 minutes. Sections were incubated with the 
primary antibody for 60 minutes at room temperature and subsequently with DAKO Envision+ 
for 30 minutes. The antigen-antibody reactions were visualized with 3,3’-diaminobenzidine. 
Sections were counterstained with hematoxylin. Paraffin embedded sections were also stained 
with anti-CD56 (clone 1B6, Monosan, Uden, The Netherlands) and anti-NKp46 (polyclonal AF1850, 
R&D systems) and subsequently, rat-anti-mousepo and goat-anti-ratpo as secondary and tertiary 
antibodies, respectively. 
Simultaneous detection of CD3, CD94 and NKG2A was performed by three color fluorescence staining 
on ten cryosections of cervical carcinomas using anti-CD3 (mouse IgG1, DAKO, clone F7.2.38), anti-
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CD94 (mouse IgG2a, Abcam, clone ab61974) and anti-NKG2A (mouse IgG2b, Immunotech, clone 
Z199). Second step antibodies were all goat-anti-mouse isotype specific antibodies with Alexa 
fluorochromes Alexa Fluor 546, Alexa Fluor 647 and Alexa Fluor 488 (Molecular Probes). Images 
were captured with a confocal laser scanning microscope (LSM510, Zeiss) in a multitrack setting 
and analyzed as previously described (64).
Scoring
All stainings were scored independently by two observers. Observers had no prior knowledge of 
clinicopathological information. To obtain a high concordance rate with whole tissue slides, it was 
decided that minimally two cores with a minimum of 20% tumor tissue had to be present on the 
TMA for a sample to be entered into analysis (63). The scoring system proposed by Ruiter et al. (18) 
was used. The intensity of staining was scored as 0, 1, 2, or 3, indicating absent, weak, positive, or 
strong positive expression, respectively. The percentage of positive tumor cells was scored as 0 
for 0%; 1 for 1–5%; 2 for 5–25%; 3 for 25–50%; 4 for 50–75% and 5 for 75–100%. The two scores 
were added up, averaged over the number of evaluable cores per tumor, and dichotomized based 
on the lowest quartile. This resulted in a cutoff score of 5.25 in ovarian cancer, and 5.00 in cervical 
cancer. We also performed analyses with previously published data on antigen processing and 
presentation molecules, as well as tumor infiltrating lymphocytes, using the same cutoff points as 
described earlier (19-22).
Flow cytometry analyses
Fresh ovarian and cervical cancer specimens were dissected in small fragments with surgical 
blades and passed through a cell strainer to obtain single cell suspensions. Patients had similar 
characteristics as those from the TMA cohort. After isolating living cells using centrifugation with 
ficoll, cells were washed twice in PBS/0.5% BSA buffer and incubated for 30 minutes with CD14-
PeCy7 (clone M5E2, BD Bioscience), CD3-PB (clone UCHT1, Dako), CD56-Alexa700 (clone B159, BD 
Biosciences), CD4-PeTxRed (clone S3.5, CALTAG), CD8-PerCP (clone SK1, BD Biosciences), CD94-
FITC (clone 131412, R&D systems), NKG2A-PE (clone z199, Beckman Coulter), and NKG2C-APC 
(clone 134591, R&D systems). After fixation in paraformaldehyde, cells were measured using an 
LSR II flow cytometer (BD Biosciences) and analyzed by FlowJo software.
Statistics
Associations between clinicopathological characteristics, antigen processing and presentation 
pathway components, and intratumoral T-lymphocytes were tested using Pearson Chi square 
tests using our previously published cutoff points (19-22). Al continuous variables were tested 
for normality by plotting histograms and performing Kolmogorov-Smirnov tests. Since none of 
these variables was normally distributed, nonparametric tests were used to compare continuous 
variables. Mann-Whitney U tests were used to determine differences between CD8 scores in 
ovarian and cervical cancer. Survival was defined as date of surgery until death of cancer, or date of 
last follow-up. Survival was estimated using the Kaplan Meier method. The Log Rank test and Cox 
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Figure 1 HLA-E expression in ovarian and cer-
vical cancer. Paraffin embedded tissue sec-
tions were stained with the monoclonal HLA-
E specific antibody MEM-E/02. (A-B) Two 
examples of the one layer epithelial cells of 
normal ovaries. No difference was observed 
between pre- and postmenopausal ovaries. 
Endothelial cells of the blood vessels in the 
connective tissue and resident leukocytes 
are known for positive HLA-E staining. (C-D) 
Two examples of tissue micro array spots 
containing ovarian cancer, one negative (C) 
and one positive (D) for HLA-E expression. 
(E-F) Examples of HLA-E staining on normal 
ectocervical squamous epithelium (E) and 
normal endocervical glands of the cervix (F). 
(G-H) A negative (G) and a positive (H) exam-
ple of HLA-E expression from the cohort of 
cervical cancer.
regression analyses were used to assess survival differences between groups. To compare CD94, 
NKG2A, and NKG2C expression among different T lymphocyte subsets, we used the Mann Whitney 
U test. For all tests, p-values <0.05 were considered significant. All p-values were two-sided. All 
statistical analyses were performed using SPSS 16.0 software package for Windows (SPSS Inc., 
Chicago, IL, USA). 
Results
HLA-E expression in gynecological cancers
Two cohorts of gynecological tumor tissue were evaluated: 270 ovarian and 150 cervical cancers. 
Supplementary table 1 summarizes clinicopathological characteristics and survival data of the two 
cohorts. Notably, ovarian cancer is generally diagnosed at a much later stage than cervical cancer. 
Hence, this cohort consists mainly of high stage tumors with an average disease-specific survival of 
only 3.5 years, whereas cervical cancer patients live on average 14 years after diagnosis. 
We first determined the expression of HLA-E on nonmalignant ovarian and cervical tissue. For 
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ovarian tissue, we selected seven pre- and postmenopausal samples with intact, nonmalignant 
ovarian epithelium. Also, we stained nine cervical sections containing normal ectocervical 
squamous epithelium and endocervical glands (Fig. 1). These are the structures that give rise to 
ovarian- and cervical cancer, respectively. The ovarian epithelium showed a weak positive staining 
in both pre- and postmenopausal samples, whereas ovarian stroma was negative (Fig. 1a, b). Both 
cervical epithelia stained negative to weak positive for HLA-E; stroma was negative (Fig. 1e, f). The 
endothelium of blood vessels was highly positive for HLA-E as well as resident leukocytes, in line 
with previous reports (15). 
Next, we assessed HLA-E expression on ovarian cancer (n=270) and cervical cancer (n=150) confined 
in tissue micro arrays using a validated specific antibody. Examples of negative and positive staining 
tumors are depicted for ovarian cancer (Fig. 1c and d, respectively) and cervical cancer (Fig. 1g and 
h, respectively). Staining of HLA-E on tumor cells was scored for intensity and percentage surface 
area, as previously described (18), giving a range from 0 to 8.0. For both tumor types the median 
score was 6.0, with a range between 0 and 7.75. On the basis of the mean intensity score of normal 
epithelium (score 1 on a scale of 0-3), ovarian tumors and cervical tumors expressed equal or 
higher levels of HLA-E in 89% and 83% of the tumors, indicating that expression of HLA-E is mostly 
conserved in these tumors.
Figure 2 Flow cytometry analysis of CD94, NKG2A and NKG2C expression on T cells.Dissociated tissues from 
fresh tumor samples from surgery were stained with fluorescently labeled antibodies against CD14, CD56, 
CD3, CD4, CD8, CD94, NKG2A and NKG2C. (A) Eight color staining of dispersed cervical tumor. Leukocytes were 
first gated on forward and sideward scatter plot and all CD14-negative cells to exclude non-specific staining to 
immunoglobulin receptors on monocytes. Natural killer cells were also excluded from the analysis by remov-
ing CD3-CD56+ cells from the selecting gate. (B) Nine tumor samples and nine age-matched PBMC samples 
were analyzed for percentage CD4 T cells and CD8 T cells that express CD94, NKG2A or NKG2C. Ovarian cancer 
contained very low numbers of CD4 T cells. Percentage CD94- and NKG2A-positive CD8 T cells in tumor tissues 
was significantly higher than the percentage in blood (p=0.0012 for CD94, p<0.0001 for NKG2A, Mann-Whit-
ney U test). Other comparisons were not significantly different.
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Table 1 Relationship of HLA-E expression in ovarian and cervical cancer with immunological characteristics
HLA-E ovarian cancer HLA-E cervical cancer
low high p-valuea low high p-valuea
LMP7
   low 17 (65.4%) 9 (34.6%) <0.001 5 (23.8%) 16 (76.2%) 0.645
   high 28 (19.6%) 115 (80.4%) 17 (19.3%) 71 (80.7%)
TAP1
   low 11 (52.4%) 10 (47.6%) 0.004 9 (42.9%) 12 (57.1%) 0.017
   high 33 (22.6%) 113 (77.4%) 16 (18.4%) 71 (81.6%)
TAP2
   low 7 (31.8%) 15 (68.2%) 0.439 14 (31.8%) 30 (68.2%) 0.007
   high 34 (24.1%) 107 (75.9%) 7 (10.9%) 57 (89.1%)
ERAP
   low 13 (40.6%) 19 (59.4%) 0.041 4 (25.0%) 12 (75.0%) 0.524
   high 32 (23.0%) 107 (77.0%) 16 (18.2%) 72 (81.8%)
ERp57
   low 17 (27.4%) 45 (72.6%) 0.805 13 (21.7%) 47 (78.3%) 0.514
   high 28 (25.7%) 81 (74.3%) 8 (16.7%) 40 (83.3%)
HLA-A
   low 25 (46.3%) 29 (53.7%) <0.001 22 (26.2%) 62 (73.8%) 0.083
   high 20 (17.2%) 96 (82.8%) 8 (14.0%) 49 (86.0%)
HLA-B/C
   low 27 (56.2%) 21 (43.8%) <0.001 22 (26.2%) 62 (73.8%) 0.083
   high 32 (17.7%) 149 (82.3%) 8 (14.0%) 49 (86.0%)
HLA-DP/DQ/DR
   low 31 (39.2%) 48 (60.8%) <0.001 13 (29.5%) 31 (70.5%) 0.028
   high 14 (15.2%) 78 (84.8%) 8 (12.5%) 56 (87.5%)
B2M
   low 26 (45.6%) 31 (54.4%) <0.001 25 (26.9%) 68 (73.1%) 0.012
   high 19 (16.7%) 95 (83.3%) 7 (10.6%) 59 (89.4%)
CTL
   low 30 (39.5%) 46 (60.5%) 0.001 8 (23.5%) 26 (76.5%) 0.656
   high 28 (18.8%) 121 (81.2%) 13 (19.7%) 53 (80.3%)
Treg
   low 30 (32.6%) 62 (67.4%) 0.126 12 (31.6%) 26 (68.4%) 0.085
   high 24 (22.9%) 81 (77.1%) 9 (16.4%) 46 (83.6%)
CTL/Treg ratio
   low 26 (36.1%) 46 (63.9%) 0.018 9 (18.0%) 41 (82.0%) 0.343
   high 32 (21.2%) 119 (78.8%) 11 (26.2%) 31 (73.8%)
a p-values were calculated using Pearson Chi square-test. Bold signifies p<0.05.
Associations between HLA-E, clinicopathologic and immunologic factors
To assess whether HLA-E expression was preferentially associated with certain patient groups, 
we determined the relationship between HLA-E expression and well-known clinicopathologic 
factors. To this end, the gradual scores of HLA-E expression were dichotomized based on the lowest 
quartile. For ovarian cancer, there was no relationship between HLA-E expression and histology, 
stage, grade, or presence of residual tumor after debulking surgery (supplementary table 1). 
Similarly, HLA-E expression in cervical cancer was not related to histology, stage, infiltration depth, 
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tumor size, Human Papillomavirus (HPV) infection, lymph node positivity, and vascular invasion 
(supplementary table 2). 
We previously collected data from these cohorts of tumor samples describing immune cell infiltration 
and HLA-related molecules (19-22). We determined associations between HLA-E and components 
of the antigen processing machinery, using the same cutoff values as previously described for 
these molecules (19-22). The proteasome subunit LMP7, peptide transporter heterodimer TAP1, 
and the aminopeptidase ERAP (23) were associated with increased HLA-E expression in ovarian 
cancer (Table 1). In cervical cancer, the TAP1 and TAP2 transporters were the only component that 
were associated with HLA-E expression. These results suggest that antigen processing components 
contribute to the protein expression of HLA-E. 
Next, the association with classical HLA class I molecules (HLA-A, HLA-B/C and β2m) and HLA class II 
molecules (HLA-DP/DQ/DR) was analyzed (Table 1). Induction of HLA class II molecules is observed 
in a majority of these cancers and can be mediated by cytokines such as interferon-γ, similar to 
HLA-E (24-26). This revealed a very strong association with HLA-E expression, especially in ovarian 
cancer. This indicates that HLA-E is present in tumors with strong classical HLA expression and 
contrasts with the idea that HLA-E expression would compensate for loss of classical HLA molecules 
in cancer. In contrast, high expression of classical HLA class I promotes the stabilization of HLA-E 
through the delivery of leader sequences which bind to the groove of HLA-E (2;6;27). 
Furthermore, expression of HLA-E was correlated with the presence of T cells. The degree of 
infiltration of CTL and regulatory T lymphocytes (Treg) was recently reported by our groups for 
these two cohorts (20;21). The number of tumor-infiltrating CTL was positively correlated to HLA-E 
expression in ovarian cancer, but not in cervical cancer (Table 1). We previously found that the ratio 
between CTL and Treg is predictive of clinical outcome in cervical cancer instead of the CTL counts 
as such (21). For the current study, we studied the relation between the CTL/Treg ratio and HLA-E 
expression, but these two parameters were not associated (p=0.343, Table 1). 
Concluding, HLA-E expression in ovarian and cervical cancers is positively associated with other 
components of HLA-mediated antigen presentation – indicative of a well functioning processing 
and presentation pathway – and the influx of T cells. These associations are especially prominent 
in ovarian cancer.
Intra-tumoral CTLs express HLA-E engaging receptors
The receptors for HLA-E, i.e. CD94/NKG2A and CD94/NKG2C, are predominantly expressed on 
natural killer (NK) cells. We therefore assessed the presence of these innate immune cells in our 
cohort of ovarian and cervical cancers using antibodies against the NK-associated markers CD56 and 
CD57, and the NK-specific marker NKp46 (28). In ovarian cancer, only 14% of the samples contained 
detectable NK cells, and the number of cells was very low in these tumors (less than 7/mm2). 
Cervical cancers also largely lacked infiltrating NK cells, and stainings with an anti-NKp46 antibody 
corroborated our previous results where we scored CD3-CD57+ cells (21). Clinicopathologic factors 
or HLA-E expression did not differ between tumors with or without NK cells. 
Besides on NK cells, the inhibiting heterodimer CD94/NKG2A and the activating CD94/NKG2C are 
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also expressed on a small subset of CTL (2). We hypothesized that HLA-E in cancers might serve 
as ligand for these receptors on intratumoral CTL. We applied 8-color flow cytometry analysis on 
fresh surgical samples, which were mechanically dissected to single cell suspensions (Fig. 2). Gating 
on CD3+CD4+ T cells and CD3+CD8+ cytotoxic T cells visualized the expression of CD94, NKG2A and 
NKG2C receptors on these T cell subsets (Fig. 2a). Importantly, a high frequency of the tumor-
infiltrating CTL displayed the inhibiting NKG2A chain, but not the activating NKG2C chain (Fig. 2a). 
Nearly all NKG2A-positive CTL also co-expressed the partner CD94 (overall 98%). In contrast, CD4+ T 
cells were largely devoid of these HLA-E interacting receptors. The ovarian cancers contained very 
low numbers of CD4+ T cells, leading to seemingly high frequencies of receptor-positive subsets. 
Interestingly, large populations of CD4-CD8- T cells were observed in the samples of ovarian cancer 
and a high percentage of these cells were positive for CD94/NKG2A and these cells are currently 
subject of further investigation. When five cervical cancer and four ovarian cancer samples were 
analyzed, up to 50% of CTL were CD94/NKG2A+ with a median of 12% (Fig. 2b). The frequency 
of CD94/NKG2A+ CTL in age-matched normal blood was found to be around 3%, indicating that 
this inhibiting HLA-E binding receptor is enriched at the site of the tumor. To substantiate this 
finding and to analyze the localization of these CD94/NKG2A positive CTL, we performed triple 
stainings on cryosections of cervical cancer using fluorescently labeled antibodies to CD3, CD94, 
and NKG2A (Fig. 3). Most T-cells resided in stoma areas and not within tumor nests, in line with 
our previous findings (20, 21). Strikingly, CD94/NKG2A expression was found on only 6% of the 
stoma T cells, whereas 48% of intratumoral T cells displayed this inhibiting receptor (SD 9% and 
32%, respectively). Together, these data implied that the frequency of tumor-interacting T cells 
expressing CD94/NKG2A (Fig. 3) is much higher than anticipated on basis of the total pool of T cells 
in the resected tumor sample (see Fig. 2b). 
Expression of HLA-E neutralizes survival benefit of infiltrating CTL in ovarian cancer 
We wondered whether the observed expression of HLA-E and CD94/NKG2A in the tumor site 
would translate into survival differences in the context of CTL infiltration. In ovarian cancer, HLA-E 
expression on its own did not affect survival (Table 3). We previously demonstrated (20) that 
high CTL counts predict improved survival in ovarian cancer (HR 0.71, Table 3 and Fig. 4a). We 
hypothesized that, due to the presence of CD94/NKG2A on infiltrating CTL, HLA-E high tumors might 
resist CTL mediated lysis. To this end, we performed survival analysis for CTL infiltration stratified by 
HLA-E expression. Indeed, the prognostic benefit of CD8+ T cells was strongly present in the stratum 
with low HLA-E expression (HR 0.53, p=0.001, Table 3, Fig. 4b). This hazard ratio was much lower 
than that of the whole population, without HLA-E stratification. Strikingly, patients with high HLA-E 
expression, representing 75% of our cohort, completely lost the benefit of infiltrating CTL (HR 0.97, 
p=0.816, Table 3, Fig. 4c). These data indicate that the minor subpopulation of patients with low 
HLA-E expression on their tumors benefits from infiltrating CTL and, moreover, that expression of 
HLA-E neutralizes the survival benefit of ovarian cancers with high numbers of CTL.
In cervical cancer, we observed a decreased risk of death associated with high HLA-E expression 
in univariate analysis. However, HLA-E expression was not an independent predictor of death in 
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Figure 2 Triple fluorescence staining of cervical cancer detecting intratumoral CD94+NKG2A+ T cells.Im-
munofluorescent staining of T cells (CD3+ in blue) expressing NKG2A (in green) and CD94 (in red). These two 
pictures of different cervical tumor samples are representative of ten tumors analyzed. Arrow heads in the 
merged picture (lower right quadrants) designate triple positive cells within tumor nests, whereas the sur-
rounding single blue cells (T cells without CD94/NKG2A) are located in stroma. 
Figure 3 Kaplan-Meier survival curves of ovarian cancer. Overall survival of 249 patients with ovarian cancer 
for whom ≥2 cores were available in months is plotted. (A) Infiltrating CD8+ T cells were counted and stratified 
in two groups with a cut off on the lowest tertile. Patients with a high CTL count showed a better survival 
than those with low CTL counts (p=0.044, log rank test). (B-C) Subsequently, HLA-E expression was added as 
parameter, dividing the population into HLA-E low expression (lowest quartile) (B) and high HLA-E expression 
(C). The beneficial effect of high CTL counts on survival was not attributable for those cancers with high HLA-E 
(p=0.815, log rank). Consequently, the beneficial role of high CTL infiltration of the whole cohort was the 
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multivariate analysis (Table 3). We previously reported that infiltrating CTL frequency is not an 
independent predictive survival factor (p=0.879, Table 3) (21). Stratified analysis of CTL infiltration 
based on HLA-E expression did not affect these results. When repeating these analyses for disease 
free survival, similar results were obtained. 
A notable difference between ovarian and cervical cancer is the number of intratumoral CTL, as 
cervical cancers are infiltrated with at least three times more CTL (median 95.3 ± 221.6/mm2; 
ovarian cancer: 28.3 ± 120/mm2; p<0.001), suggesting that the virus-positive cervical cancers 
are relatively overloaded with infiltrating CTL. When we repeated the stratified analysis in the 
subpopulation of cervical cancer with CTL counts comparable to ovarian cancer, HLA-E expression 
seemed to have the same impact as in ovarian cancer. However, the numbers of cervical cancer 
with such low numbers of CTL were insufficient for proper statistical analysis. We are currently 
further evaluating the differences between CTL numbers in several tumor types.
In conclusion, HLA-E is regularly expressed in ovarian and cervical cancer, often concurrently 
with classical MHC molecules. Instead of inhibiting NK cells, which are hardly present in these 
tumor types, the main role of HLA-E seems to be the inhibition of infiltrating CD8+ CTL. This effect 
translates into survival differences in ovarian cancer, which contains fewer CTL and might therefore 
be more affected by a decrease of CTL below a certain threshold. 
Discussion
In the current study, we determined the clinical and immunological relevance of HLA-E expression 
in ovarian and cervical cancer. Knowledge on the expression of HLA-E in these two cancer types was 
limited to small cohorts, and here we show that 89.4% of ovarian cancers and 83.7% of cervical 
cancers display higher levels compared to their normal epithelial counterparts. Total lack of 
HLA-E is rare in these tumors. Importantly, HLA-E protein expression was strongly associated with 
expression of classical HLA molecules (class I and class II) and components of the antigen processing 
machinery (immunoproteasome, peptide transporter TAP, trimming enzyme ERAP and chaperone 
Erp57) (Table 1). This implies that tumor expression of HLA-E is regulated in a comparable fashion to 
classical HLA and that its presence on tumors is not a defense mechanism against NK cell mediated 
lysis in classical class I-negative tumors, as sometimes suggested in literature (26;29-31). Instead, 
our data argue that HLA-E expression arises in the setting of an intact antigen processing apparatus 
and, in ovarian cancer, abundant CTL infiltration. A positive association between classical and non-
classical HLA expression has recently also been reported for a large cohort of breast cancers (32), 
and is moreover anticipated on basis of the stabilization of HLA-E by leader peptides derived from 
classical HLA molecules (2;33). 
Traditionally, interaction with NK cells via receptors CD94/NKG2A and CD94/NKG2C was considered 
the main purpose of HLA-E. The presence of infiltrating NK cells in ovarian and cervical cancers 
was previously reported by several groups (34-39). Detection of NK cells in tumor samples has 
predominantly been performed with antibodies against CD56 and CD57, whereas these molecules 
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can also be found on T lymphocytes. We carefully analyzed NK infiltration by inclusion of the CD3-
specific T lymphocyte marker, or using the really specific molecule NKp46, which is not expressed 
on T lymphocytes (28). Our data reveal that NK cells hardly infiltrate ovarian and cervical cancers, 
conform the general impression in solid tumors (40), in contrast to leukemias, where NK cell 
responses have been connected to better survival (41). 
In addition to NK cells, the inhibiting receptor CD94/NKG2A and activating receptor CD94/NKG2C 
are expressed by minor populations of CD8+ T cells. Although this subset is generally very scarce 
in PBMC of healthy subjects (approximately 4%) (Fig. 2) (32;42), the frequency of CD94/NKG2A 
expressing CD8+ T cells is much higher in tumor infiltrating lymphocytes, as shown in our study and 
by others (43;44). 
Interestingly, the immunosuppressive cytokine TGF-β, which is regularly detected in ovarian and 
cervical cancer (45-47), seems to induce this inhibiting receptor on T cells (44). Several studies have 
shown that the inhibiting receptor CD94/NKG2A dampens the incoming activation signals of T cells 
by recruitment of phosphatases like SHP-1 to the signal transducing synaps, resulting in decreased 
effector functions (1;44;48). Strikingly, the activating receptor CD94/NKG2C was absent on tumor 
infiltrating T cells (Fig. 2), whereas it is expressed in other inflammatory situations (49-51). This 
implies that expression of the NKG2 chains is differentially and independently regulated and that 
NKG2A is selectively upregulated in tumors.   
Protein expression of HLA-E was previously analyzed on cultured cancer cell lines and small cohorts 
of surgical specimen of some cancer types (16;26;52-54). HLA-E expression was correlated with 
increased infiltration of CD8+ CTL in glioblastoma (53), and decreased infiltration of NK cells as well 
as a worse progression free survival in colorectal cancer (26). In cervical cancer, HLA-E expression 
seemed to gradually increase from cervical intraepithelial neoplasia (CIN) I to invasive cervical 
cancer (54). Intriguingly, we and others (55) found no associations with tumor stage or grade. 
We have to note, however, that our cervical cancer cohort represented early stage patients with 
Table 3 Cox regression survival analysis
HR (95% C.I) p-value
Ovarian cancer univariate analysis
   HLA-E high vs. HLA-E low 1.10 (0.74-1.64) 0.653
   CD8 high vs. CD8 low 0.71 (0.50-0.99) 0.047
   HLA-E low: CD8 high vs. CD8 low 0.53 (0.36-0.78) 0.001
   HLA-E high: CD8 high vs. CD8 low 0.97 (0.77-1.22) 0.816
Cervical cancer univariate analysis
   HLA-E high vs. low 0.43 (0.21-0.87) 0.020
   CD8 high vs. low 0.94 (0.40-2.19) 0.879
   HLA-E low: CD8 high vs. low 1.68 (0.34-8.36) 0.524
   HLA-E high: CD8 high vs. low 0.75 (0.27-2.05) 0.569
Cervical cancer multivariate analysis
   Infiltration depth >15 mm 1.57 (0.70-3.54) 0.277
   Tumor size >4 cm 4.88 (2.17-11.00) <0.001
   Lymph node positivity 2.73 (1.33-5.59) 0.006
   HLA-E high vs. HLA-E low 0.58 (0.28-1.23) 0.582
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relatively highly differentiated tumors, whereas the ovarian cancer cohort consisted of mostly late 
stage, high grade tumors. The expression pattern and frequency of HLA-E was quite similar in our 
two studied cancer types as well as its positive association with antigen presenting molecules. The 
effect on survival was however clearly different. High HLA-E expression in ovarian cancer appeared 
to neutralize the beneficial effect of CTL infiltration. These results are in line with the in vitro data 
by Malmberg et al. (56), who demonstrated that HLA-E on freshly isolated ovarian cancer cells 
was upregulated by IFN-γ treatment, resulting in a CD94/NKG2A-mediated resistance to CTL lysis. 
However, in cervical cancer HLA-E did not influence the prognostic effects of CTL nor the CTL/
Treg ratio. This difference might be explained by the significantly higher numbers of infiltrating 
CTL in cervical cancer. At least three times more intratumoral CTL can be found in this tumor type 
(20;21;57), which is most likely the result of the presence of viral antigens from HPV and an active 
inflammatory response. 
In conclusion, our results suggest that HLA-E expression in ovarian and cervical cancer is the result 
of a smoldering inflammatory response. This concept, described by Coletta et al. (58), entails the 
presence of an inflammatory milieu which can either promote tumor progression or antitumor 
activity. The inhibiting impact of HLA-E in cervical cancer is limited due to beneficial signs of 
inflammation such as high CTL infiltrate, strong viral antigens and stimulating HLA ligands (MICA 
and classical HLA). In ovarian cancer, the presence of HLA-E is able to neutralize the protective role 
of the relatively scarce intratumoral CTL (19-21;59;60).
Acknowledgements
The authors like to thank Claudia Cunha Oliveira for critical reading of the manuscript. Financial 
support was received from the Dutch Cancer Society (UL2007-3897), (RUG 2007-3919). 
Supplementary information






Rodgers JR, Cook RG. MHC class Ib molecules bridge innate and acquired immunity. Nat Rev 
Immunol 2005 Jun;5(6):459-71.
van Hall T, Oliveira CC, Joosten SA, Ottenhoff TH. The other Janus face of Qa-1 and HLA-E: 
diverse peptide repertoires in times of stress. Microbes Infect 2010 Nov;12(12-13):910-8.
Grimsley C, Kawasaki A, Gassner C, Sageshima N, Nose Y, Hatake K, et al. Definitive high 
93
5
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes 
resolution typing of HLA-E allelic polymorphisms: Identifying potential errors in existing allele 
data. Tissue Antigens 2002 Sep;60(3):206-12.
Strong RK, Holmes MA, Li P, Braun L, Lee N, Geraghty DE. HLA-E allelic variants. Correlating 
differential expression, peptide affinities, crystal structures, and thermal stabilities. J Biol Chem 
2003 Feb 14;278(7):5082-90.
O’Callaghan CA, Tormo J, Willcox BE, Braud VM, Jakobsen BK, Stuart DI, et al. Structural features 
impose tight peptide binding specificity in the nonclassical MHC molecule HLA-E. Mol Cell 1998 
Mar;1(4):531-41.
Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends 
on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J 
Immunol 1998 May 15;160(10):4951-60.
Braud VM, Allan DS, Wilson D, McMichael AJ. TAP- and tapasin-dependent HLA-E surface 
expression correlates with the binding of an MHC class I leader peptide. Curr Biol 1998 Jan 
1;8(1):1-10.
Braud VM, Allan DS, O’Callaghan CA, Soderstrom K, D’Andrea A, Ogg GS, et al. HLA-E binds to 
natural killer cell receptors CD94/NKG2A, B and C. Nature 1998 Feb 19;391(6669):795-9.
Speiser DE, Valmori D, Rimoldi D, Pittet MJ, Lienard D, Cerundolo V, et al. CD28-negative 
cytolytic effector T cells frequently express NK receptors and are present at variable proportions 
in circulating lymphocytes from healthy donors and melanoma patients. Eur J Immunol 1999 
Jun;29(6):1990-9.
Zhou J, Matsuoka M, Cantor H, Homer R, Enelow RI. Cutting edge: engagement of NKG2A on 
CD8+ effector T cells limits immunopathology in influenza pneumonia. J Immunol 2008 Jan 
1;180(1):25-9.
Hu D, Ikizawa K, Lu L, Sanchirico ME, Shinohara ML, Cantor H. Analysis of regulatory CD8 T cells 
in Qa-1-deficient mice. Nat Immunol 2004 May;5(5):516-23.
Mingari MC, Ponte M, Bertone S, Schiavetti F, Vitale C, Bellomo R, et al. HLA class I-specific 
inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/
NKG2A in superantigen- or alloantigen-activated CD8+ T cells. Proc Natl Acad Sci U S A 1998 
Feb 3;95(3):1172-7.
Bertone S, Schiavetti F, Bellomo R, Vitale C, Ponte M, Moretta L, et al. Transforming growth 
factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. 
Eur J Immunol 1999 Jan;29(1):23-9.
Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, et al. Characterization 
of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of 
nonclassical HLA class I molecules. Hum Immunol 2003 Mar;64(3):315-26.
Coupel S, Moreau A, Hamidou M, Horejsi V, Soulillou JP, Charreau B. Expression and release of 
soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood 2007 Apr 
1;109(7):2806-14.
Derre L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau-Aubry A, et al. Expression 














94 HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes 
5
cytotoxic effector cells. J Immunol 2006 Sep 1;177(5):3100-7.
Perera L, Shao L, Patel A, Evans K, Meresse B, Blumberg R, et al. Expression of nonclassical class 
I molecules by intestinal epithelial cells. Inflamm Bowel Dis 2007 Mar;13(3):298-307.
Ruiter DJ, Ferrier CM, Van Muijen GN, Henzen-Logmans SC, Kennedy S, Kramer MD, et al. Quality 
control of immunohistochemical evaluation of tumour-associated plasminogen activators and 
related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases 
in Tumour Invasion and Metastasis. Eur J Cancer 1998 Aug;34(9):1334-40.
Leffers N, Gooden MJ, Mokhova AA, Kast WM, Boezen HM, ten Hoor KA, et al. Down-regulation 
of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian 
cancer. Gynecol Oncol 2009 May;113(2):256-63.
Leffers N, Gooden MJ, De Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, et al. Prognostic 
significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced 
stage ovarian cancer. Cancer Immunol Immunother 2009 Mar;58(3):449-59.
Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, et al. Human leukocyte antigen 
class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable 
determines survival of cervical cancer patients? Clin Cancer Res 2008 Apr 1;14(7):2028-35.
Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing 
machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. 
Cancer Immunol Immunother 2007 Jul 12;57(2):197-206.
Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated 
antigen presentation. Curr Opin Immunol 2004 Feb;16(1):76-81.
Satoh A, Toyota M, Ikeda H, Morimoto Y, Akino K, Mita H, et al. Epigenetic inactivation of class 
II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR 
expression in colorectal and gastric cancer cells. Oncogene 2004 Nov 25;23(55):8876-86.
Wright KL, Ting JP. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol 2006 
Sep;27(9):405-12.
Levy EM, Bianchini M, Von Euw EM, Barrio MM, Bravo AI, Furman D, et al. Human leukocyte 
antigen-E protein is overexpressed in primary human colorectal cancer. Int J Oncol 2008 
Mar;32(3):633-41.
Braud V, Jones EY, McMichael A. The human major histocompatibility complex class Ib molecule 
HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 
9. Eur J Immunol 1997 May;27(5):1164-9.
Walzer T, Blery M, Chaix J, Fuseri N, Chasson L, Robbins SH, et al. Identification, activation, 
and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci U S A 2007 Feb 
27;104(9):3384-9.
Dutta N, Majumder D, Gupta A, Mazumder DN, Banerjee S. Analysis of human lymphocyte 
antigen class I expression in gastric cancer by reverse transcriptase-polymerase chain reaction. 
Hum Immunol 2005 Feb;66(2):164-9.
Dutta N, Gupta A, Mazumder DN, Banerjee S. Down-regulation of locus-specific human 

















HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes 
implication for viral-induced immune evasion. Cancer 2006 Apr 15;106(8):1685-93.
Bianchini M, Levy E, Zucchini C, Pinski V, Macagno C, De Sanctis P, et al. Comparative study of 
gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. 
Int J Oncol 2006 Jul;29(1):83-94.
de Kruijf EM, Sajet A, van Nes JG, Natanov R, Putter H, Smit VT, et al. HLA-E and HLA-G 
Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome 
of Early Breast Cancer Patients. J Immunol 2010 Dec 15;185(12):7452-9.
Sullivan LC, Clements CS, Rossjohn J, Brooks AG. The major histocompatibility complex class Ib 
molecule HLA-E at the interface between innate and adaptive immunity. Tissue Antigens 2008 
Nov;72(5):415-24.
Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, et al. Clinical significance of the 
NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator 
of poor prognosis. Cancer Immunol Immunother 2009 May;58(5):641-52.
Liu M, Matsumura N, Mandai M, Li K, Yagi H, Baba T, et al. Classification using hierarchical 
clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with 
high levels of COX expression. Mod Pathol 2008 Nov 7;22(3):373-84.
Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, et al. NK- and B-cell infiltration 
correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 2006 
Mar;125(3):451-8.
Garcia-Iglesias T, Toro-Arreola A, Albarran-Somoza B, Toro-Arreola S, Sanchez-Hernandez PE, 
Ramirez-Duenas MG, et al. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic 
activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 2009;9:186.
Textor S, Durst M, Jansen L, Accardi R, Tommasino M, Trunk MJ, et al. Activating NK cell receptor 
ligands are differentially expressed during progression to cervical cancer. Int J Cancer 2008 Nov 
15;123(10):2343-53.
Papadopoulos N, Kotini A, Cheva A, Jivannakis T, Manavis J, Alexiadis G, et al. Gains and losses 
of CD8, CD20 and CD56 expression in tumor stroma-infiltrating lymphocytes compared with 
tumor-associated lymphocytes from ascitic fluid and lymphocytes from tumor draining lymph 
nodes in serous papillary ovarian carcinoma patients. Eur J Gynaecol Oncol 2002;23(6):533-6.
Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008 Oct 
6;27(45):5932-43.
Velardi A, Ruggeri L, Mancusi A, Aversa F, Christiansen FT. Natural killer cell allorecognition 
of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of 
leukemia. Curr Opin Immunol 2009 Oct;21(5):525-30.
Tilburgs T, van der Mast BJ, Nagtzaam NM, Roelen DL, Scherjon SA, Claas FH. Expression of NK 
cell receptors on decidual T cells in human pregnancy. J Reprod Immunol 2009 Jun;80(1-2):22-
32.
Chang WC, Huang SC, Torng PL, Chang DY, Hsu WC, Chiou SH, et al. Expression of inhibitory 
natural killer receptors on tumor-infiltrating CD8+ T lymphocyte lineage in human endometrial 














96 HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes 
5
Sheu BC, Chiou SH, Lin HH, Chow SN, Huang SC, Ho HN, et al. Up-regulation of inhibitory 
natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of 
tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma. Cancer Res 2005 Apr 
1;65(7):2921-9.
Henriksen R, Gobl A, Wilander E, Oberg K, Miyazono K, Funa K. Expression and prognostic 
significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and 
type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest 1995 
Aug;73(2):213-20.
Santin AD, Bellone S, Ravaggi A, Roman J, Smith CV, Pecorelli S, et al. Increased levels of 
interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients 
with advanced ovarian cancer. BJOG 2001 Aug;108(8):804-8.
Hazelbag S, Gorter A, Kenter GG, van den Broek L, Fleuren G. Transforming growth factor-
beta1 induces tumor stroma and reduces tumor infiltrate in cervical cancer. Hum Pathol 2002 
Dec;33(12):1193-9.
Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-74.
Guma M, Busch LK, Salazar-Fontana LI, Bellosillo B, Morte C, Garcia P, et al. The CD94/NKG2C 
killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8+ T 
cells. Eur J Immunol 2005 Jul;35(7):2071-80.
Meresse B, Curran SA, Ciszewski C, Orbelyan G, Setty M, Bhagat G, et al. Reprogramming of 
CTLs into natural killer-like cells in celiac disease. J Exp Med 2006 May 15;203(5):1343-55.
van Stijn A, Rowshani AT, Yong SL, Baas F, Roosnek E, ten Berge IJ, et al. Human cytomegalovirus 
infection induces a rapid and sustained change in the expression of NK cell receptors on CD8+ 
T cells. J Immunol 2008 Apr 1;180(7):4550-60.
Marin R, Ruiz-Cabello F, Pedrinaci S, Mendez R, Jimenez P, Geraghty DE, et al. Analysis of HLA-E 
expression in human tumors. Immunogenetics 2003 Feb;54(11):767-75.
Mittelbronn M, Simon P, Loffler C, Capper D, Bunz B, Harter P, et al. Elevated HLA-E levels in 
human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. 
J Neuroimmunol 2007 Sep;189(1-2):50-8.
Goncalves MA, Le Discorde M, Simoes RT, Rabreau M, Soares EG, Donadi EA, et al. Classical 
and non-classical HLA molecules and p16(INK4a) expression in precursors lesions and invasive 
cervical cancer. Eur J Obstet Gynecol Reprod Biol 2008 Nov;141(1):70-4.
Hanak L, Slaby O, Lauerova L, Kren L, Nenutil R, Michalek J. Expression pattern of HLA class I 
antigens in renal cell carcinoma and primary cell line cultures: methodological implications for 
immunotherapy. Med Sci Monit 2009 Dec;15(12):CR638-CR643.
Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, et al. IFN-gamma 
protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent 
mechanism. J Clin Invest 2002 Nov;110(10):1515-23.
Cannistra SA. Cancer of the ovary. N Engl J Med 2004 Dec 9;351(24):2519-29.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the 


















HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes 
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-
infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable 
prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005 Dec 20;102(51):18538-43.
Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen L, Boer JM, et al. Tumor-expressed B7-H1 
and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. 
Clin Cancer Res 2009 Oct 15;15(20):6341-7.
Cancer Committee of the Internaltional Federation of Gynaecology and Obstetrics. Staging 
announchement: FIGO Cancer Committee. Gynecol Oncol 1986;25:383-5.
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays 
for high-throughput molecular profiling of tumor specimens. Nat Med 1998 Jul;4(7):844-7.
Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J. Validation of tissue microarray 
technology in ovarian carcinoma. Mod Pathol 2004 Jul;17(7):790-7.
van Dongen M, Savage ND, Jordanova ES, Briaire-de Bruijn IH, Walburg KV, Ottenhoff TH, et 
al. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase 










Elevated serum CXCL16 is an independent 
predictor of poor survival in ovarian 















Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer 
and may predict pro-metastatic ADAM protease activity
6
Abstract
Background: The chemokine CXCL16 exists as a transmembrane protein, but can be processed into 
a soluble form (sCXCL16) by ADAMs. CXCL16 and its receptor CXCR6 have been reported to be 
associated with lymphocyte infiltration and can have both pro- as well as anti-tumorigenic effects 
depending on tumor type. In the current study, we aimed to characterize the role of sCXCL16, 
CXCL16, and CXCR6 in ovarian cancer.
Methods: Immunohistochemical stainings were performed for CXCL16 and CXCR6 using a tissue 
microarray containing tissue from 306 ovarian cancer patients. Serum sCXCL16 levels were 
determined in 118 patients using ELISA. Disease specific survival was estimated using the Kaplan 
Meier method. To assess ADAM effects on CXCL16 processing, ovarian cancer cell line A2780 and 
primary ovarian cancer samples were treated with ADAM inhibitor TAPI-2. CXCL16 expression was 
evaluated by confocal microscopy and sCXCL16 was quantified in culture supernatants using ELISA. 
The effect of TAPI-2 on cell migration was assessed using scratch assays. 
Results: sCXCL16 was an independent predictor of poor survival (Hazard Ratio 2.28, 95% confidence 
interval 1.29-4.02, p=0.005). Expression of CXCL16 and its receptor CXCR6 did not correlate with 
survival. CXCL16/CXCR6 expression and serum sCXCL16 were not associated with lymphocyte 
infiltration. In vitro inhibition of ADAM10/17 decreased shedding of CXCL16 from the cell surface 
and strongly reduced cell migration of primary ovarian cancer derived malignant cells. 
Conclusion: High serum sCXCL16 is a prognostic marker for poor survival, possibly as a reflection of 
ADAM-10 or -17 activity. Therefore, serum sCXCL16 levels may be a pseudo marker that identifies 
patients with highly metastatic tumors.
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Introduction
Epithelial ovarian cancer is the most lethal gynecologic cancer (1). Chances of survival are highly 
dependent on a timely diagnosis, i.e. before the cancer has spread beyond the ovaries. However, 
due to the relatively asymptomatic nature of early stage varian cancer, the disease usually goes 
unrecognized for an extended period of time (2). Hence, 70% of ovarian cancer cases are detected 
in a late and metastatic disease stage, by which time survival rates have dropped to a mere 10-30% 
(3). 
Metastasis is a multifactorial process, which according to recent evidence, is influenced by 
chemokines and chemokine receptors interactions (4,5). Chemokines are a family of structurally 
similar proteins, with overlapping functions. Chemokines are classified into four subfamilies based 
on the configuration of their N-terminal cysteine residues, i.e. CXC, CC, C, and CX
3
C (6). Among these, 
CXCL16 is a relatively unusual chemokine, as it exists both in a transmembrane form and a soluble 
(sCXCL16) form (7). CXCL16 is normally expressed on macrophages, dendritic cells, monocytes, and 
B-cells and serves as an adhesion molecule for neighboring cells expressing the cognate chemokine 
receptor CXCR6 (also known as Bonzo, TYMSTR, and STRL33). In addition, CXCL16 is a scavenger 
receptor for oxidized low density lipoproteins (LDL) and phosphatidylserines (7). The soluble form 
of CXCL16 is produced upon cleavage of CXCL16 by metalloproteases (8-10). 
Various types of cancer have been reported to express CXCL16 and its receptor CXCR6. The 
physiological role of CXCL16 and CXCR6 in cancer is unclear, with pro-metastatic as well as 
anti-tumorigenic functions being reported. On the one hand, chemokines can promote tumor 
progression, by facilitating angiogenesis, proliferation, and hatching of tumor cells at a metastatic 
site. However, they are also implicated in the recruitment of effector lymphocytes toward the 
tumor, thereby contributing to an anti-tumor immune response. To which side the balance between 
pro- and antitumor effects inclines depends on the type of chemokines and chemokine receptors 
present, as well as tumor type and microenvironment . 
In prostate cancer, expression of CXCL16, CXCR6 and high serum sCXCL16 levels were associated 
with a more aggressive tumor phenotype (11-13) and increased formation of metastases (14-16). 
Similarly, high serum levels of sCXCL16 in colorectal cancer patients were associated with recurrent 
liver metastasis and poor prognosis (17). Other studies in colorectal cancer report a beneficial 
effect of CXCL16, mediated by attraction of immune cells. For instance, sCXCL16 was found to act 
as a chemoattractant for CXCR6 positive immune cells including CD4+ and CD8+ T-cells, natural killer 
(NK) cells, and B-cells (7). In a mouse model of colorectal cancer, the expression of CXCL16 inhibited 
formation of liver metastases by recruitment of CXCR6+ T-cells and NK-cells (18). These data 
corroborate with the finding that CXCL16 expression in colorectal cancer patients was associated 
with an increased in CD4+ and CD8+ tumor infiltrating lymphocytes and a better prognosis (19). 
Interestingly, similar conflicting data have been published for ovarian cancer. For instance, a 
microarray based study reported that CXCR6 gene expression is associated with tumor-infiltration 
of CD8+ T-cells and thus better survival (20). In contrast, high CXCL16 expression was associated 
with poor survival in a univariate analysis in an immunohistochemical study in 56 ovarian cancer 
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patients (21).
In the current study, we set out to evaluate whether the CXCL16/CXCR6 pair and serum sCXCL16 levels 
were associated with pro-metastatic or pro-inflammatory/anti-tumorigenic properties in ovarian 
cancer. Our results indicate that CXCL16 and CXCR6 are not predictive of survival, nor associated 
with T-lymphocyte infiltration. In contrast, serum sCXCL16 proved to be an independent prognostic 
factor for poor survival in ovarian cancer patients, although not associated with T-lymphocyte 
infiltration. In an ovarian cancer cell line and primary ovarian cancer-derived malignant cells, 
sCXCL16 appeared to be associated with pro-metastatic behavior, with ADAM dependent shedding 
of sCXCL16. Inhibition of ADAM activity reduced invasiveness of ovarian cancer cells in a scratch 
assay. These data suggest that serum sCXCL16 levels may be a useful pseudomarker for ADAM 
activity, reflecting a higher risk for metastases. Thus, determination of serum sCXCL16 levels might 
help to stratify patients into a high risk group that may require more aggressive treatment.
Patients and methods
Patient selection for tissue microarray and serum analysis
Since 1985, the University Medical Center Groningen keeps a computerized database of patients 
with malignant epithelial ovarian cancer treated at this hospital at any time point during the course 
of their disease, prospectively collecting information on clinicopathological characteristics and 
follow-up. 
Tissue samples for tissue microarray construction were selected if primary surgery was performed 
by a gynecological oncologist from the UMCG between May 1985 and June 2006 and if paraffin-
embedded tumor tissue was available. Serum is also routinely collected and stored at -80°C until 
further use. For the current study, serum was selected from patients for whom tumor tissue was 
also available. All serum samples were taken before primary surgery. 
Patients were staged according to FIGO classification (22). Tumors were graded and classified 
according to WHO criteria by a gynecological pathologist (23). Adjuvant chemotherapy generally 
consisted of different platinum-based treatment regimens. Response to chemotherapy was 
evaluated according to WHO criteria (24). After treatment, patients were followed-up for at least 
10 years with gradually increasing intervals. 
Information on clinicopathological characteristics and follow-up of patients was obtained from a 
computerized database in which information of all patients with epithelial ovarian cancer treated 
at our institute is prospectively recorded. For the present study, relevant data were transferred 
into a separate anonymous database. In this separate database, patient identity was protected by 
study-specific, unique patient codes. In case of uncertainties with respect to clinicopathological 
and follow-up data, the larger databases could only be checked through two data managers who 
have daily responsibilities for the larger database, thereby ascertaining the protection of patients’ 
identity. According to Dutch law no approval from our IRB was needed.
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Tissue microarray construction
Tissue microarrays were constructed as previously described (25,26). For 306 patients, enough 
tumor tissue was available to construct a tissue microarray. The majority of patients presented 
with advanced stage, serous, high grade tumors. After surgery, 56% of all patients were optimally 
debulked. Most patients received (neo)adjuvant platinum-based chemotherapy. The median 
survival for all patients was 42 months. Patient characteristics are summarized in table 1. 
In brief, paraffin-embedded tissue blocks containing tumor in ovarian and omental tissue, and 
corresponding hematoxylin & eosin (H&E) stained slides were retrieved from the pathology 
archives. Representative areas of tumor were marked on the H&E stained slides. Next, using these 
H&E slides for reference, four 0.6 mm core biopsies were taken from each tumor specimen and 
arrayed on a recipient paraffin block using a tissue microarrayer (Beecher instruments, Silver 
Spring, Maryland, USA). Adhesion of cores to the recipient block was accomplished by placing the 
blocks in a 37oC incubator for fifteen minutes. For staining, 4μm sections were cut from each TMA 
block. H&E staining was performed to verify the presence of tumor in the arrayed samples. 
Immunohistochemistry
In brief, TMA sections were dewaxed in xylene and rehydrated using graded concentrations of 
ethanol to distilled water. After antigen retrieval, endogenous peroxidase activity was blocked 




 solution for 30 minutes. Sections were incubated with 
the primary antibody for 60 minutes at room temperature (dilutions: anti-CXCR6 1:40, anti-
CXCL16 1:50). Sections were subsequently incubated with Dako Envision+ for 30 minutes at room 
temperature. The antigen-antibody reactions were visualized with 3,3’-diaminobenzidine. Sections 
were counterstained with haematoxylin. Furthermore, previously published CD8, CD45R0, and 
FoxP3 stainings were used in statistical analyses (27).
To obtain a high concordance rate with whole tissue slides, it was decided that minimally two cores 
with a minimum of 20% tumor tissue had to be present on the TMA for a sample to be entered 
into analysis (26). For all stainings, the scoring system proposed by Ruiter et al. (28) was used. The 
intensity of staining was scored as 0, 1, 2, or 3, indicating absent, weak, positive, or strong positive 
expression, respectively. For further analysis, the mean of the all cores available per patient was 
taken as final score. In total, 273 patients (89%) were evaluable for TM-CXCL16 expression and 268 
patients (87.6%) for CXCR6 expression.
Cells, reagents, and antibodies
Ovarian cancer cell line A2780 (American Type Culture Collection) was cultured in RPMI 1640 
(Lonza), supplemented with 10% fetal calf serum (FCS). Fresh tissue and ascites samples were 
collected at primary surgery. Tissues were minced and adherent cells were cultured in RPMI 1640 
with 10% FCS. Informed consent was obtained for the collection and storage of tumor samples. 
ADAM17 inhibitor TNF-α Protease Inhibitor-2 (TAPI-2) was purchased from Enzo Life sciences.
For immunohistochemistry and confocal microscopy, primary antibodies were purchased from 
R&D systems (anti-CXCL16 polyclonal goat IgG, anti-CXCR6 mouse IgG
2B
, clone 56811), and Santa 
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Table 1 Clinicopathological characteristics of all included patients 
Tissue microarray (n=306) ELISA (n=118)*
Age (years)
Mean (SD) 57.3 (13.5) 56.2 (13.5)
Histology
Serous 172 (56.2%) 59 (50.0%)
Mucinous 38 (12.4%) 15 (12.7%)
Endometrioid 45 (14.7%) 20 (16.9%)
Clear cell 20 (6.5%) 12 (10.2%)
Adeno 14 (4.6%) 3 (2.5%)
Mixed/other 17 (5.5%) 9 (7.2%)
FIGO Stage
Stage I 67 (22.0%) 32 (27.1%)
Stage II 25 (8.2%) 10 (8.5%)
Stage III 170 (55.9%) 62 (52.5%)
Stage IV 42 (13.8%) 14 (11.9%)
Missing 2
Tumor Grade 
Grade I/II 133 (47.2%) 53 (48.2%)
Grade III / undifferentiated 149 (52.8%) 57 (51.8%)
Missing 24 8
Residual disease
< 2 cm 159 (56.0%) 72 (62.1%)
>= 2 cm 125 (44.0%) 44 (37.9%)
Missing 22 2
Type of chemotherapy
None 41 (13.8%) 21 (17.9%)
Platinum 102 (34.2%) 30 (25.6%)
Platinum & taxane 127 (42.6%) 55 (47.0%)
Other 28 (9.4%) 11 (9.4%)
Missing 8 1
FIGO = International Federation of Gynecology and Obstetrics; SD = standard deviation. *Serum for ELISA 
was available for 118 out of the 306 patients in our database. Clinicopathological characteristics did not 
differ between these two groups (data not shown).
Cruz Biotechnology (anti-CXCL16 polycloncal goat IgG, N-20). For fluorescent stainings, secondary 
antibodies were purchased from Invitrogen (Alexa Fluor® 488 Donkey Anti-Goat IgG (H+L)).
ELISA kits were purchased from R&D Systems, Minneapolis, MN, USA (Quantikine human CXCL16 
immunoassay, catalog number DCX160), and used according to the manufacturer’s instructions.
CXCL16 detection (confocal microscopy) and scratch assays 
A2780 and primary ovarian cancer cells were plated (25.000 cells/well, borosolicate chambred 
coverglass, Lab-Tek™) and subsequently cultured in the presence or absence of ADAM inhibitor 
TNF-α Protease Inhibitor-2 (TAPI-2) at 100 μM for 48 hours. Supernatants and lysates were stored 
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for ELISA. Expression of CXCL16 was assessed using confocal microscopy. Fluorescent intensity was 
quantified with ImageJ software and used to perform statistic analysis.
Scratch assays were used to assess in vitro motility of ovarian cancer cells. To this end, A2780 and 
primary ovarian cancer cells were plated (500.000 cells/ well) overnight and subsequently cultured 
in serum free medium for an additional 48 hours to achieve a monolayer in a 6 wells plate. Then a 
scratch was made using a 200 μl pipette tip, and cells were incubated in the presence or absence 
of TAPI-2 in media containing 10% FCS. Wound healing was visualized daily for 3 days (EVOS, digital 
inverted microscope), and the distance covered by the cells was determined using ImageJ software.
Statistics
Immunohistochemistry scores of CXCL16 and CXCR6 were dichotomized for statistical analysis, in 
which scores 0 and 1 were considered low expression, while scores 2 and 3 were considered high 
expression. When ovarian tissue was not available or lost during histological processing, omental 
tissue was used in statistical analysis. For sCXCL16 concentrations in serum, the median (3.35 ng/
ml) was used as cut off point, considering <3.35 ng/ml serum sCXCL16 as low (score 0), and >3.35 
ng/ml as high (score 1).
Associations between chemokines and clinicopathological characteristics were tested using logistic 
regression. Mann-Whitney U tests were used to determine differences between chemokine 
(receptor) expression and tumor infiltrating lymphocyte counts. Disease specific survival (DSS) 
was defined as date of surgery until death of ovarian cancer, or date of last follow-up. DSS was 
estimated using the Kaplan Meier method. Univariate and multivariate analysis were performed 
using the Cox proportional hazards model. Only variables associated with DSS in univariate analysis 
were entered into multivariate analysis. Associations in CXCL16 or sCXCL16 expression between 
medium and TAPI-2 treated samples were assessed using Wilcoxon signed rank tests. 
For all tests, p-values <0.05 were considered significant. All p-values were two-sided. All statistical 
analyses were performed using PASW 18.0.3 software package for Windows (IBM, Armonk, NY, 
USA). 
Results
CXCL16 and CXCR6 are co-expressed and do not differ between primary tumor and metastases
The expression of CXCL16 and CXCR6 was analyzed on an in-house constructed TMA comprising 
material of 306 ovarian cancer patients. In this TMA, CXCL16 and CXCR6 levels were scored 
according to low and high staining intensity (see Figure 1A for representative examples). CXCL16 
expression was low in 179 (65.6%) patients, and high in 94 (34.4%) patients, whereas CXCR6 
expression was low in 131 (48.9%) patients and high in 137 (51.1%) patients. Expression levels of 
CXCL16 and CXCR6 in tumor tissue were correlated (Odds Ratio (OR) 2.28, 95% confidence interval 
(CI) 1.36-3.82, p=0.002), indicating that CXCL16 and CXCR6 are often co-expressed. Of note, ovarian 
cancer often spreads intraperitoneally, most notably to the omentum. The TMA contains paired 
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Figure 1 CXCL16 and CXCR6 expression do not 
differ between primary tumor and metastases. A. 
Representative examples of CXCL16 and CXCR6 
staining. I. CXCL16 weak, II. CXCL16 strong, III. CXCR6 
weak,  IV. CXCR6 strong. B. CXCL16 score between 
primary ovarian cancer and omental tissue. C. CXCR6 
score between primary ovarian cancer and omental 
tissue.
ovarian and omental tumor samples for 111 patients, but no significant differences were detected 
between ovarian and omental CXCL16 and CXCR6 expression (Wilcoxon signed rank test, p=0.517, 
Figure 1B-1C). Thus, CXCL16 and CXCR6 are often co-expressed and show no differential expression 
pattern between primary tumor and metastases.
CXCL16 and CXCR6 expression do not associate with clinicopathological factors or tumor infiltrating 
lymphocytes
CXCR6 and CXCL16 expression did not associate with any of the well-known clinicopathological 
factors such as age, stage, tumor grade, histology, and the presence of residual tumor after 
debulking surgery, although high expression of CXCL16 was more often seen in serous tumors 
(table 2). Similarly, co-expression of CXCL16/CXCR6 was not associated with these factors (data 
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Table 2 Logistic regressions of chemokine expression levels and clinicopathological characteristics
High sCXCL16 High TM-CXCL16
Age >=58 years 3.28 (1.54-6.97) 0.002 0.99 (0.60-1.63) 0.958
High stage tumors 2.12 (0.98-4.58) 0.056 0.93 (0.52-1.66) 0.817
High grade tumors 2.63 (1.22-5.67) 0.014 1.05 (0.58-1.89) 0.869
Serous tumors 2.11 (0.97-4.61) 0.060 1.94 (1.05-3.56) 0.034
>2 cm residual tumor 2.45 (1.137-5.31) 0.023 1.26 (0.70-2.27) 0.434
High CXCR6 expression
Age >=58 years 1.43 (0.89-2.32) 0.142
High stage tumors 0.90 (0.52-1.56) 0.704
High grade tumors 0.76 (0.44-1.32) 0.760
Serous tumors 0.80 (0.46-1.40) 0.437
>2 cm residual tumor 0.86 (0.49-1.51) 0.604































































Figure 2 Serum sCXCL16 levels predict poor 
survival in ovarian cancer patients. Kaplan-
Meier survival curve for (A) CXCL16, (B) 
CXCR6, and (C) serum sCXCL16.
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not shown). In addition, in univariate analysis, high or low CXCL16 and CXCR6 expression in ovarian 
cancer was not associated with survival (Figure 2A and 2B respectively, table 3). Earlier studies 
in colorectal cancer indicated that CXCL16/CXCR6 expression are associated with T-lymphocyte 
infiltration (19). In our TMA, we previously identified that the presence of CD8+ CTL and especially 
a high ratio between CD8+ CTL and FoxP3+ Treg predicts improved prognosis (27). However, there 
was no association between CXCL16 or CXCR6 expression and tumor infiltrating CD8+ CTL, FoxP3+ 
Treg, or CD45R0+ memory T lymphocytes (table 4). Furthermore, the ratio between CD8+ CTL and 
FoxP3+ Treg did not differ between high and low CXCL16 or CXCR6 expression (Figure 3A and 3B), 
nor were differences detected between CXCL16:CXCR6 high/low groups (Fig 3C). This suggests that 
in our cohort of ovarian cancer patients, the CXCL16/CXCR6 chemokine/receptor pair does not 
directly modulate anti-tumor immune responses.
Table 3 Cox regression survival analysis of chemokine (receptor) protein expression and serum levels
Univariate analysis Multivariate analysis
High sCXCL16 2.34 (1.44-3.81) 0.001 2.47 (1.38-4.39) 0.002
High TM-CXCL16 1.13 (0.82-1.55) 0.461 n.a.
High CXCR6 expression 1.18 (0.86-1.60) 0.308 n.a.
Age >=58 years 1.81 (1.34-2.44) <0.001 1.31 (0.70-2.47) 0.399
High stage tumors 9.77 (5.64-16.93) <0.001 7.44 (2.27-24.42) 0.001
High grade tumors 3.40 (2.43-4.76) <0.001 1.66 (0.89-3.11) 0.115
Serous tumors 3.56 (2.43-5.22) <0.001 1.86 (0.88-3.92) 0.104
>2 cm residual tumor 4.97 (3.59-6.88) <0.001 1.41 (0.73-2.70) 0.307


















































































Figure 3 CXCL16, CXCR6 and sCXCL16 are 
not associated with tumor infiltrating 
lymphocytes. Our previous study showed 
an association between the ratio of CD8+ 
TILs and Tregs. This TILs ratio was not 
regulated by the expression of A. CXCL16, 
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High serum sCXCL16 levels independently predicts poor survival in ovarian cancer but does not 
associate with clinicopathological factors or tumor T-cell infiltration
The cleavage of the extracellular domain of CXCL16 into sCXCL16 has been previously described 
(8,9). Therefore, serum levels of sCXCL16 were determined for 118 ovarian cancer patients of 
which pre-treatment serum samples were stored. The concentration of sCXCL16 ranged from 
0.02 to 6.66 ng/ml, with a median of 3.35 ng/ml. Notably, although sCXCL16 is generated by 
cleavage of CXCL16 from the cell membrane, no association between CXCL16 staining intensity 
and sCXCL16 concentration was detected (data not shown). In the evaluable ovarian cancer 
patients, pre-treatment levels of serum sCXCL16 was not associated with any of the established 
clinicopathological factors (table 2). However, serum levels of sCXCL16 did correlate with survival 
in ovarian cancer patients, with high serum sCXCL16 being predictive of poor survival in univariate 
analysis (Figure 2C, table 3). Specifically, patients with high sCXCL16 had a mean survival time of 58 
months (95% CI 40.0-77.8), whereas patients with low serum sCXCL16 had an approximate 3-fold 
increase in mean survival of 156 months (95% CI 123.5-188.6). A subsequent multivariate analysis 
with established prognostic factors as covariates revealed that high serum sCXCL16 levels retained 
its prognostic value, independent of age, stage, grade, histology, and residual tumor after debulking 
surgery (table 3). Thus, sCXCL16 is an independent predictor of poor survival in ovarian cancer 
patients. In previous studies in colorectal cancer, serum sCXCL16 levels were found to associate 
with immune infiltration. However, in our cohort the level of serum sCXCL16 did not correlate with 
Table 3 Relationships between chemokine (receptor) expression and TIL
Intratumoral CD8+ CTL Intratumoral FoxP3+ Treg
Median IQR p-value Median IQR p-value
sCXCL16
  Low 35.4 7.1-95.5 0.150 0.0 0.0-14.1 0.816
  High 19.5 3.5-64.5 3.5 0.0-14.1
TM-CXCL16
  Low 28.3 7.1-81.3 0.793 3.5 0.0-14.1 0.463
  High 31.8 7.1-85.8 3.5 0.0-14.1
CXCR6 expression
  Low 35.4 8.8-92.0 0.084 3.5 0.0-15.9 0.056
  High 28.3 3.5-69.0 0.0 0.0-9.7
Intratumoral CD45R0+ memory cells
Median IQR p-value
sCXCL16
  Low 3.5 0.0-12.4 0.700
  High 0.0 0.0-10.6
TM-CXCL16
  Low 0.0 0.0-10.6 0.712
  High 3.5 0.0-7.1
CXCR6 expression
  Low 3.5 0.0-10.6 0.276
  High 0.0 0.0-7.1
All TIL counts are expressed as number/mm2. p-values from Mann Whitney U tests
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Figure 4 ADAM proteases regulate CXCL16 shedding. A. Representative picture of CXCL16 staining on the 
ovarian cancer cell line A2780 and a small panel of primary patient derived ovarian cancer cells with or without 
TAPI-2 treatment, determined by confocal microscopy. B. Analyzed CXCL16 levels on A2780 cells (n=5) with or 
without TAPI-2 treatment. C. Analyzed CXCL16 levels depicted as corrected total cell fluorescence (CTCF) on 
primary ovarian cancer (n=7) with or without TAPI-2 treatment. D. sCXCL16 levels in supernatants of untreated 
versus TAPI-2 treated A2780 and primary ovarian cancer cells. 
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the number of tumor infiltrating CD8+ CTL, FoxP3+ Treg, or CD45R0+ memory T lymphocytes (table 
4), nor with the ratio between CD8+ CTL and FoxP3+ Treg (Figure 3D). Thus, the predictive value of 
serum sCXCL16 is not related to a pro-inflammatory immune phenotype as identified in colorectal 
cancer.
ADAM proteases regulate CXCL16 shedding and invasive behavior of ovarian cancer cells
Serum sCXCL16 did not associate with immune parameters, nor correlated with sCXCL16 and CXCL16/
CXCR6 expression. This suggests that sCXCL16 is probably not associated with CXCL16/ CXCR6 
signaling itself, but may indirectly reflect other tumorigenic processes. It has been described that 
ADAM-10 and ADAM-17 cleave CXCL16, thereby generating sCXCL16 (8,9). ADAM metalloprotease 
activity is known to be associated with increased metastatic behavior. Hence, CXCL16 processing 
into sCXCL16 may be a pseudo-marker for ADAM activity. To evaluate this possibility in vitro, 
A2780 ovarian cancer cells were incubated with the ADAM-10/ADAM-17 inhibitor TAPI-2, which 
significant upregulated membrane CXCL16 levels (Figure 4A and 4B). Similarly, membrane CXCL16 
expression was highly increased by TAPI-2 treatment in a small panel of primary ovarian cancer-
derived malignant cells (Figure 4A and 4C). Correspondingly, the supernatant of A2780 and primary 
ovarian cancer cell cultures contained high levels of sCXCL16 in standard culture conditions that 
were significantly reduced upon TAPI-2 treatment (Figure 4D). Thus, sCXCL16 shedding from the 
membrane of ovarian cancer cells is clearly ADAM dependent. 
To evaluate the functional consequences of ADAM activity, cell migration was assessed using scratch 
assays as a measure of tumor aggressiveness. Non-treated A2780 cells reduced the total scratch 
size by ~50% within 24 hours (Figure 5A), equaling an average distance covered of 125 μm (Figure 
5B). In contrast, migration of TAPI-2 treated A2780 cells was strongly inhibited (Figure 5A), with 
only 60 μm of the scratch covered on average after 24h (Figure 5B). Of note, this inhibitory effect of 
TAPI-2 lasted up to at least 4 days (Figure 5C). TAPI-2 treatment had similar effects on the migration 
of a small panel of primary ovarian cancer cells, again significantly reducing the distance covered 
within 24 hours (Figure 5D). These results suggest that ADAMs regulate the invasive behavior of 
ovarian cancer cells and that sCXCL16 may reflect ADAM activity.
Discussion
The role of CXCL16 and CXCR6 in cancer is ambiguous and probably cancer type specific, as their 
expression has been associated with pro-metastatic as well as anti-tumorigenic functions. The 
current study, performed in a large cohort of 306 ovarian cancer patients, indicates that neither 
expression of membrane CXCL16 nor expression of membrane CXCR6 is associated with better or 
worse survival. On the other hand, pre-treatment serum levels of sCXCL16 independently predict 
survival, showing decreased survival time along with increasing serum sCXCL16 levels. Since 
serum sCXCL16 levels did not correlate with immune infiltration this finding may be predictive for 
increased metastatic behavior of cancer cells. In line with this, in vitro experiments identified that 
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Figure 5 ADAM proteases regulate invasive behavior of ovarian cancer cells. A. Representative picture of the 
scratch assay at t=0 versus t=24h in medium or TAPI-2 treated A2780 cells. B. Analyzed distance covered by 
medium or TAPI-2 treated A2780 cells within 24h. C. Long-term follow-up (4 days) of scratch size in medium or 
TAPI-2 treated A2780 cells. D. Analyzed distance covered by medium or TAPI-2 treated primary ovarian cancer 
cells within 24h.
sCXCL16 shedding from the membrane of (primary) ovarian cancer cells is ADAM metalloprotease 
mediated, as ADAM inhibition strongly reduced tumor cell motility. Thus, sCXCL16 might be a 
pseudomarker of ADAM activity, reflecting the metastatic potential of tumors.
This study highlights the negative predictive value of pre-treatment serum levels of sCXCL16 in 
ovarian cancer patients. This finding is in line with a previous study in colorectal cancer patients 
where high sCXCL16 serum levels also negatively correlated with survival (17). Additionally, serum 
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levels of sCXCL16 were elevated in prostate (15) and pancreatic (29) cancer patients compared to 
healthy controls.
In contrast, no correlation was found between membrane CXCL16 levels and survival, although 
there was a modest association between CXCL16 and serous histology, an ovarian cancer subtype 
with an unfavorable prognosis. This contrast with a previous study in 56 ovarian cancer patients 
in which CXCL16 associated with decreased survival (21). However, no multivariate analysis was 
performed and compared to our study, median follow up was shorter. In addition, the included 
patients presented with more favorable clinicopathological characteristics, and thus a considerably 
better 5-year survival (70% vs. 39%), which might influence outcome. CXCL16 expression was 
associated with improved prognosis in renal cell (30) and colorectal cancer (19). In these studies, the 
survival benefits were attributed to the T-lymphocyte attracting properties of CXCL16. However, we 
did not find an association between tumor infiltrating lymphocytes and sCXL16, CXCL16 or CXCR6.
The high serum sCXCL16 levels identified here thus do not correlate with immune infiltration as 
in colorectal cancer, nor do they directly correlate with membrane CXCL16 levels in TMA analysis. 
Therefore, high serum sCXCL16 levels are probably not associated with CXCL16/CXCR6 signaling 
itself, but may indirectly reflect other tumorigenic processes. In this respect, previous studies 
identified ADAM-10 and -17 to be responsible for CXCL16 cleavage (8,9,30). Of note, expression 
of ADAM metalloproteinases promotes cancer cell growth, metastatic behavior and tumor 
progression (31,32). Taken together, this might indicate that serum levels of sCXCL16 reflect tumor-
associated ADAM activity. Such an association has previously been reported for serum levels of 
sALCAM (33). In line with this, in vitro inhibition of ADAM-10 and -17 enhanced CXCL16 levels on 
the membrane of (primary) ovarian cancer cells and reduced sCXCL16 levels in supernatant. In 
addition, ADAM inhibition reduced metastatic behavior of ovarian cancer cells in a scratch assay. 
Thus, CXCL16 shedding from ovarian cancer cells is regulated by ADAM-10 and -17 and inhibition of 
ADAM activity prevents metastatic features. 
Based on these findings, serum sCXCL16 levels may reflect higher ADAM activity and a more 
aggressive ovarian cancer subtype. Of note, it has been shown that direct in vivo quantification 
of ADAM activity is complicated. Specifically, mRNA expression of ADAM-17 in ovarian cancer was 
not representative of protein expression due to posttranslational modifications (34). Furthermore, 
measurement of ADAM activity is hampered by endogenous inhibitors, such as tissue inhibitor of 
metalloproteinases. Therefore, sCXCL16 may be a useful pseudomarker to predict an aggressive 
tumor type with higher ADAM activity in ovarian cancer.
Previously, CXCL16 and CXCR6 were reported to be differentially expressed between primary tumor 
and metastases, with e.g. elevated CXCL16 and CXCR6 mRNA levels in bone and liver metastases 
compared to corresponding primary tumors in prostate cancer (13). Similarly, immunohistochemical 
analysis of breast cancer (35), nasopharyngeal carcinomas (36), and melanomas (37) revealed 
CXCR6 expression in metastatic carcinoma, whereas primary tumors largely lacked CXCR6. In 
prostate cancer and renal and hepatocellular carcinoma, CXCL16 induced migration of CXCR6 
expressing cell lines (12,13,35,38,39). Moreover, it was demonstrated that CXCL16 treatment 
induced proliferation, migration and invasive growth in CXCR6 expressing colorectal cancer cell 
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lines (17). In this way, CXCL16/CXCR6 signaling contributes to detachment of tumor cells and 
promotes subsequent migration. In line with this, constitutive expression of CXCL16 and/or CXCR6 
was found in many cancer cell lines, among which prostate (13,14,16), breast (35), nasopharyngeal 
(36), and pancreatic cancer (29). However, in our cohort, TM-CXCL16 and CXCR6 expression levels 
did not differ between primary ovarian tumor tissue and omental metastases. The lack of such an 
association in ovarian cancer could be due to the route of metastasis in ovarian cancer. All other 
tumor types predominantly metastasize hematogenous or via lymph nodes. In contrast, omental 
metastases in ovarian cancer arise from an exfoliative spread from the surface of the ovaries into 
the abdominal cavity. The detachment of tumor cells per se may thus be more important than the 
homing of tumor cells to a specific location, as is necessary in case of hematogenous metastasis. 
In conclusion, high serum sCXCL16 is a prognostic marker for poor survival, possibly reflecting 
higher ADAM-10 or -17 activity. Therefore, serum sCXCL16 levels may be a pseudomarker that 
identifies patients with more aggresive tumors.
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Galectin-9 activates and expands human T-helper 1 cells
Abstract 
Galectin-9 (Gal-9) is known for induction of apoptosis in IFN-γ and IL-17 producing T-cells and 
amelioration of autoimmunity in murine models. On the other hand, Gal-9 induced IFN-γ positive 
T-cells in a sarcoma mouse model and in food allergy, suggesting that Gal-9 can have diametric 
effects on T-cell immunity. Here, we aimed to delineate the immunomodulatory effect of Gal-9 
on human resting and ex vivo activated peripheral blood lymphocytes. Treatment of resting 
lymphocytes with low concentrations of Gal-9 (5-30 nM) induced apoptosis in ~60% of T-cells after 
1 day, but activated the surviving T-cells. These viable T-cells started to expand after 4 days with 
up to 6 cell divisions by day 7 and an associated shift from naïve towards central memory and 
IFN-γ producing phenotype. In the presence of T-cell activation signals (anti-CD3/IL-2) Gal-9 did 
not induce T-cell expansion, but shifted the CD4/CD8 balance towards a CD4-dominated T-cell 
response. Thus, Gal-9 activates resting T-cells in the absence of typical T-cell activating signals and 
promotes their transition to a TH1/C1 phenotype. In the presence of T-cell activating signals T-cell 




Galectin-9 activates and expands human T-helper 1 cells
Introduction
The galectin family is a group of glycan-binding proteins characterized by conserved carbohydrate 
recognition domains (CRDs) that bind glycosylated proteins. Galectins are involved in various 
processes including embryonic development, tumor biology and regulation of the immune 
system (1). Within this family, Galectin-9 (Gal-9) has gained attention as a multifaceted player in 
adaptive and innate immunity, in particular in T-cell development and homeostasis (2). The most 
prominent effects reported for Gal-9 are the induction of apoptosis in subsets of differentiated 
T-cells, particularly in CD4+ T-helper 1 (TH1) and T-helper 17 (TH17) cells (3-7), and a stimulatory 
effect on regulatory T-cell (Treg) activity (6,8). In view of these immunomodulatory effects, Gal-
9 has been tested as a potential therapeutic agent for various autoimmune diseases. Treatment 
with Gal-9 ameliorated disease in mouse models of experimental autoimmune encephalomyelitis 
(3), arthritis (9) and diabetes (10,11), by reducing the number of autoreactive TH1 and TH17 cells 
and decreasing circulating IFN-γ concentrations. In contrast, treatment with Gal-9 stimulated anti-
tumor T-cell immune responses in a sarcoma bearing mouse model (12). Here, recombinant Gal-9 
induced cytotoxic T-cells (CTLs) and increased IFN-γ concentrations. In addition, in a recent study 
focused on food-allergy treatment of ex vivo activated human T-cells with Gal-9 promoted TH1 
generation as well as IFN-γ production (13). These data imply that Gal-9 can have a Janus-like dual 
activity; inhibiting immunity in autoimmune disease on the one side and stimulating immunity in 
cancer and allergy on the other side. 
The immunomodulatory effects of Gal-9 were initially attributed to signaling via T-cell 
immunoglobulin and mucin domain-3 (TIM-3) (3), a prominent T-cell inhibitory receptor and 
a marker for T-cell exhaustion that is currently being evaluated as a target for antibody-based 
therapy in cancer (14). However, it has become clear that, aside from TIM-3, Gal-9 can signal via 
other receptors on T-cells (15), like protein disulfide isomerase (16,17), CD40 (18) and possibly 
other, yet unidentified receptors. Indeed, the outcome of Gal-9 signaling on T-cells likely depends 
on the specific receptor being activated by Gal-9 as well as the presence of additional (T-cell) 
skewing stimuli. In this respect, most experimental murine autoimmune models used to evaluate 
therapeutic effects of Gal-9 rely on specific antibodies or disease inducing peptides in combination 
with infection stimulating adjuvants and/or bacteria (3,9,19). In contrast, the CTL stimulatory 
effects via dendritic cell (DC) activation and induction of IFN-γ found in a sarcoma did not require 
additional skewing stimuli (12). Together, this suggests that the outcome of Gal-9 signaling varies 
greatly, depending on experimental conditions and/ or the balance of immunity in specific disease 
settings. 
Here, we aimed to establish the effect of Gal-9 treatment on freshly isolated and non-skewed 
human peripheral blood immune cells in the absence of other stimuli. In line with current thinking, 
Gal-9 triggered cell death in >95% of T-cells at high concentrations. However, at lower doses, Gal-9 
activated and strongly expanded surviving T-cells in a TIM-3-independent manner. In addition, the 
T-cell expansion induced by Gal-9 was characterized by a shift from a naïve towards a central memory 
(Tcm) and IFN-γ producing TH1 phenotype. Further, a shift in monocytes towards a DC-phenotype 
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was detected. However, monocyte depletion did not affect T-cell activation, indicating that Gal-9 
had a direct effect on T-cells. In the presence of anti-CD3/IL-2 T-cell activation signals, Gal-9 did not 
trigger expansion of T-cells, but shifted the normal CD8/CD4 balance towards a predominant CD4+ 
phenotype. Taken together, these data indicate that Gal-9 has diverse immunomodulatory effects 
depending on concentration and skewing signals available and is therefore likely to have a disease-
specific role that needs to be evaluated in depth for both autoimmunity and cancer. 
Materials & Methods
Antibodies & reagents
The following fluorophore-conjugated anti-human antibodies from Immunotools (Friesoythe) 
were used in this study; anti-CD3-FITC (MEM-57), anti-CD3-Dy647 (MEM-57), anti-CD4-PE (MEM-
241), anti-CD4-PE/Dy647 (MEM-241), anti-CD8-Pe/Dy47 (MEM-31), anti-CD14-Dy647 (MEM-15), 
anti-CD19-APC (LT19), anti-CD25-PE (MEM-181), anti-CD62L-FITC (LT-TD180). The following anti-
human antibodies were from eBioscience; anti-CD8-PEcy7 (RPA-T8), anti-CD45R0-APC (UCHL1), 
anti-CD56-APC (MEM188), anti-TIM-3-APC (F38-2E2), anti-PD-1-PERCP (eBioI105), anti-CCR7-
PerCP-Cy5.5 (3D12), anti-FoxP3-APC (236A/E7), anti-IL-2-PERCP-Cy5.5 (MQ1-17H12), anti-IL-4-PE-
Cy7 (8D4-8), anti-IFNy-PERCP-Cy5.5 (4S-B3), and anti-IL-17-PERCP-Cy5.5 (eBio64DEC17). The anti-
CD3-CyQ antibody was from IQ-products (IQP-519C). Streptavidin-Alexa488 was from Invitrogen. 
Recombinant Gal-9 (truncated form Gal-9(0)) and the physiologically occurring short isoform of 
Gal-9 (Gal-9(S)) were produced as described before (20). Gal-1, Gal-2, Gal-3, Gal-8 were purchased 
commercially (R&D systems). 
Isolation of peripheral blood mononuclear cells (PBMCs) and activation of T-cells
Peripheral blood mononuclear cells (PBMCs) were obtained from venous blood from healthy 
volunteers using standard density gradient centrifugation (Lymphoprep). The ethics review board 
of the Multi- Regional Ethics Committee approved the study (MREC 06/Q2102/56), and all blood 
samples were obtained with written consent from the healthy subjects. Activated T-cells were 
generated by culturing PBMCs with anti-CD3 mAb (0.5µg/mL; 72 h, UCHT1, Immunotools) followed 
by 96 h IL-2 (100ng/mL, Immunotools). Monocyte depletion prior to treatment was performed by 
magnetic-activated cell sorting (MACS) using anti-CD14-beads (Miltenyi Biotec), resulting in >99% 
depletion of monocytes as verified by flow cytometry (data not shown). Cells were cultured at 
37˚C exposed to 21% O2/5% CO2 in X-VIVO medium (Lonza), a chemically defined and serum-
free hematopoietic cell medium, or RPMI-1640 (Lonza) supplemented with 10% v/v FBS (Thermo 
Scientific). Cell numbers were quantified using a cell counter (Sysmex).
Flow cytometry
All flow cytometric analyses were performed on a BD Accuri C6 flow cytometer (BD Biosciences) 
and accessory CFlow Plus analysis software. Positively and negatively stained populations were 
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calculated by quadrant dot plot analysis (for representative dot-plots of stainings see Fig. S1-S3). 
For cell surface marker analysis with antibodies, viable cells were gated based on forward and 
sideward scatter plot (for example see Fig. S1b).
Assessment of apoptosis and Gal-9 binding
PBMCs were treated for 1-7 days with medium with or without the indicated concentration of 
Gal-9 and analyzed for apoptosis using flow cytometric staining for phosphatidylserine exposure 
using an Annexin-V-FITC staining kit according to the manufacturer’s protocol (Immunotools). In 
brief, cells were washed once with calcium binding buffer, resuspended in calcium buffer with 
Annexin-V, incubated for 10 min at 4˚C, and analyzed by flow cytometry. To determine if Gal-9 
bound to PBMCs in a CRD-dependent manner, competitive binding experiments were performed in 
which cells were incubated with biotinylated Gal-9 for 1 h, in the presence and absence of 40 mM 
α-lactose, followed by 3 washes to remove excess and non-bound Gal-9. Cell surface binding was 
detected using streptavidin-Alexa488.
Phenotypic analyses
Phenotype assessment was determined by immunofluorescent flow cytometric staining essentially 
as described before (21). Briefly, distribution of cell populations was analyzed gating on peripheral 
blood lymphocytes from forward scatter/sideward scatter, detecting CD3+ and CD19+ populations. 
In addition, CD3-/ CD19- cells were gated and analyzed for CD56-PE binding. The balance of CD4 
and CD8 was analyzed within the viable cell population gated from forward scatter/sideward scatter 
using anti-CD4-PE and anti-CD8-PEcy7. TEM staining was performed on 0.5x106 cells per condition 
by incubation of PBMCs with APC-conjugated anti-CD45R0, PERCP-Cy5-conjugated anti-CCR7, and 
FITC-conjugated anti-CD3 for 30 min at room temperature in the dark. Alternatively, cells were 
stained with FITC-conjugated anti-CD62L, CyQ-conjugated anti-CD3 and APC-conjugated CD45R0. 
Isotype-matched non-specific antibodies were used as negative controls. Staining was analyzed 
on viable cells on forward scatter/sideward scatter plot selected within the CD3+ cell population.
Carboxyfluorescein succinimidyl ester (CFSE) analysis 
To determine the number of cell divisions after Gal-9 treatment, a CFSE cell proliferation kit was 
used according to manufacturer’s protocol (CellTrace™ CFSE Cell Proliferation Kit, Invitrogen). In 
brief, harvested PBMCs were stained with 2.5 μM CFSE in 0.1% w/v BSA/PBS for 10 min at 37oC. 
Subsequently, PBMCs were incubated in fresh medium for 10 min on ice and excess dye was 
removed by 3 washes. CFSE-stained cells were then used to establish in vitro cell cultures. During 
a time course of 7 days, cells were harvested and an additional staining was performed, incubating 
CFSE-labeled PBMCs with anti-CD3-Dye647, anti-CD4-PE/Dye647, anti-CD8-PE/Dye647, anti-CD19-
APC or CD56-APC for 30 min at 4oC. Staining was analyzed gating on the cell populations positive 
for the different phenotypic cellular markers, in which their CFSE-staining pattern was detected.
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Figure 1 Gal-9 triggers TIM-3-inde-
pendent cell death and PBMC ex-
pansion. A. Resting PBMCs were 
incubated with anti-TIM3-APC or 
isotype control antibody or B. with 
streptavidin-Alexa488, biotinylated 
Gal-9+streptavidin-Alexa488 in the 
presence or absence of α-lactose. 
Cell surface staining was evaluated 
by flow cytometry C. Resting PBMCs 
(n=3) were treated with medium or 
15nM of recombinant Gal-9 for up to 
7 days. Cell death was determined by 
Annexin-V staining. D. PBMCs (n=8) 
treated as in (C) were analyzed for cell 
number. E. Resting PBMCs (n=8) were 
treated as in (C) in the presence of 
α-lactose or sucrose, and analyzed for 
cell number. F. Resting PBMCs (n=3) 
were treated with medium or 15nM 
of recombinant Gal-9, Gal-1, Gal-2, 
Gal-3, or Gal-8 for up to 7 days, after 
which cell number was determined. 
All graphs represent mean +/- SD.
TH1, TH2, TH17 and regulatory T-cell (Treg) immunofluorescence staining
To determine the effect of Gal-9 treatment on TH1, TH2, TH17, PBMCs were treated for 7 days with 
medium supplemented with or without 15 nM Gal-9, then washed and subsequently stimulated 
with phorbol 12-myristate 13-acetate (PMA) for 4 h. Subsequently, cells were washed in wash 
buffer (PBS, 5% v/v FBS, 0.1% w/v sodium azide) and stained with FITC-conjugated anti-CD3 for 
15 min at room temperature. Cells were fixed with Reagent A (Caltag) for 10 min. After washing, 
cells were resuspended in permeabilization Reagent B (Caltag) and labeled with PERCP-Cy5-
conjugated anti-IL-2, PERCP-Cy5-conjugated anti-IL-4, PERCP-Cy5-conjugated anti-IFN-γ, or PERCP-
Cy5-conjugated anti-IL-17 for 20 min in the dark. Cells were analyzed for T-cell phenotype after 2 
subsequent washes with PBS. Cytokine staining was performed on CD3+-gated cells. Treg staining 
was performed by cell surface staining of PBMCs with PE-conjugated anti-CD4, FITC-conjugated 
anti-CD3, fixation/permeabilization as for cytokine staining above, and subsequent intracellular 
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staining for the transcription factor FoxP3 with APC-conjugated anti-FoxP3. Staining for FoxP3 was 
assessed within the CD3 and CD4 double-positive population of cells.
Analysis of cytokine secretion
ELISAs were used to quantify the secretion of IFN-γ and IL-17 from PBMCs treated with and without 
Gal-9. In brief, in vitro experiments were set-up as described above and supernatant of treated 
cells was collected at day 7. The IFN-γ (Immunotools) and IL-17 (Thermo Scientific) ELISAs were 
performed according to manufacturer’s protocol. 
Statistical analysis
Statistical analysis was performed by one-way ANOVA followed by Tukey-Kramer post-test or, where 
appropriate, by two-sided unpaired Student’s t-test using Prism software. p < 0.05 was defined as a 
statistically significant difference. Where indicated * = p<0.05; ** = p<0.01; *** = p<0.001.
Results
Galectin-9 triggers cell death but also expands resting peripheral blood cells 
Initial evidence suggested that the predominant effect of treatment of T-cells with Gal-9 is the 
induction of apoptotic cell death in T-helper 1 (TH1) and T-helper 17 (TH17) cells via the receptor 
TIM-3 (3). However, flow cytometric analysis on resting PBMCs revealed that expression of TIM-3 
was negligible, whereas ex vivo activated T-cells did express TIM-3 (Fig. 1A and Supplementary 
Fig. 1A). Despite the lack of cell surface-expressed TIM-3 Gal-9 bound to resting PBMCs (Fig. 1B). 
Binding of Gal-9 was inhibited in a lectin-specific manner by co-incubation with 40 mM α-lactose 
(Fig. 1B), but not by an anti-TIM-3 blocking antibody (data not shown). Thus, the binding of Gal-9 
was carbohydrate recognition domain (CRD)-dependent and TIM-3-independent. 
Treatment of PBMCs with Gal-9 at a concentration of 150nM, falling within the previously published 
range, eliminated the vast majority of cells within 1 day (Supplementary Fig. 1B). However, a 10-fold 
lower concentration of Gal-9 (15nM) only triggered cell death in ~half of the cells (Supplementary 
Fig. 1B). Quantification of cell death during prolonged treatment of up to 7 days, revealed that 
the percentage of apoptotic cells in Gal-9 treated conditions gradually declined from ~60% at day 
1 to that of medium control within 4 days (Fig. 1C). In line with this, treatment with 15 nM Gal-9 
decreased cell counts compared to control at days 1-3 (Fig. 1D). This initial depletion was followed 
by strong PBMC expansion, as evidenced by a 3-fold increase in cell count at day 7 from 1x106 
cells/ml to ~3x106 cells/ml in Gal-9 treated conditions (Fig. 1D). This PBMC expansion by Gal-9 
was inhibited by co-treatment with α-lactose, but not sucrose, and thus CRD-dependent (Fig. 1E). 
Various other immunomodulatory members of the galectin family, i.e. Galectin-8, which is a tandem-
repeat Galectin like Gal-9, as well as Galectin-1, Galectin-2 (prototypic Galectins) and Galectin-3 
(chimeric Galectin) did not trigger significant increase of PBMC counts at these concentrations (Fig. 
1F), nor significant induction of apoptosis (data not shown). Thus, in addition to initial induction of 
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Figure 2 Recombinant and Gal-9(s) 
dose dependently activate T-cells. A. 
Resting PBMCs (n=5) were incubated 
in medium for up to 7 days. Distri-
bution of cell populations was ana-
lyzed every day by flow cytometry. B. 
Similar as (A), but in the presence of 
15nM Gal-9. C. Resting PBMCs (n=5) 
treated with medium or 15nM of 
recombinant Gal-9 for up to 7 days 
were analyzed for T-cell activation by 
staining for activation marker CD25. 
D. Resting PBMCs were treated as in 
(C) in the presence of α-lactose, af-
ter which CD25 expression was ana-
lyzed at 1 day. E. Resting PBMCs (n=5) 
were treated as in (C) and analyzed 
for expression of TIM-3. F. PBMCs 
or monocyte-depleted PBMCs were 
treated with Gal-9 for 7 days, and 
analyzed for CD25 expression G. Rest-
ing PBMCs (n=6) were treated with a 
concentration range of recombinant 
Gal-9 or physiologically occurring 
isoform Gal-9(S) for 7 days and ana-
lyzed for cell density. H. Resting PB-
MCs (n=6) were treated as in G and 
CD25 expression was determined. All 
graphs represent mean +/- SD.
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apoptosis, Gal-9 triggers expansion of peripheral blood cells.
Galectin-9 and the short isoform of Gal-9 (Gal-9(S)) dose-dependently activate T-cells 
To specify the stimulatory effect of Gal-9 on the PBMC fraction, the relative proportion of T-cells, 
B-cells and NK-cells was analyzed in medium and Gal-9 treated PBMCs. In medium control, the 
percentages of all lymphocyte populations remained stable from day 0-7 (Fig. 2A). In contrast, 
treatment with Gal-9 reduced the percentage of CD3+ positive T-cells during the first 3 days, followed 
by a concomitant increase in T-cells and decrease in B-cells and NK-cells from day 4 onwards (Fig. 
2B). Further, in the viable population of CD3+ T-cells, treatment with 15nM Gal-9 also triggered 
T-cell activation, as evidenced by the upregulation of surface CD25-expression from ~50% at day 1 
to a maximum of ~80% after 5-7 days (Fig. 2C, representative dot-plots in Supplementary Fig. 1C). 
Activation of T-cells by Gal-9 was inhibited by co-treatment with α-lactose and thus CRD-dependent 
(Fig. 2D). Other galectin family members did not trigger T-cell activation (Supplementary Fig. 1D). 
Interestingly, during this time-course, the expression of TIM-3 was induced in only 20-30% of T-cells 
after 4-7 days of treatment with Gal-9 (Fig. 2E). These T-cells did not become double-positive for 
TIM-3 and PD-1 (Supplementary Fig. 2E), a marker profile associated with T-cell exhaustion (22). 
Thus, Gal-9 interacted with T-cells via an as yet unidentified receptor, resulting in apoptosis of part 
of the T-cells. However, the remaining population of viable T-cells underwent activation as well as 
strong expansion.
In addition to lymphocytes, the isolated PBMC fraction contains monocytes. These monocytes 
responded to Gal-9 treatment with a marked stretching and loss of CD14 expression, indicative of a 
shift towards a DC-phenotype (Supplementary Fig. 2A). Importantly, depletion of monocytes from 
the PBMC population prior to Gal-9 treatment did not affect Gal-9-induced activation of T-cells, as 
determined by CD3/CD25 double staining (Fig. 2F). Thus, although Gal-9 activated monocytes, this 
was not required for activation and expansion of T-cells. 
In addition to recombinant Gal-9, the short isoform of Gal-9 (Gal-9(S)) was included to evaluate 
whether naturally occurring isoforms of Gal-9 could have similar immunomodulatory effects. Both 
Gal-9 and Gal-9(S) dose-dependently triggered activation and expansion of T-cells, with maximal 
effects of recombinant Gal-9 at 15nM (0.5µg/ml) and Gal-9(S) at 30nM (1 µg/ml) (Fig. 2G and H). 
Thus, both recombinant Gal-9 and Gal-9(S) triggered dose-dependent activation of T-cells at low 
concentrations.
Galectin-9 treatment results in expansion of CD4+ T-cells
The effect of treatment of T-cells with Gal-9 on cell division was evaluated by determining T-cell 
proliferation by CFSE staining. In control conditions, the CD3+ T-cells did not divide during the 7 day 
time-course, as evidenced by a single CFSE fluorescence peak (Fig. 3A). In contrast, treatment with 
Gal-9 triggered up to 6 cell divisions within the CD3+ T-cell population (Fig. 3B), with ~7% of T-cells 
having divided 6 times at day 7 (Fig. 3C). In line with the data on apoptosis and cell counts, T-cell 
division was first detected after 3 days of Gal-9 treatment (Fig. 3D). 
Further analysis within the Gal-9 treated populations identified that most dividing T-cells were 
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Figure 3 Galectin-9 treatment 
expands CD4+ T-cells. A. Repre-
sentative plot of 6 independent 
experiments of resting PBMCs 
stained with CFSE and subse-
quently incubated in medium 
for up to 7 days. At Day 7, PB-
MCs were harvested, stained 
with the T-cell marker CD3, 
and CFSE peak pattern was 
analyzed within the CD3+ cells 
by flow cytometry. B. Repre-
sentative plot of 6 independ-
ent experiments of resting 
PBMCs as treated in A, but in 
the presence of 15 nM Gal-9. 
C. Analysis of (A) and (B) show-
ing percentage of CD3+ T-cells 
in the respective peak of all in-
dependent experiments (mean 
+/- SEM). D. Analysis of (B) 
showing the number of CFSE 
peaks of all independent exper-
iments. E. Representative plots 
of 3 independent experiments 
of resting PBMCs stained with 
CFSE and subsequently incu-
bated in medium or 15nM 
Gal-9 (+/- lactose) for up to 7 
days. At Day 7, PBMCs were 
harvested, stained with the T-
cell marker CD4, and CFSE peak 
pattern was analyzed within 
the CD-3+ cells by flow cytom-
etry. F. As in (E) but stained for 
the T-cell maker CD8. G. Rest-
ing PBMCs (n=4) were treated 
for up to 7 days with medium 
or Gal-9 and analyzed for CD4 
and CD8 distribution. All graphs 
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Figure 4 Gal-9 treatment of resting PBMCs shifts T-cells towards central memory and T-helper 1 phenotype. A-C. 
PBMCs were treated for 7 days with Gal-9 or Gal-9(S) after which the percentage of naïve (A), central memory 
(B), and effector memory (C) was evaluated by flow cytometry. D-G. Resting PBMCs were treated for 7 days with 
Gal-9 or Gal-9(S), after which T-cell cytokine production was analyzed by flow cytometry as described in M&M. 
The percentage of IL-2 (n=11) (D), IFN-γ (E), IL-17 (F) and IL-4 (G) was determined. H. Supernatants of medium 
and Gal-9 (15nM) treated PBMCs was harvested at day7 after which the amount of secreted IFN-γ and IL-17 was 
determined with ELISA. I. PBMCs (n=11) were treated for 7 days with Gal-9 or Gal-9(S) after which the percent-
age of regulatory T-cells was determined. Unless indicated otherwise; (n=12).
130
7
Galectin-9 activates and expands human T-helper 1 cells
Figure 5 Gal-9 treatment of TCR-activated T-cells reverses CD8/CD4 distribution and shifts T-cells towards a 
central memory phenotype. A-B. T-cells were activated by anti-CD3/IL-2, or additionally with 15nM Gal-9 or 
Gal-9(S). After 7 days the percentage of CD4 (A) and CD8 (B) were determined by flow cytometry. C. T-cells were 
activated as in (A) and percentage of T-cells with central memory phenotype was determined. D-G. T-cells were 
activated as in A, after which T-cell cytokine production was analyzed by flow cytometry as described in M&M. 
The percentage of IL-2 (n=11) (D), IFN-γ (E), IL-17 (F) and IL-4 (G) was determined. H. T-cells were activated as 
in (A), after which the percentage of regulatory T-cells was determined. Unless indicated otherwise (n=12). 
CD4+ (~76% of total PBMCs at day 7, Fig. 3E), although the remaining CD8+ T-cells (~20%) also 
divided in the final days (Fig. 3F). In line with this, Gal-9 treatment induced a steady increase in 
the percentage of CD4+ T-cells during the 7 day time-course, whereas the percentage of CD8+ 
T-cells initially decreased, but returned to base levels at day 7 (Fig. 3G; representative dot-plot in 
Supplementary Fig. 2B). Again, Gal-9 induced effects were CRD-specific as α-lactose completely 
inhibited cell division in both CD4+ and CD8+ T-cells (Fig. 3E and 3F).
Galectin-9 expands central memory and T-helper 1 cells
As Gal-9 clearly activated and expanded T-cells, the relative proportion of naïve, central memory 
(TCM), and effector memory (TEM) phenotypes in the PBMCs was evaluated (for representative 
dot-plots of staining see Supplementary Fig. 2C). As expected, the majority of T-cells in medium 
control were of a naïve CCR7+/CD45R0- phenotype (Fig. 4A). However, upon treatment with Gal-
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9 or Gal-9(S), the percentage of naïve T-cells was strongly and statistically significantly reduced 
(Fig. 4A), with the majority of T-cells acquiring a central CCR7+/CD45R0+ memory phenotype (Fig. 
4B). This dramatic shift was confirmed by a second staining for central memory using CD62L and 
CD45R0, which revealed a similar increase in CD62L+/CD45R0+ TCM (Supplementary Fig. 2D). In 
contrast, no significant changes were detected in the CCR7-/CD45R0+ TEM population (Fig. 4C). 
To characterize T-cells expanded by Gal-9 on a more functional level, cytokine profiles were 
determined in medium control and Gal-9 treated T-cells (see Supplementary Fig. 3 for representative 
dot-plots). In line with the immunophenotyping data, there was a marked and statistically significant 
increase in IL-2 producing T-cells, indicative of TCM cells (Fig. 4D). In addition, treatment with Gal-9 
resulted in a statistically significant increase in IFN-γ producing T-cells (Fig. 4E), but not in IL-17 and 
IL-4 producing T-cells (Fig. 4F and 4G, respectively). In line with these findings, analysis of secreted 
cytokines within the supernatant of Gal-9 treated cells revealed an ~100-fold increase in IFN-γ 
levels compared to medium control at day 7 (Fig. 4H). Further, a low but significant increase in IL-
17 was also detected upon treatment with Gal-9 (Fig. 4H). In line with earlier findings, treatment 
with 15 nM Gal-9(S) but not Gal-9 also triggered a small but statistically significant increase in 
regulatory T-cells (Tregs) after 7 days (Fig. 4I). Thus, in resting PBMCs the treatment with Gal-9 
triggers a selective expansion of central memory T-cells and a predominant induction of IFN-γ-
producing CD4+ T-cells.
T-cell receptor-mediated activation in the presence of Gal-9 shifts the balance towards CD4+ T-cells
The results above provide evidence that Gal-9 has a potent immunomodulatory effect on resting 
T-cells. This T H1-stimulatory effect is in line with a recent report in which CD3/CD28 co-stimulation 
of T-cells stimulated TH1 development (13). To further characterize the modulatory effect of Gal-9 
during T-cell receptor (TCR)-stimulation, PBMCs were stimulated with anti-CD3 antibody for 3 days, 
followed by IL-2 stimulation for 4 days. In the absence of Gal-9, this stimulation regime led to a 
slight preferential induction of CD8+ T-cells compared to CD4+ T-cells (Fig. 5A and 5B; median CD4+ 
42.7% vs. median CD8+ 47%). However, treatment with Gal-9 or Gal-9(S) induced a dramatic shift 
in percentages of CD8+ and CD4+ T-cells after 7 days of activation (Fig. 5A and 5B; median CD4+ 
86.1% vs. median CD8+ 7.2%). Of note, no significant increase in apoptotic cells or cell counts was 
detected upon treatment with Gal-9 or Gal-9(S) after 7 days of treatment (data not shown). TCR/
IL-2 mediated activation of T-cells in the presence of Gal-9 shifted T-cells toward a central memory 
phenotype, as defined by immunophenotyping for CD45R0/CCR7 or CD45R0/CD62L (Fig. 5C), and 
intracellular cytokine staining for IL-2 (Fig. 5D). In contrast to treatment of resting PBMCs, treatment 
of anti-CD3/IL-2 activated T-cells with Gal-9 did not trigger an increase in the percentage of IFN-γ 
producing cells (Fig. 5E). Similarly, no increase in IL-17 or IL-4 producing T-cells or regulatory T-cells 
was observed (Fig. 5F-H). Taken together, TCR-mediated activation and IL-2 induced expansion of 
T-cells in the presence of Gal-9 shifts the T-cell response towards a CD4+ helper response that is 
further characterized by a central memory phenotype.
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Discussion
Gal-9 is a strong modulator of T-cell immunity known for its apoptotic effects on TH1 and TH17 
cells in autoimmunity, but also for its stimulatory activity on CTLs and TH1 cells in cancer and 
food allergy. These apparent diametrical outcomes of Gal-9 signaling on T-cell immunity suggests 
that the balance of immunomodulatory signals is crucial for Gal-9 signaling. Data presented in 
the current study indicate that single-agent treatment of resting PBMCs with low Gal-9 doses is, 
after initial apoptotic elimination, accompanied by activation and subsequent expansion of CD4+ 
T-cells. Furthermore, Gal-9 treatment shifts T-cells from a naïve to a central memory phenotype 
and increases the percentage of IFN-γ producing T-cells. In activated (anti-CD3/IL-2) T-cells, Gal-9 
skews the CD4+/CD8+ balance towards a CD4+ phenotype. 
As evident from the data, the reported differences in T-cell responses upon Gal-9 treatment 
can be partly ascribed to the amount of Gal-9 that is used. In particular, a concentration of 
150nM eliminated the vast majority of T-cells within one day, whereas a dose-response analysis 
demonstrated that 15–30 nM Gal-9 is the optimal concentration for T-cell stimulatory effects. In 
previous reports, T-cell apoptosis was induced with relatively high doses of up to 1000 nM Gal-9 (3, 
23). Furthermore, a recent study using murine T-cell clones also required high Gal-9 concentrations 
to induce T-cell apoptosis (400 nM), whereas non-lethal doses had T-cell stimulatory effects (15). 
In addition to concentration, most studies were designed to evaluate Gal-9 activity at relatively 
short incubation periods varying from 1h to 4 days (3,4,7,23,24). In the current study, Gal-9 effects 
were evaluated for up to 7 days. Notably, significant T-cell expansion in the current study was 
only seen after 4 days of treatment, whereas the induction of apoptosis occurred rapidly within 
1 day. Of note, these effects were independent of TIM-3, as freshly isolated T-cells lacked TIM-3 
expression, and only ~35% of T-cells became TIM-3+ after 4-7 days of Gal-9 treatment. Such TIM-3 
independent binding has been described earlier (3,6,7,15), and several alternate binding partners 
have been reported, e.g. CD40 (18), several adhesion molecules (25,26), immunoglobulin E (IgE) 
(27), and protein disulfide isomerase (16,17). Whether the TIM-3 independent binding observed in 
the current study can be attributed to binding of Gal-9 to one of these alternate receptors, or an as 
yet unidentified receptor, is subject of an ongoing study. 
Binding of Gal-9 to resting blood lymphocytes activated T-cells and shifted T-cell phenotype from 
naïve toward IL-2 producing central memory T-cells (CD62+/CCR7+/CD45R0+) and IFN-γ producing 
TH1 cells. This single-agent stimulatory effect of Gal-9 on resting T-cells has not been reported 
before and appears to contrast with published studies that describe predominant elimination of 
TH1 cells by Gal-9. However, our findings are in line with several recent reports on the stimulatory 
effect of Gal-9 on activated TH1 cells (13,15), and the induction of central memory cytokines 
by Gal-9 upon CD3/CD40 co-stimulation in murine T-cells (18). The mechanism by which Gal-9 
induces T-cell activation and proliferation is currently unknown. However, other lectins, such as 
concanavalin A, also potently stimulate T-cell proliferation. Concanavalin A does so by directly 
interacting with activating receptors, like CD3 (28). Within the Galectin family of lectins, it has been 
reported that Galectin-1 can directly bind to CD3 on T-cells (29). It was suggested that Galectin-1 
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mediated ligation of the CD3-complex mimics antigen-induced TCR signaling, which induces early 
events in T-cell activation comparable to those elicited by agonistic anti-CD3 antibodies. Therefore, 
it is tentative to speculate that Gal-9 interacts with activating receptors such as CD3 on the T-cell 
surface. This is currently subject for further study in our laboratory.
Besides direct Gal-9 effects on T-cells, indirect T-cell stimulation by Gal-9 via the activation of 
DCs and DC-like macrophages was reported in sarcoma and melanoma bearing mouse models 
(12,25). Furthermore, Gal-9 induced the maturation of human monocyte-derived dendritic cells, 
resulting in IL-12, IL-2 and IFN-γ secretion (30). In line with these findings, monocytes did undergo 
phenotypic changes towards DC-phenotype in the current study. However, monocyte depletion 
did not affect the activity of Gal-9 towards resting T-cells, which suggests that Gal-9 has a direct 
immunostimulatory effect on T-cells. Gal-9 was also reported to enhance production of IFN-γ by 
NK-cells (31), but our analysis of lymphocyte distribution/activation in the current study showed 
only an increase in T-cells and a decrease in NK-cells. Further, a clear increase in IFN-γ producing 
T-cells was detected. Thus, our data suggest that IFN-γ is secreted by T-cells and not NK-cells. In 
addition to TH1 cells, a statistically significant increase in Treg cells by Gal-9(S) was detected, which 
is in line with recent murine studies (32,33).
The here reported activating effect of low dose Gal-9 on resting T-cells may be of relevance in 
certain human diseases. For instance, elevated Gal-9 serum levels were detected in patients with 
type 2 diabetes and chronic kidney disease (34). Here, serum Gal-9 levels negatively correlated 
with renal function and increased along with disease progression. Of note, aberrant recruitment 
and activation of T-cells has been described in diabetic nephropathy (35). Hence, Gal-9 may be 
involved in T-cell activation, which contributes to kidney damage in diabetes type 2. In addition, 
dietary supplementation of pre-biotic oligosaccharides and Bifidobacterium breve reduced allergic 
symptoms in a murine model of food allergy and in infants with atopic dermatitis, as an effect of 
increased serum Gal-9 levels and subsequent TH1 and Treg responses (13). Thus, depending on 
type of disease and immunological environment, serum Gal-9 can have both positive and negative 
effects on disease progression by the activation of T-cells.
In conclusion, treatment of human resting blood T-cells with Gal-9 induces apoptosis in a substantial 
proportion of the cells, but also activates and expands IFN-γ producing TH1 cells and central memory 
T-cells in surviving population. In the presence of activating signals (anti-CD3/IL2), the treatment 
with Gal-9 does not expand T-cells, but skews the CD4+/CD8+ balance towards a CD4+ phenotype. 
This study thus uncovers the stimulatory effect of Gal-9 treatment on resting lymphocytes and 
highlights the complexity of immunomodulatory signaling by Gal-9 on human T-cells. Indeed, in 
various diseases settings the influence of Gal-9 on T-cell immunity will be determined by micro-
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Ovarian cancer remains an extremely challenging disease, in terms of unraveling its histopathological 
origins, as well as optimizing diagnosis and treatment. A testimony to this fact is the relatively 
unchanged long-term survival for ovarian cancer patients over the last 30 years (1). Importantly, 
the inability to improve prognosis using standard surgery and chemotherapy suggests that the 
ceiling has been reached for these conventional treatment modalities and new approaches are 
needed. 
In the past decades, the re-activation of active antitumor immunity has gained prominence as 
a possible means of achieving curative ovarian cancer treatment. After all, ovarian cancer has 
proven to be immunogenic, with both cellular and humoral immune responses often present and 
correlating with disease outcome (2). In clinical trials on active immunotherapy in ovarian cancer, 
successful immune responses were induced against the targeted tumor antigen(s). However, 
these immunological responses have not yet translated into meaningful clinical responses 
(3). This discrepancy may be caused by the fact that the tumor microenvironment is typically 
immunosuppressive, for instance due to the presence of Treg (chapter 1 & 2) or lack of appropriate 
antigen presentation (chapter 3). These findings underline the extreme complexity of the immune 
environment in ovarian cancer. 
This thesis was dedicated to gaining a better understanding of the interaction between ovarian 
cancer and immune cells, focusing on factors that influence the number and activity of T lymphocytes 
in the tumor. Ultimately, a better understanding of the factors at play here may contribute to the 
rational design of immunotherapeutic modalities or combinations thereof. 
Summary
Chapter 1 provides a general introduction on ovarian cancer and the adaptive immune response 
against ovarian cancer, in particular of the adaptive immune system, followed by a short outline of 
each chapter. 
In brief, the immune system is capable of recognizing and responding to ovarian cancer cells. This 
translates into a survival advantage for patients with high numbers of intratumoral T lymphocytes 
and especially a high CTL/Treg ratio. These intratumoral lymphocytes can mount an immune 
response to several identified tumor antigens. At the same time, tumor specific factors may 
negatively impact the cytotoxic potential of effector T lymphocytes. Therefore, current tumor 
immunology research focuses on the identification and manipulation of such immunomodulatory 
factors.
In chapter 2, we performed a systematic review and meta-analysis of studies investigating the 
prognostic impact of TIL in solid tumors, aiming to establish pooled hazard ratios for survival 
outcomes. Studies were included in which the prognostic significance of intratumoral CD3+, CD4+, 
CD8+, and FoxP3+ lymphocytes, as well as ratios between these subsets, were determined in ≥100 




In pooled analysis, CD3+ TIL had a positive effect on survival with a hazard ratio (HR) of 0.58 (95% 
confidence interval (CI) 0.43-0.78) for death, as did CD8+ CTL with a HR of 0.71 (95% CI 0.62-0.82). 
FoxP3+ Treg were not linked to overall survival, with a HR of 1.19 (95% CI 0.84-1.67). The CTL/Treg 
ratio produced a more impressive HR (risk of death: HR 0.48, 95% CI 0.34-0.68) but was used in 
relatively few studies. Smaller sample size and a shorter follow-up time were associated with an 
increased likelihood of finding statistically significant survival outcomes. 
In conclusion, not the number of infiltrating T lymphocytes, but the ratio between CTL and Treg 
may be the strongest predictor of patient survival, as this ratio more accurately reflects the balance 
of powers within a tumor. Any future studies should have a very strict design, with large sample 
sizes to increase statistical power, a uniform way of analyzing survival outcomes, and an adequate 
follow-up period.
In chapter 3 we assessed the prognostic value of CD8+ CTL, FoxP3+ Treg, and CD45R0+ memory T 
lymphocytes in ovarian cancer. Immunohistochemical stainings were performed on ovarian tumor 
tissue and/or omental metastases from 306 stage I-IV ovarian cancer patients. In ovarian derived 
tumor tissue, the presence of FoxP3+ Treg was associated with high grade and advanced stage 
disease. High numbers of CD8+ CTL and a high CTL/Treg ratio were independent predictors for 
improved survival. When only advanced stage patients were included in the analysis, CD8+ CTL 
and FoxP3+ Treg in ovarian derived tumor tissue were both independent predictors of improved 
survival. The latter finding was surprising, in view of the immunosuppressive effects of Treg. 
Interestingly, such a contra-intuitive prognostic benefit of Treg was also reported in some other 
malignancies, most notably colorectal cancer and head and neck cancer (4). In our cohort, this 
finding may be explained by the strong positive associations between numbers of infiltrating Treg 
and CTL and a strong prognostic benefit of a high CTL/Treg ratio. Taken together, it seems likely 
that some degree of Treg infiltration accompanies an otherwise effective immune response, and 
the proportions of different T lymphocyte subsets determine its final outcome. Another possible 
explanation that was offered previously is that the role of Treg differs with tumor stage, and that 
their detrimental role is confined to early stage cancer (4). Also, the use of FoxP3 as a marker for 
Treg may slightly overestimate the Treg population, in view of some reports that FoxP3 is also 
expressed on a small population of CD8+ CTL.
In chapter 4, we analyzed components of the antigen processing and presentation pathway, to 
determine which of these are prone to downregulation in ovarian cancer and whether this impacts 
patient prognosis. The antigen processing and presentation pathway is instrumental in the ability 
of the adaptive immune system to recognize cancer cells. The final product of functioning antigen 
processing machinery is the presentation of a peptide on the (tumor) cell surface by the MHC class 
I complex, consisting of an HLA molecule with a β2m unit. In our ovarian cancer cohort, expression 
of a stable MHC class I complex was frequently lost, with co-expression of HLA-A/β2m observed in 
only 49.1% of patients and HLA-B/C/β2m in 69.8% of patients. In multivariate survival analysis, an 




The proteasome plays an important role in generating immunogenic peptides by cleaving proteins 
into smaller fragments. The proteasome exists in two main varieties, i.e. the constitutive proteasome 
and the immunoproteasome, as well as some intermediate forms. Stimulation with IFN-γ converts 
the constitutive proteasome into the immunoproteasome. The immunoproteasome is thought to 
be more capable of producing immunogenic peptides than the constitutive proteasome. In line 
with this notion, we found that expression of the immunoproteasome and MHC class I complex 
was associated with higher numbers of infiltrating CD8+ T lymphocytes. Furthermore, in patients 
with normal MHC class I expression the IFN-γ inducible immunoproteasome was more prevalent 
than the constitutive proteasome, and vice versa. 
Expression of MB1, a component of the constitutive proteasome, was independently associated 
with reduced survival. This negative effect of MB1 may stem from multiple downstream pathways 
regulated by the constitutive proteasome. For instance, pro-survival and mitogenic signaling by 
the Nuclear Factor Kappa B (NF-κB) pathway is activated by proteasomal degradation of I-κB, an 
inhibitor that normally blocks NF-kB activation. Presence of the proteasome may thus enable such 
tumor promoting signaling. Indeed, a recent study in ovarian cancer suggests that NF-κB pathway 
activation via proteasomal I-κB degradation triggers production of pro-inflammatory chemokines, 
leading to a chronic pro-inflammatory tumor microenvironment. Such an environment is frequently 
present during tumor development, and characterized by aspecific activation of innate immunity, 
as opposed to a targeted adaptive immune response. This chronic inflammatory environment 
subsequently promotes ovarian cancer dissemination (5). 
Of note, proteasome activity can clinically be modulated via proteasome inhibitor bortezomib 
(Velcade ®). An in vitro study showed that bortezomib treatment suppressed proliferation and 
increased autophagy in ovarian cancer cells in vitro (6). Moreover, bortezomib increased tumor 
immunogenicity in a murine ovarian cancer model, by upregulating heat shock proteins 60 and 90 
and enhancing dendritic cell (DC) function (7). Despite these results, phase II trials of bortezomib in 
ovarian cancer patients have only shown minimal benefits (8,9).
In chapter 5 we investigated the expression of HLA-E in 270 ovarian and 150 cervical cancer 
samples. HLA-E is a nonclassical HLA molecule, characterized by its nonpolymorphic nature. It can 
only bind a very limited spectrum of peptides, most importantly the leader sequences of classical 
HLA class I molecules. These leader sequences are shed when the classical MHC class I molecule 
enters the endoplasmatic reticulum, and subsequently undergo complete processing by the 
antigen presentation pathway. The presentation of leader sequences by HLA-E can thus be viewed 
as a sensor of the integrity of the entire MHC class I pathway (10). The principal receptors for HLA-E 
are the inhibitory CD94/NKG2A and stimulatory CD94/NKG2C, which are mainly expressed on NK 
cells. An important function of NK cells is as a ‘back up’ for CTL in case of viral infection. Viruses 
often downregulate the MHC class I pathway in host cells, to avoid killing by CTL. NK cells can 
subsequently recognize and remove these cells. Thus, the presence of HLA-E on the cell surface 
indicates to NK cells that the MHC class I pathway is intact and no action needs to be taken.




as stage, histology, and grade. In ovarian cancer, HLA-E expression was strongly associated with 
HLA-A, -B, and -C, consistent with the binding of HLA class I peptides by HLA-E. As mentioned 
above, NK cells are the principle HLA-E interacting cells. However, using antibodies against NK cell 
markers CD56, CD57, and NKp46, we found that NK cells were lacking in the overwhelming majority 
of samples. Thus, it is unlikely that HLA-E on ovarian and cervical cancer cells interacts with NK cells. 
CD94/NKG2A and CD94/NKG2C can also be expressed on a subset of activated T-lymphocytes. 
Indeed, we found CD94/NKG2A co-expression on up to 50% of tumor infiltrating CTL (median: 12%) 
in a focused panel of nine fresh surgical ovarian and cervical cancer samples, whereas CD94/NKG2C 
expression was negligible. 
Importantly, in ovarian cancer, HLA-E expression negatively affected the previously observed 
survival benefits of CD8+ CTL infiltration. Survival analysis revealed that the survival benefit of tumor 
infiltrating CTLs, as earlier identified in chapter 3, was completely neutralized in the subpopulation 
of patients with high HLA-E expression. In conclusion, these results suggest that HLA-E expression 
on ovarian and cervical cancers is a powerful immune escape mechanism, by active inhibition of 
intratumoral CD8+ CTL via CD94/NKG2A. 
In a previous microarray study by our group, gene expression patterns were compared between 
ovarian cancer samples with few and many CD8+ CTLs (11). CXCL16 and its receptor CXCR6 
emerged as differentially expressed, and therefore possibly involved in CTL infiltration. In chapter 
6, the possible role of CXCL16/CXCR6 in tumor behavior and lymphocyte infiltration was evaluated 
further. 
CXCL16 exists in both a transmembrane form (TM-CXCL16) and a soluble form (sCXCL16). sCXCL16 
is generated by cleavage of TM-CXCL16 by the enzymes A Disintegrin And Metalloproteinase 
(ADAM)-10 and -17. TM-CXCL16 and CXCR6 were assessed by immunohistochemical stainings on 
306 ovarian cancer tissue samples, and sCXCL16 by ELISA on serum samples of 118 of these patients. 
High levels of sCXCL16 were a strong predictor of decreased survival time (median survival: 57 
months vs. 149 months), even after correction for age, stage, grade, histology, and residual tumor 
in multivariate analysis. There were no associations between CXCL16 or CXCR6 and numbers of 
infiltrating CD8+ CTL, FoxP3+ Treg, or CD45R0+ memory T lymphocytes. 
Next, we performed in vitro experiments to confirm that ADAM-10 and -17 are involved in shedding 
of sCXCL16 in ovarian cancer. Incubation of an ovarian cancer cell line and primary ovarian cancer 
samples with ADAM-10/17 inhibitor TAPI-2 resulted in an accumulation of TM-CXCL16 on the cell 
surface. This suggests that ADAM-10 and/or 17 are indeed responsible for cleavage of CXCL16 
in ovarian cancer. Furthermore, ADAM-17 inhibition diminished the invasive behavior of ovarian 
cancer cells as assessed by scratch assay. Since ADAMs are involved in the cleavage of a multitude 
of proteins other than CXCL16, it seems that the negative prognostic value of sCXCL16 is at least in 
part a reflection of ADAM activity. Indeed, since ADAM activity is difficult to assess in vivo, sCXCL16 
might be a convenient pseudomarker for identifying ovarian cancer patients with highly aggressive 




In chapter 7, we focused on activation of T lymphocytes using Gal-9, a glycan binding protein which 
is known for inducing apoptosis in certain T lymphocyte subsets via its receptor TIM-3. Our results 
demonstrate that TIM-3 is not expressed on resting peripheral blood mononuclear cells (PBMCs). 
Nevertheless, Gal-9 binds to resting PBMCs, indicating that (an)other receptor(s) must be present. 
In line with previous studies, treatment of PBMCs with Gal-9 triggered dose dependent induction 
of apoptosis. However, at relatively low concentrations (5-30 nM), the remaining population of 
viable T-lymphocytes was activated, as evidenced by upregulation of CD25 within 1 day. Moreover, 
this was accompanied by a strong expansion of the T-lymphocyte population, with a 4-fold increase 
in cell number and up to 6 cell divisions after 7 days. During this activation, a shift occurred from 
a naïve towards a central memory (CD62+/CCR7+/CD45R0+) and IFN-γ producing Th1 phenotype. 
In the presence of T-lymphocyte activating signals anti-CD3 and IL-2, Gal-9 treatment reversed the 
normal CD8+/CD4+ balance in favor of CD4+ T lymphocytes. Taken together, these results show that 
at low concentrations Gal-9 can activate T lymphocytes via an as of yet unidentified receptor. Since 
Gal-9 was detected in serum and ascites of ovarian cancer patients, this protein may modulate 
T-lymphocyte immune responses in cancer. Further, a recombinant form of Gal-9 may be suitable 
for use as therapeutic immunostimulatory molecule. 
Perspectives
A large part of tumor immunology research, like the studies presented in this thesis, is dedicated 
to characterizing pro- and anti-tumor effects of immune processes. The ultimate goal of this 
preclinical research is to idendify immunological markers for patient stratification and to 
identify targets for intervention, i.e. immunotherapy. However, although understanding of the 
immunologic microenvironment in ovarian cancer has greatly increased over the past decades, 
clinical applications remain to be optimized. One important hurdle that still needs to be taken 
in the search for effective immunotherapy is finding the Achilles heel in the immunosuppressive 
environment of advanced ovarian cancer.
Standardized characterization of immune infiltrates
To improve clinical success of immunotherapy, the Society for Immunotherapy of Cancer (STIC), 
an international collaboration of immunotherapy researchers, compiled a list of nine hurdles 
and accompanying ‘opportunities’ to improve translation from fundamental to clinical tumor 
immunology research (12). The data presented in this thesis highlight the importance of hurdle 
number 3: ‘complexity of cancer, tumor heterogeneity and immune escape’. To tackle this hurdle, 
the STIC recommends better characterization of tumors, including ‘a global standardization of the 
tumor microenvironment’ (12).
In colorectal cancer, standardized characterization of immune infiltrates is being taken one step 
further. Currently, a world wide task force is working on establishing an ‘Immunoscore’ for colorectal 




was shown in several cohorts that the composition of the immune infiltrate in colon cancer was a 
better predictor for survival than TNM staging (14). The Immunoscore consists of a semiquantitative 
score of CD8+ and CD45R0+ T lymphocytes in the central tumor region and invasive margin, ranging 
from 0 (low densities of both cell types in both locations) to 4 (high densities in both locations). The 
task force is now working on world wide validation of the Immunoscore in colorectal cancer, but 
future goals include expanding it to other cancer types (13). 
In ovarian cancer, it is not yet determined whether including a similar Immunoscore in routine 
histopathological examination could improve the prediction of clinical outcome. However, if 
this turns out to be the case, implementation of such a protocol would not only add to a more 
precise characterization of ovarian cancer, but also assist in selecting patients most eligible for 
immunotherapeutic intervention. Moreover, from a research point of view, a uniform Immunoscore 
would deal with some of the issues mentioned in chapter 2. There, we describe how methodological 
heterogeneity affects outcomes of prognostic studies. A standardized way of reporting immunologic 
parameters will minimize these differences and improve reproducibility of biomarker studies.  
The immunosuppressive environment in ovarian cancer: dendritic cells as central players?
Even though the presence of certain intratumoral lymphocyte subsets is associated with longer 
survival, the immune system is not capable of eradicating advanced cancer altogether. In other 
words, once the tumor has entered the so-called escape phase of the tumor immunogenicity 
concept, the immune system has lost the battle. However, knowing what exactly is responsible for 
the transition of equilibrium to escape could provide a window of opportunity for intervention.
In recent studies, important new insights in this transition have been gained by mapping the immune 
infiltrate over time. Such a ‘longitudinal’ approach to anti-tumor immunity is one important aspect 
that is very difficult to study and has been lacking up to now. However, studies are starting to 
emerge in which a clear transition from a pro-immunogenic to immunosuppressive environment is 
described in ovarian cancer, with a prominent negative role for DCs.
DCs are professional antigen presenting cells, capable of activating naïve or memory T lymphocytes. 
Immature, i.e. resting, DCs reside in epithelia, which are the most common site of entry for microbes. 
Once they encounter a suitable antigen for presentation by MHC class I or II, DCs become activated 
and migrate to lymph nodes. At this point, they upregulate several costimulatory receptors on their 
cell surface, such as CD40, CD80, and CD86. Upon arrival in the lymph nodes, DCs can activate 
B lymphocytes, CD4+ and CD8+ T lymphocytes via the MHC bound antigen and co-stimulatory 
molecules. 
The concept that defective DCs are involved in the inability of the immune system to eradicate 
tumors is not new (19). However, the importance of DCs in tumor progression was perhaps 
underestimated. Whereas the tumor immunosurveillance concept is mainly based on loss of tumor 
immunogenicity as causal factor in the transition from equilibrium to escape, recent studies raise 
the possibility that this progression depends largely on intrinsic characteristics of the immune 
infiltrate.   




ovarian cancer was recapitulated using an inducible p53-dependent mouse model (20). In this study, 
it was found that in the early stages of tumor development, immunocompetent DCs were able 
to control tumor outgrowth, consistent with the equilibrium phase of the cancer immunoediting 
concept. However, in later stages a crucial shift in DC function was observed, which coincided with 
aggressive tumor growth. Further experiments revealed the underlying mechanism, namely that 
prostaglandin E2 and Transforming Growth Factor (TGF-)β secretion by tumor cells induced an 
immunosuppressive phenotype in DCs, characterized by decreased expression of MHC class II and 
the co-stimulatory molecule CD40. At the same time, increased expression of PD-L1 and increased 
arginase activity by DCs actively suppressed immune effector cells. Subsequent experiments in 
which DCs were depleted at different stages of tumor development corroborated this evidence: DC 
depletion accelerated tumor growth in early stage tumors, whereas it decreased tumor growth in 
late stage tumors (20). 
Similarly, another study reported that immunosuppressive myeloid DCs play a major role in 
Treg recruitment, by secreting CCL22 in response to IFN-γ (21). This phenomenon was observed 
in late, but not in early stage ovarian cancers. Again, this points to a quite distinct change from 
immunostimulatory to an immunosuppressive environment which revolves around a change in DC 
function.
Taken together, these data demonstrate a dual effect by which tumor cells manage to take the 
immunologic circumstances from bad to worse: DCs are prevented from effective antigen 
presentation, but also induced to actively sabotage the anti-tumor immune response by suppressing 
effector T lymphocytes and attracting Treg. 
Regaining DC functionality would therefore be a crucial step in reversing the immunosuppressive 
environment as whole. This could be accomplished either at a causative level (targeting the 
inhibitory cytokines or the production thereof by the tumor cells), or at a more symptomatic level 
(reprogramming the DCs). Although the causative approach may be more elegant from a physiological 
point of view, it may not be feasible due to the multitude of inhibitory cytokines possibly involved in 
DC malfunction. The study by Scarlett et al. mentioned above identifies prostaglandin E2 and TGF-β 
as culprits (20), but from previous research factors such as VEGF, macrophage colony stimulating 
factor (M-CSF), IL-6, and IL-10  are also known to negatively affect DC function (22). Targeting the 
DC directly may thus be more efficient. As mentioned below, encouraging results have already been 
reported, although the proverbial silver bullet remains to be identified. 
How to reverse immunosuppression?
Many individual factors contributing to the immunosuppressive environment of advanced ovarian 
cancer have already been defined, often accompanied by possible remedies. For instance, as 
mentioned in chapter 1 and chapter 2, Treg negatively affect the function of other T lymphocytes, 
but they can be selectively inhibited by cyclophosphamide (15). Other inhibitory factors that 
have gained some notoriety over recent years include the enzyme indoleamine 2,3-dioxygenase 
(IDO) (16), the endothelin-B receptor (ETbR) (17), and PD-L1 (18). IDO depletes the tumor 




promotes the generation of Treg. ETbR is expressed on tumor endothelium and prevents entry 
of T lymphocytes into the tumor epithelium. PD-L1 directly inhibits T lymphocytes via interaction 
with receptor PD-1, which is expressed on activated T lymphocytes. For each of these mechanisms, 
specific targeting methods have been identified and tested in animal models: 1-methyl-tryptophan 
against IDO, and antibody mediated blockades of ETbR and PD-L1. 
These mechanisms are, however, not universally present in ovarian cancers. In fact, each ovarian 
cancer possesses a unique profile of tumor characteristics and immunomodulatory mechanisms. 
Thus, for immunotherapy to be successfully applied in the clinical setting, it might eventually come 
down to either a) designing personalized immunotherapy, based on which immunosuppressive 
mechanisms are at play in the individual patient or b) finding a common denominator earlier in 
tumor development that converts a pro-immunogenic into an immunosuppressive environment, 
such as the DCs mentioned previously. 
Up to now, the agents with the most success in clinical trials are cytotoxic T lymphocyte associated 
antigen 4 (CTLA4) and PD1 blockers, albeit mostly in non-gynecologic malignancies. Importantly, 
since these agents target DC function, they may positively impact the DC malfunction mentioned 
above.
CTLA4 negatively regulates TCR signaling, by competing with the costimulatory molecule CD28 for 
binding of ligands CD80 and CD86. Since CTLA4 has a much higher affinity for both CD80 and CD86, 
CD28 is effectively outcompeted (23). Currently, the humanized anti-CTLA4 antibody ipilimumab 
(Yervoy®) is approved for use in advanced melanoma, increasing median overall survival by 3-4 
months (23). Phase II and III trials are ongoing in a multitude of cancers, among which ovarian 
cancer (http://www.cancer.gov/clinicaltrials, NCT01611558). 
A major difference between CTLA4 and PD1 is that PD1 regulates already activated T lymphocytes 
in the tumor or inflammatory environment, while CTLA4 inhibits the initial activation stages. 
Clinical application of PD1 blocking antibodies is not yet as far as for CTLA4. Initial trials show some 
promising results in melanoma, colon, renal, and lung cancer (23). Currently, there are no ongoing 
trials in which PD1 blockade is evaluated in ovarian cancer. 
Currently, targeted delivery of costimulatory ligands to properly activate DCs is being investigated in 
our group, especially focusing on those belonging to the Tumor Necrosis Factor (TNF) superfamily. 
TNF ligands and their cognate receptors are normally expressed as transmembrane proteins. 
However, proteolytic cleavage and/or alternative splicing can result in the presence of soluble 
TNFLs (sTNFLs). sTNFLs are, unfortunately, not ideal for therapeutic use. First of all, sTNFLs have a 
very short serum half-life, e.g. 30 minutes for sTRAIL, leading to a lack tumor accumulation. More 
importantly, sTNFLs are poor activators of agonistic receptors compared to the cognate full-length 
transmembrane proteins. 
These disadvantages can be transformed into advantages by incorporating sTNFLs in targeted 
immunotherapeutic approaches. In brief, an sTNFL is fused to an antibody fragment (scFv) selective 
for the desired target tissue, yielding a scFv:sTNFL fusion protein. While being essentially inactive 
when soluble, antibody fragment mediated binding converts the sTNFL to membrane-bound 




TNFL concentrations in the desired location and reduces glomerular excretion. Moreover, such 
an approach may reduce the systemic toxicity which is otherwise likely to occur in view of the 
ubiquitous expression of the target molecules (24,25).
Integrating immunotherapy with non-immunotherapeutic modalities
In addition to local immunosuppression, the pleiotropic nature of ovarian cancer is a major hurdle 
to successful therapy, including non-immunotherapeutic modalities. As mentioned in chapter 1, 
ovarian cancer has distinct histopathologic origins and is therefore currently more viewed as a 
collection of separate entities instead of one illness (26). Such heterogeneity does not only exist 
between tumors, but also within individual tumors. For instance, it was demonstrated that a single 
ovarian cancer cell can give rise to six different cell subpopulations, with varying capacities for self-
renewal and different tumorigenic phenotypes (27). 
One consequence of these observations is that multimodal treatment is likely needed to adequately 
suppress or eliminate the tumor as a whole. Thus, conventional surgery and chemotherapy 
may be combined with immunotherapy to achieve a curative therapy. In this context, it would 
probably be most effective and efficient to find synergistic effects between conventional and 
immunotherapeutic treatment. 
An example of such a synergistic effect is the induction of immunogenic cell death (ICD). Immunogenic 
cell death is specifically capable of inducing an immune response against antigens present in the 
dying cells (28). On a molecular level, ICD is characterized by the exposure of calreticulin and heat 
shock proteins on the plasma membrane and secretion of ATP and High Mobility Group Box 1 
(HMGB1). These factors subsequently bind receptors on DC’s, resulting in phagocytosis of dying 
cells and the presentation of (tumor) antigens to T lymphocytes and protective immunity in 
syngeneic mouse models (28). Therefore, induction of ICD may provide the immunostimulatory 
shift searched for in ovarian cancer.
ICD can be elicited by several anti-cancer agents, such as anthracyclins, cyclophosphamide, and 
oxaliplatin. In ovarian cancer specifically, only a limited number of studies are available. Poly(I:C) 
induced ICD in ovarian cell lines and patient material (29). Similarly, anthracyclins were found to 
induce ICD in ovarian cancer cell line OV70 (30). Notably, with regard to anthracyclins, current 
Dutch standards for ovarian cancer incorporate liposomal doxorubicine as an option in case of 
platinum resistant disease (31). This might therefore be a lead candidate for evaluation of ICD 
induction.
Further research is needed to determine whether these agents can effectively induce ICD in vivo. 
Moreover, since the nonimmunogenic platinum-based compounds are the mainstay of ovarian 
cancer chemotherapy, it is not clear yet if and how ICD inducing agents could be integrated into 
standard therapy. In this context, using other drugs to induce ICD may be more appropriate. For 
instance, a recent study suggests that cardiac glycosides, e.g. digoxin, could efficiently induce ICD in 
tumors treated with agents other than the abovementioned ICD inducing chemotherapeutics (32). 
Whether these drugs can be safely administered to non-cardiac patients and if so, in which dose, 




Another perhaps unanticipated way to achieve immune activation is via angiogenesis inhibitors. 
Angiogenesis inhibitors were designed to block vascularization of tumors. However, it became 
evident that angiogenic factors secreted by tumor cells under hypoxic conditions, for instance 
Vascular Endothelial Growth Factor (VEGF)-A and CC-chemokine Ligand 28 (CCL28), recruit a number 
of immunosuppressive cells to the tumor (33). These include Treg, tumor associated macrophages 
(TAMs), myeloid-derived suppressor cells (MDSCs), neutrophils, and immature DC’s. These cells 
then also secrete pro-angiogenic factors, thus resulting in a synergy between pro-angiogenic and 
immunosuppressive effects (34).
In ovarian cancer, anti-angiogenic therapy in the form of the VEGF-A blocking antibody bevacizumab 
is currently the subject of many clinical trials. Up to now, bevacizumab has not yet lived up to its 
expectations, although small improvements in progression free survival have been observed when 
combined with standard chemotherapy (35). Interestingly, Treg and MDSC were shown to induce 
resistance to bevacizumab (34). Thus, combining anti-angiogenic therapy with immunomodulation 
may disrupt the pro-angiogenic and immunosuppressive tumor environment. 
Concluding, there are ways to design a multimodal approach to ovarian cancer, in which immune 
modulation is combined with other types of therapy. Preclinical research can be used to find 
promising treatment combinations, with the emphasis on issues regarding dosage and timing 
regarding the administration of the individual compounds. 
Conclusion
In conclusion, the immune system is a defining factor in the clinical course of ovarian cancer.  In 
optima forma, it has the power to directly kill tumor cells through CD8+ CTL, thereby substantially 
contributing to the patients’ chance of survival. However, once an immunosuppressive 
environment has arisen, these effects can be largely negated. Reversing an immunosuppressive 
tumor microenvironment is a formidable challenge, due to the many factors at play. Finding which 
cell populations or tumor characteristics contribute most to this process will be key to developing 
successful immunotherapy strategies. In other types of cancer, substantial survival gains have already 
been achieved using immunotherapy. Since knowledge on ovarian tumor immunology is increasing 
day by day, similar steps forward might be taken in the search for curative (immunotherapeutic) 
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Eierstokkanker is de meest dodelijke vorm van gynaecologische kanker. De ziekte wordt jaarlijks bij 
ongeveer 1100 vrouwen in Nederland vastgesteld, waarvan er uiteindelijk 900 komen te overlijden 
(1). 
Dit hoge sterftecijfer is grotendeels toe te schrijven aan het feit dat eierstokkanker bij 70% van 
de patiënten pas in een gevorderd stadium wordt gediagnosticeerd (1). De symptomen treden 
namelijk pas laat in het ziekteproces op en zijn bovendien aspecifiek, zoals een opgezette buik, 
verlies van eetlust, of een vol gevoel (2). Deze klachten worden begrijpelijkerwijs niet onmiddellijk 
in verband gebracht met een ernstige ziekte. 
De behandeling van eierstokkanker bestaat uit chirurgie en/of chemotherapie. De ziekte keert 
echter bij veel patiënten terug, zelfs wanneer de initiële behandeling succesvol was. In die gevallen 
behoort genezing niet meer tot de mogelijkheden. Er zijn nieuwe middelen in ontwikkeling die 
doelgericht bepaalde eiwitten in de tumor kunnen remmen. Tot nu toe hebben dergelijke middelen 
echter nog geen significante toename van overleving laten zien. Het blijft dus zoeken naar nieuwe 
behandelmogelijkheden, waarbij het aanvallen van de tumor via het eigen  immuunsysteem een 
realistische optie is.
Het aangeboren en het verworven immuunsysteem
Het immuunsysteem bestaat uit een aangeboren en een verworven tak. Het aangeboren 
immuunsysteem vormt een eerste verdedigingslinie en bestaat onder andere uit granulocyten, 
dendritische cellen (DC’s), natural killer (NK) cellen en macrofagen. Een belangrijk kenmerk van 
het aangeboren immuunsysteem is dat het geen specifieke antigenen, dat zijn eiwitfragmenten 
specifiek voor een bepaald micro-organisme, kan herkennen. In plaats daarvan reageert het op 
bepaalde moleculaire patronen van micro-organismen of op cytokines (ontstekingseiwitten) die 
door andere cellen worden geproduceerd. Een ander belangrijk kenmerk is dat het aangeboren 
immuunsysteem niet over een immunologisch geheugen beschikt, waardoor een volgende 
herkenning van het zelfde micro-organisme tot een gelijke reactie leidt. 
Dit proefschrift is voornamelijk gericht op de rol van het verworven immuunsysteem bij kanker. 
Een belangrijk kenmerk van het verworven immuunsysteem is dat het geactiveerd raakt door 
herkenning van specifieke antigenen. Dit betekent dat waar het aangeboren immuunsysteem 
‘een micro-organisme’ herkent, het verworven immuunsysteem bijvoorbeeld Mycobacterium 
tuberculosis van het influenzavirus kan onderscheiden. Dit heeft wel tot gevolg dat het verworven 
immuunsysteem een langzamere respons levert dan het aangeboren immuunsysteem. Een tweede 
kenmerk van het verworven immuunsysteem is de vorming van geheugencellen. Deze zorgen 
voor een snellere en omvangrijkere immuunreactie bij een volgende confrontatie met het zelfde 
antigeen. 




de T-lymfocyten aan de orde zullen komen. T-lymfocyten worden gekarakteriseerd door de 
expressie van de oppervlaktemarker CD3. CD3+ T-lymfocyten kunnen vervolgens weer worden 
verdeeld in verschillende subgroepen, op basis van hun functionele karakteristieken. CD3+ 
CD8+ cytotoxische T-lymfocyten (CTL’s) zijn de belangrijkste effectorcellen. Zij kunnen doelcellen 
direct doden via uitscheiding van perforines en granzymes of via Fas-ligand (FasL) geïnduceerde 
apoptose (geprogrammeerde celdood). CD3+ CD4+ T helper (Th) lymfocyten scheiden cytokines 
uit, die tumorgroei zowel kunnen bevorderen als remmen. De Th lymfocyten kunnen worden 
onderverdeeld in Th type 1 (Th1), Th type 2 (Th2), Th17 en FoxP3+ regulatoire T cellen (Treg). In 
het kader van tumor immunologie hebben Treg in de afgelopen jaren veel aandacht gekregen. Deze 
cellen zijn in staat om andere T-lymfocyten, maar ook macrofagen en DC’s actief te remmen. Zij 
beïnvloeden de immuunreactie tegen de tumor daarmee op negatieve wijze.
Tumorantigenen: hoe herkent het immuunsysteem tumorcellen?
Kankercellen wijken op verschillende punten af van gezonde lichaamscellen. Een belangrijk verschil 
is de expressie van tumorantigenen op het oppervlak van kankercellen. Tumorantigenen zijn 
eiwitten die in gezonde lichaamscellen niet of anders tot expressie worden gebracht, waardoor 
het immuunsysteem een afweerreactie kan richten tegen deze eiwitten en daarmee tegen de 
tumorcellen waarin deze eiwitten tot expressie komen. 
Voorbeelden van tumorantigenen zijn differentiatie-antigenen (bijv. tyrosinase), mutatie-antigenen 
(bijv. β-catenine), amplificatie-antigenen (bijv. HER-2/neu), splice variant antigenen (bijv. ING1), 
glycolipide-antigenen (bijv. MUC1), virale antigenen (bijv. HPV), en cancer testis antigenen (bijv. 
NY-ESO-1) (3).
Tumor immunologie vanuit een historisch perspectief
Het belang van tumor immunologie werd reeds in de 19e eeuw beschreven door William Coley (4). 
Eén van zijn patiënten genas ‘spontaan’ van zijn sarcoom, een vorm van botkanker, na een door 
Streptokokken veroorzaakte huidinfectie. Coley onderzocht dit vervolgens door een Streptokokken 
toxine toe te dienen aan patiënten met inoperabele sarcomen, hetgeen in enkele gevallen leidde 
tot genezing van de ziekte. Dit wees erop dat activatie van het immuunsysteem kan bijdragen aan 
genezing van kanker.
Ondanks deze initiële successen bleef concept ‘tumor immunologie’ controversieel, tot in de 
jaren ’80 van de 20e eeuw werd ontdekt wat de onderliggende mechanismen van herkenning van 
kankercellen door immuuncellen zijn. Sindsdien is het zwaartepunt van tumor immunologisch 
onderzoek aan het verschuiven van het karakteriseren van de afweerreactie tegen kanker naar het 
actief beïnvloeden hiervan door middel van immuuntherapie. 




immunoediting’. Hierbinnen vallen de drie stadia van interactie tussen immuuncellen en kanker, 
ook wel de 3 E’s genoemd (5): 
- Elimination: Kankercellen worden herkend en opgeruimd door het immuunsysteem.
- Equilibrium: Enkele kankercellen ontsnappen aan eliminatie waardoor er een tijdelijk 
evenwicht ontstaat tussen groei van kankercellen en het verwijderen van kankercellen 
door het immuunsysteem.
- Escape: Er is een grote populatie kankercellen ontstaan die ontsnapt is aan controle door 
het immuunsysteem, waardoor een klinisch merkbare tumor ontstaat. 
In het laatste stadium zijn lokaal in de kanker verschillende immuunsuppressieve (het 
immuunsysteem onderdrukkende) mechanismen actief. Kankercellen kunnen zichzelf bijvoorbeeld 
‘onzichtbaar’ maken voor het immuunsysteem, door de uitschakeling van bepaalde eiwitten. 
Daarnaast kan er ter plaatse een ophoping ontstaan van Treg. Deze zijn normaal gesproken 
bedoeld om auto-immuunziekten te voorkomen, maar in het geval van kanker belemmeren zij 
de afweerreactie tegen de tumor. Het beïnvloeden van dergelijke ongunstige immunologische 
omstandigheden kan de herkenning en vernietiging van kankercellen door immuuncellen weer 
herstellen en is dus van groot belang om tot effectieve immuuntherapie te komen. 
Tumorimmunologie bij eierstokkanker
Het begrip van de rol van immunologische afweer bij eierstokkanker is in de afgelopen tien jaar 
aanzienlijk toegenomen. In 2003 verscheen een invloedrijk artikel, waarin werd beschreven dat 
de aanwezigheid van CD3+ T-lymfocyten in tumorweefsel van patiënten met eierstokkanker een 
belangrijke voorspeller is voor langere overleving (6). Dit vormde de aanleiding voor verschillende 
vervolgstudies, waarin de prognostische waarde van verschillende subgroepen van T-lymfocyten 
werd onderzocht. Een belangrijke bevinding was de negatieve invloed van verhoogde aantallen 
intratumorale Treg op de prognose van eierstokkankerpatiënten (7). Uit meer recent onderzoek 
bleek echter dat niet het absolute aantal Treg, maar vooral de verhouding tussen CTL en Treg van 
belang is. Een hoge CTL/Treg ratio, waarbij de afweerreactie  relatief ongehinderd kan plaatsvinden, 
is meer voorspellend voor een betere overleving dan aantallen CTL of Treg op zichzelf (8). 
Recent onderzoek heeft zich vooral gericht op het identificeren van factoren die de infiltratie en/of 
functie van lymfocyten beïnvloeden. Zo werd gevonden dat de aanwezigheid van de endotheline-B 
receptor (ETbR) op vaten in eierstokkankerweefsel de infiltratie van lymfocyten in het tumorweefsel 
belemmert (9). Daarnaast bleken eierstokkankercellen immuuncellen actief te kunnen remmen, 
bijvoorbeeld via programmed death ligand (PD-L)-1. PD-L1 bindt de receptor PD-1 op geactiveerde 
lymfocyten, waardoor deze inactief worden of in apoptose gaan. Voor eierstokkanker werd 
aangetoond dat de expressie van PD-L1 leidde tot lagere aantallen intratumorale CTL, maar ook 
een slechtere prognose (10). 
Op dit moment is veel onderzoek gericht op het actief moduleren van dergelijke negatieve 




met eierstokkanker is het weliswaar gelukt om immuunreacties op te wekken tegen aanwezige 
tumorantigenen, maar dit heeft zich nog niet vertaald in klinische effectiviteit (11). In andere 
kankersoorten zijn zeer veelbelovende resultaten geboekt, bijvoorbeeld met anti-cytotoxic T 
lymphocyte associated antigen 4 (anti-CTLA4) antilichamen bij melanoompatiënten (12) en 
vaccinatie met peptiden (eiwitfragmenten) van het humaan papillomavirus (HPV) bij patiënten met 
voorstadia van vulvakanker (13). Dergelijke successen zijn bij eierstokkanker nog toekomstmuziek, 
maar bevestigen wel het principe dat modulatie van het immuunsysteem bij kanker gunstige 
effecten kan hebben.
Dit proefschrift
Het belangrijkste doel van dit proefschrift is het verder karakteriseren van de afweerreactie die 
plaatsvindt tegen eierstokkanker. Allereerst hebben we de tumorinfiltratie van verschillende 
soorten T-lymfocyten en andere immunologische markers gekwantificeerd in een groot 
cohort eierstokkankerpatiënten. Daarnaast hebben we een potentieel T-lymfocyt activerend 
eiwit, genaamd galectin-9 in vitro onderzocht. Het uiteindelijke doel van dit onderzoek is het 
identificeren van merkers die voorspellend kunnen zijn voor overleving en de effectiviteit van 
immuuntherapeutische behandelingen, evenals het identificeren van mogelijke aangrijpingspunten 
voor dergelijke immuuntherapie.
Het kwantificeren van het aantal tumor infiltrerende lymfocyten (TIL) is een veelgebruikte methode 
om de intensiteit van een immuunreactie tegen een tumor bij benadering vast te stellen. In 
hoofdstuk 2 hebben we de literatuur van de laatste tien jaar systematisch doorzocht op studies 
waarin de prognostische waarde van aantallen CD3+, CD4+, CD8+ en FoxP3+ T cellen werd bepaald 
in solide tumoren. Tussen deze studies bestaat veel verschil in opzet, bijvoorbeeld op het gebied 
van patiëntenaantallen of follow-up duur, waardoor de voorspellende waarde van individuele 
studies beperkt is. De resultaten van deze studies werden vervolgens in een zogeheten meta-
analyse opnieuw geanalyseerd om tot een gepoolde en meer correct voorspellende uitkomst voor 
overleving te komen voor elk van deze T-lymfocyt subgroepen. Hieruit bleek dat CD3+ T lymfocyten 
en CD8+ CTL een positieve voorspellende waarde hadden voor overleving. De aanwezigheid van 
FoxP3+ Treg op zichzelf was niet voorspellend voor overleving, wat gezien de resultaten van de 
eerste studies naar Treg verrassend is. Een hoge CTL/Treg verhouding was daarentegen wel een 
sterke voorspeller voor langere overleving. 
Een interessante uitkomst was dat methodologische factoren van invloed leken te zijn op de 
gevonden uitkomsten. Statistisch significante uitkomsten van TIL op overleving werden vooral 
gevonden in studies waarin minder patiënten waren geïncludeerd en patiënten gedurende kortere 
tijd werden vervolgd. Een mogelijke oorzaak hiervoor is publicatie bias, hetgeen betekent dat 
studies waarin een statistisch zeer significant resultaat wordt gevonden gemakkelijker worden 




deze alleen al op grond van hun grootte worden gepubliceerd, ook wanneer geen effect van de 
onderzochte marker gevonden wordt. Dit fenomeen onderstreept het belang van een zorgvuldige 
methodologische opzet van prognostische studies, waarbij speciale aandacht voor het aantal 
geïncludeerde patiënten en de follow-up duur van belang zijn. 
In hoofdstuk 3 hebben we de prognostische waarde van CD8+ CTL, FoxP3+ Treg en CD45R0+ 
geheugencellen onderzocht in 306 patiënten met eierstokkanker. De aanwezigheid van Treg bleek 
geassocieerd te zijn met agressievere tumorkenmerken en een gevorderd ziektestadium, maar in 
de groep patiënten als geheel niet geassocieerd met overleving. Hoge aantallen CTL en een hoge 
CTL/Treg ratio waren daarentegen voorspellend voor betere overleving, ook wanneer gecorrigeerd 
werd voor stadium, graad, histologisch tumortype en resttumor na operatie. Wanneer alleen 
patiënten met hoog stadium ziekte werden geïncludeerd in de analyse, waren hoge aantallen CTL 
en Treg geassocieerd met een betere overleving. Dit laatste was een verrassende bevinding, gezien 
de immuunsuppressieve rol van Treg. Dit berust echter waarschijnlijk op een statistische interactie 
tussen aantallen Treg en aantallen CTL, in het bijzonder het feit dat een zekere mate van Treg 
infiltratie vaak aanwezig is bij een overigens effectieve CTL gemedieerde anti-tumor afweerreactie. 
In lijn met deze hypothese bleek een hoge CTL/Treg ratio sterk voorspellend voor langere overleving. 
T-lymfocyten kunnen antigenen op kankercellen alleen herkennen wanneer delen hiervan, 
zogeheten peptiden, worden gepresenteerd in een Major Histocompatibility Complex (MHC) klasse 
I of II complex. Voordat een peptide van een antigeen in een MHC molecuul geladen en aan het 
celoppervlak gepresenteerd kan worden, moet er een lange weg afgelegd worden binnen de cel. 
Hierbij wordt het eiwit geknipt tot peptide en deze peptiden worden uiteindelijk samen met het 
MHC molecuul en een β2M subeenheid aan het celoppervlak gebracht. In kanker zijn verschillende 
componenten van deze zogenaamde antigeenpresentatie route vaak uitgeschakeld, hetgeen de 
herkenning van tumorcellen door T-lymfocyten kan bemoeilijken. 
In hoofdstuk 4 staan de resultaten van ons onderzoek naar de expressie van verschillende 
componenten van de antigeenpresentatie route in weefsel van eierstokkankerpatiënten. Hierbij 
bleek dat ruim de helft van de eierstokkankers geen stabiel MHC complex op het celoppervlak 
heeft. De afwezigheid hiervan ging gepaard met een slechtere prognose. 
Naast deze correlatie bleek er een sterke associatie te zijn tussen het proteasoom en T-lymfocyt 
infiltratie. Het proteasoom bevindt zich in de cel en knipt langere peptiden tot een geschikte 
lengte om in het MHC complex geladen te worden. Er zijn twee soorten proteasomen: het 
constitutieve proteasoom en het immuunproteasoom. Het constitutieve proteasoom is normaal 
gesproken altijd aanwezig, maar kan door de cytokine interferon (IFN)-γ worden omgezet in 
het immuunproteasoom. Het immuunproteasoom produceert peptiden die beter in staat zijn 
een immuunreactie op te wekken. In onze populatie bleek zoals verwacht de aanwezigheid van 
het immuunproteasoom gerelateerd te zijn aan hogere aantallen CTL in het tumorweefsel. De 
aanwezigheid van het constitutieve proteasoom had echter een beduidend ongunstiger effect, 




hiervoor is dat het constitutieve proteasoom ook betrokken is bij de regulatie van andere, 
tumorbevorderende celprocessen. In andere kankersoorten is in lijn hiermee ook aangetoond dat 
medicamenteuze remming van het constitutieve proteasoom een effectieve behandelmethode is. 
Voor eierstokkanker is dit nog niet bewezen.
Tumorcellen kunnen zich daarnaast bewapenen tegen immuuncellen door moleculen tot expressie 
te brengen die immuuncellen onderdrukken. Eén hiervan is het Human Leucocyte Antigen (HLA)-E. 
HLA-E is een zogenaamd niet-klassiek MHC molecuul, dat net als de klassieke MHC moleculen 
eiwitten op het celoppervlak kan presenteren. Een verschil is echter dat HLA-E maar een zeer 
beperkt aantal eiwitten kan presenteren. De belangrijksten hiervan zijn bepaalde onderdelen, 
zogenaamde leader sequenties, van klassieke MHC moleculen. Het HLA-E met de gebonden leader 
sequenties kan op het celoppervlak vervolgens de receptor CD94/NKG2A of CD94/NKG2C binden. 
Deze receptoren worden met name op NK-cellen gevonden en hebben een activerend (CD94/
NKG2C) of een remmend (CD94/NKG2A) effect op de NK-cel. Daarnaast is bekend dat een klein 
deel van de geactiveerde T-lymfocyten ook deze receptor op het oppervlak tot expressie kunnen 
brengen. De belangrijkste functie van NK cellen is het uitschakelen van lichaamscellen die geen 
klassieke MHC moleculen op hun oppervlak (meer) hebben, wat kan voorkomen bij virale infecties. 
Een HLA-E molecuul met de leader sequence van een klassiek MHC molecuul gebonden is voor 
de NK cel dus een signaal dat de antigeenpresentatie pathway intact is en dat er geen actie hoeft 
worden ondernomen.
In hoofdstuk 5 beschrijven we de expressie van HLA-E in eierstok- en baarmoederhalskanker. Bij 
eierstokkanker was expressie van HLA-E sterk gerelateerd aan de expressie van klassieke MHC 
moleculen, dat wil zeggen dat HLA-E en klassieke MHC moleculen vaak samen tot expressie werden 
gebracht of beide juist afwezig waren. Dit is in lijn met het feit dat HLA-E onderdelen van het 
klassieke MHC molecuul kan binden. 
In principe zijn NK-cellen de belangrijkste doelcellen voor HLA-E. Verrassend genoeg waren deze 
in het merendeel van de tumoren afwezig, ongeacht de mate waarin het klassieke MHC complex 
tot expressie kwam. Het is dus onwaarschijnlijk dat de expressie van HLA-E op eierstok- en 
baarmoederhalskanker een effect op NK cellen kan hebben. Echter, de remmende receptor voor 
HLA-E, CD94/NKG2A, bleek aanwezig te zijn op maximaal 50% van de tumor infiltrerende CTL in 
enkele vers verkregen eierstok- en baarmoederhalskankerweefsels. De stimulerende receptor 
CD94/NKG2C bleek niet aanwezig. Dit suggereert dat HLA-E in deze tumoren de potentie heeft om 
CTL te remmen via CD94/NKG2A. 
In hoofdstuk 3 werd beschreven dat de infiltratie van CTL in eierstokkankerweefsel een positieve 
voorspellende waarde heeft voor langere overleving. Echter, wanneer deze analyse opnieuw werd 
uitgevoerd, maar nu afzonderlijk binnen patiënten met en zonder HLA-E expressie, bleek dat het 
effect van CTL volledig werd geneutraliseerd in de patiënten die HLA-E tot expressie brachten. In de 
patiënten zonder HLA-E konden de CTL blijkbaar relatief ongehinderd hun werk doen en deze waren 
derhalve voorspellend voor een betere overleving. Deze resultaten suggereren dus dat de expressie 




doordat HLA-E expressie bijdraagt aan remming van CTL via de receptor CD94/NKG2A.
Chemokines zijn eiwitten die in staat zijn cellen te laten migreren langs een chemische gradiënt. Dit 
houdt in dat deze cellen zich bewegen in de richting van de toenemende concentraties chemokines 
en zodoende bij de bron van de chemokineproductie uitkomen. Bij kanker kunnen chemokines 
immuuncellen in de richting van de tumor laten migreren, maar ze kunnen ook uitzaaiingen 
bevorderen wanneer tumorcellen de betreffende chemokinereceptor tot expressie brengen. In 
eerder onderzoek vonden we aanwijzingen dat de chemokine CXCL16 betrokken zou kunnen zijn 
bij CTL infiltratie in eierstokkanker (14). In hoofdstuk 6 wordt aanvullend onderzoek beschreven 
naar de rol van CXCL16 bij eierstokkanker.
CXCL16 is een unieke chemokine, want behalve een oplosbare vorm (sCXCL16) heeft het ook een 
transmembrane (celgebonden) vorm. Transmembraan CXCL16 kan worden gekliefd door de A 
Disintegrin And Metalloproteinase (ADAM) enzymen, waarbij sCXCL16 vrijkomt. We verrichtten 
kleuringen voor CXCL16 en diens receptor CXCR6 op eierstokkankerweefsel en bepaalden sCXCL16 
in het bloed van een groot deel van deze patiënten. 
Een hoge concentratie sCXCL16 bleek een zeer sterke voorspeller voor slechtere overleving. TM-
CXCL16 en CXCR6 waren niet voorspellend voor overleving. Er werden geen verbanden gevonden 
tussen CXCL16 expressie en het aantal infiltrerende CTL, Treg of geheugencellen. 
Klieving van CXCL16 leek dus geassocieerd met een agressiever gedrag van de tumor. Om dit nader 
te specificeren hebben we vervolgens in vitro experimenten verricht met de eierstokkankercellijn 
A2780 en enkele verse eierstokkankerweefsels. Wanneer de klievende ADAM’s werden geremd door 
middel van TAPI-2, trad een sterke toename op van CXCL16 en een afname van sCXCL16. Dit bevestigt 
dat ADAM’s betrokken zijn bij klieving van CXCL16 van de membraan van eierstokkankercellen. 
Echter, uit eerdere literatuur is bekend dat ADAM’s ook vele andere, tumorbevorderende eiwitten 
kunnen klieven. Het lijkt er dus op dat de negatieve effecten van sCXCL16 een afspiegeling zijn van 
ADAM activiteit in de tumoren. Omdat ADAM activiteit echter lastig in vivo te kwantificeren is, lijkt 
sCXCL16 een nuttige pseudomarker voor ADAM activiteit, waarmee patiënten met meer agressieve 
tumoren kunnen worden geïdentificeerd.
In hoofdstuk 7 beschrijven we de activatie van T-lymfocyten middels het molecuul galectin (Gal)-9. 
Wij hebben de effecten van Gal-9 onderzocht op niet-geactiveerde perifere bloed mononucleaire 
cellen (PBMC’s, hieronder vallen lymfocyten, monocyten en macrofagen). Van Gal-9 is bekend 
dat het apoptose kan induceren in bepaalde T-lymfocyten via de receptor TIM-3. Echter, onze 
resultaten laten zien dat PBMC’s geen TIM-3 tot expressie brengen, maar dat Gal-9 desondanks 
aan deze cellen bindt. Er moet(en) dus één of meerdere alternatieve receptoren aanwezig zijn. 
In lijn met eerdere studies werd gevonden dat Gal-9 inderdaad apoptose induceerde in het 
merendeel van de cellen. Echter bij relatief lage doseringen trad juist een activatie en toename van 
het overblijvende aantal T-lymfocyten op. Hierbij veranderden deze T-lymfocyten van naïef (nog 
niet geactiveerd geweest) naar geheugencellen en IFN-γ producerende Th1 cellen. 




vaak aanwezig bij eierstokkanker) van eierstokkankerpatiënten, zou dit dus een factor kunnen 
zijn die de immuunreactie tegen de tumor beïnvloedt. Verder onderzoek moet uitwijzen of Gal-9 
inderdaad een rol kan spelen bij immuuntherapie.
Conclusies
Het immuunsysteem speelt een belangrijke rol bij het bepalen van het beloop van eierstokkanker. In 
optimale omstandigheden kunnen CTL tumorcellen vernietigen, waardoor de kansen van de patiënt 
op overleving toenemen. Echter, in een vergevorderd stadium van eierstokkanker zijn vaak meerdere 
immuunsuppressieve mechanismen aanwezig die ervoor zorgen dat de immuunreactie tegen de 
tumor uiteindelijk faalt. Om tot effectieve immuuntherapie te komen is het zaak de mechanismen 
die de tumorcel laten ontsnappen aan het immuunsysteem therapeutisch te beïnvloeden. In andere 
kankersoorten zijn al veelbelovende resultaten geboekt met immuuntherapie. De kennis over de 
rol van het immuunsysteem bij eierstokkanker is in de afgelopen jaren enorm toegenomen. Het 
komende decenium zal de vooruitgang in kennis zich moeten vertalen in nieuwe klinisch effectieve 
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